WO2010007376A2 - Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation - Google Patents

Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation Download PDF

Info

Publication number
WO2010007376A2
WO2010007376A2 PCT/GB2009/001762 GB2009001762W WO2010007376A2 WO 2010007376 A2 WO2010007376 A2 WO 2010007376A2 GB 2009001762 W GB2009001762 W GB 2009001762W WO 2010007376 A2 WO2010007376 A2 WO 2010007376A2
Authority
WO
WIPO (PCT)
Prior art keywords
dom21
amino acid
antagonist
acid sequences
acid sequence
Prior art date
Application number
PCT/GB2009/001762
Other languages
English (en)
Other versions
WO2010007376A3 (fr
Inventor
Carolyn Enever
Steven Grant
David Sansom
Steve Holmes
Original Assignee
Domantis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Limited filed Critical Domantis Limited
Priority to EP09784717A priority Critical patent/EP2315778A2/fr
Priority to JP2011517992A priority patent/JP2012507260A/ja
Publication of WO2010007376A2 publication Critical patent/WO2010007376A2/fr
Publication of WO2010007376A3 publication Critical patent/WO2010007376A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • T cell costimulatory signals that generate T cell responses to antigen (Jenkins and Johnson (1993) Curr. Opin. Immunol. 5:361 367). Costimulatory signals determine the magnitude of a T cell response to antigen, and whether this response activates or inactivates subsequent responses to antigen (Mueller et al. (1989) Annu. Rev. Immunol. 7: 445 480). T cell activation in the absence of costimulation results in an aborted or anergic T cell response (Schwartz, R. H. (1992) Cell 71:1065 1068).
  • T cell surface receptor CD28 B 7 related molecules on antigen presenting cells (e.g., also known as B7-1 and B7-2, or CD80 and CD86, respectively) (P. Linsley and J. Ledbetter (1993) Annu. Rev. Immunol. 11:191 212).
  • CD28 on the surface of T cells can receive a costimulatory signal delivered by a ligand on B cells or other APCs.
  • Ligands for CD28 include members of the B7 family of B lymphocyte activation antigens, such as B7-1 and/or B7-2 (Freedman, A. S. et al. (1987) J. Immunol. 137, 3260-3267; Freeman, G. J. et al. (1989) J. Immunol. 143, 2714-2722; Freeman, G. J. et al. (1991) J.
  • B7-1 and B7-2 are also ligands for another molecule, CTLA4, present on the surface of activated T cells.
  • CD28 is constitutively expressed on the surface of T cells, virtually all human CD4+ T cells, 50% of human CD8 + T cells, some natural killer cells and all murine T cells.
  • CD28 is a type I transmembrane glycoprotein and is a member of the Immunoglobulin family by virtue of its single Ig variable -like extracellular domain which has a MYPPPY motif required for binding CD80 and 86, (Peach et al. 1994, J.Exp.Med. 180:2049-2058). CD28 has a cysteine residue located after the Ig variable -like domain, which is involved in its homodimerization.
  • CD28 transmits a signal that synergizes with the T cell receptor (TCR) signal to promote the activation of naive T cells (Lanzavecchia et al. (1999) Cell 96:1-4).
  • CD28 signaling regulates the threshold for T- cell activation and significantly reduces the number of TCR engagements needed for effective T cell activation (Viola et al. 1996. Science 273: 104-6).
  • CD28 co-stimulation results in enhanced T cell proliferation, production of multiple cytokines, and cytokine receptors, increased expression of proteins involved in cell cycle progression, sustaining T cell survival, and sustained CD40Ligand (CD40L) expression on T cells (Sharpe et al. Fundamental Immunology, W.E. Paul Ed. Fifth Edition, Page 396).
  • CD28 signals have a critical role in regulating CD4 and CD8 T cell differentiation.
  • CD28 also optimizes the responses of previously activated T cells, promoting EL-2 production, and T- cell survival.
  • IL-4 production by na ⁇ ve T cells is highly dependent on B 7-1 /B 7-2 co- stimulation. Interruption of the CD28/B7 pathway during activation of na ⁇ ve T cells impairs T- cell proliferation and differentiation, while interruption of the CD28/B7 pathway in previously activated T cells diminishes T- cell expansion but not effector cytokine production (Sharpe et al. Fundamental Immunology, W.E. Paul Ed. Fifth Edition, Page 393-404).
  • T helper cell- dependent antibody responses use the B7-CD28 pathway to provide co- stimulatory signals essential for cognate T cell B cell interactions required for Immunoglobulin class switching and germinal center formation.
  • CD28 knock out mice potentially reactive B cells accumulate within lymphoid follicles after antigenic stimulation, but are not able to proliferate or undergo somatic mutation, (Ferguson et al. J. Immunol. (1996) 156:4576-4581).
  • B7-1/B7-2 co-stimulation of inhibitory signals occur when B7-1/B7-2 bind a second, higher affinity receptor on T cells, CTLA-4 (CD152), (Brunet et al. Nature (1987)328:267-270, Linsley et al. (1991) J. Exp. Med.174:561-569).
  • CTLA-4 CD152
  • the outcome of an immune response involves a balance between CD28 mediated T cell activation and CTLA-4 mediated T cell inhibition. Inhibition of CD28 mediated T cell activation could inhibit undesired T cell responses occurring during autoimmunity, transplant rejection, or allergic responses.
  • inhibiting CD28 mediated T cell activation could delay graft rejection, prevent acute allograft rejection, induce donor specific tolerance, and prevent development and interrupt the progression of chronic allograft rejection, as well as prevent graft versus host disease (GVH), i.e., when transplanted, T cells mount a vigorous immune response against host tissue alloantigens, (Salama et al. (2001) J. Clin. Invest. 108:943-48). Not only would inhibiting CD28 mediated T cell activation dampen the immune response through negating activation signaling through CD28, it may also increase the amount of binding of CD86 and CD80 to CTLA-4, thereby further hastening inhibition of the T cell response.
  • VH graft versus host disease
  • inhibiting CD28 mediated T cell activation could be used to prevent induction of autoimmunity and moderate the progression and/or severity of established autoimmune diseases, including models of collagen induced arthritis, autoimmune thyroiditis, autoimmune uveitis, myasthenia gravis and lupus, (Saloman et al. Ann. Rev. Immunol. (2001)) 19:225-252).
  • Inhibiting CD28 mediated T cell activation could be used to prevent graft rejection and/or graft versus host disease, and/or moderate the progression and/or severity of transplantation related diseases, including models.
  • Inhibiting and/or reducing inflammation mediated at least in part through CD28 signaling is also desirable. What is needed is a way to inhibit CD28-mediated T cell activation, without stimulation of CD28 signaling pathways. The disclosure set forth herein meets and addresses this need.
  • monovalent binders of CD28 including antibody single variable domains that monovalently bind CD28.
  • the monovalent binders of CD28 including antibody single variable domains that monovalently bind CD28, antagonize an activity of CD28.
  • CD28/B7 (CD80 and CD86) interaction and pathways present important targets for the development of therapeutic approaches for the treatment of diseases and disorders that involve inappropriate and/or undesirable cellular immune responses, and /or excessive antibody responses, such as transplantation rejection, inflammation and autoimmunity.
  • an antagonist of CD28 that specifically binds CD28 in a monovalent fashion has unique advantages in antagonizing CD28 mediated T cell responses, e.g., T cell activation and/or T cell proliferation, over an anti-CD28 dimeric antibody which clusters the cell surface CD28 molecules, promoting T cell stimulation.
  • an antagonist antibody single variable domain which is monovalent for binding of CD28 can inhibit CD28 activity, dampening an immune response, while avoiding potential undesirable stimulatory affects that can occur with antibodies capable of divalent or multivalent binding of cell surface CD28.
  • a monovalent antibody single variable domain which specifically binds CD28 can also be applied to any of a number of uses for which a standard divalent antibody is used, e.g., in vivo imaging and diagnosis.
  • CD28 antagonists which comprise or consist of a monovalent binder of CD28, including an antibody single variable domain, which inhibits CD28 mediated signaling.
  • the inhibited CD28 mediated signaling results from reduced binding to CD28 by CD80 and/or CD86.
  • the amount of inhibition or reduction in CD28 mediated signaling as a result of the presence of monovalent antagonists to CD28, including CD28 specific antibody single variable domains described herein, can be measured based on receptor binding assays well known in the art.
  • the antagonist monovalent binders of CD28 described herein do not bind the common motif, MYPPPY found on the extracellular portion on CTLA4 and CD28.
  • the antagonist monovalent binders of CD28 described herein, including antibody single variable domains do not cross-react with CTLA4, allowing CD80 and CD86 to be available for binding to CTLA4, further contributing to inhibition of the T cell response.
  • CTLA4 is a known inhibitor of T cell responsiveness.
  • the CD28 antagonist described herein which comprises or consists of a monovalent binder of CD28, including a single domain antibody, that specifically binds and antagonizes an activity of CD28, without substantially agonizing CD28 activity.
  • Administering a human or a humanized monovalent binder of CD28, such as an antibody single variable domain is particularly useful for the treatment or prevention of disease, especially a disease where it is desirable to avoid the generation of an alloreactive immune response and/or to suppress a T cell mediated immune response.
  • the antibody single variable domain is essentially a human antibody single variable domain that monovalently binds CD28, which, in an exemplary embodiment, binds and antagonizes CD28 signaling without substantially agonizing CD28 activity.
  • the monovalent domain which specifically binds CD28 competes for binding to CD28 with DOM21-4, DOM21-18 and/or DOM21-28, and/or competes for binding with one or more of D0M21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, DOM21-7, DOM21-8, DOM21-9, DOM21-10, D0M21-11, DOM21-12, DOM21-13, D0M21- 14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24, DOM21-25, DOM21-26, DOM21-27, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36, DOM21-37, DOM21-38, DOM21-39, DOM21-40,
  • the monovalent domain which specifically binds CD28 and/or antagonizes CD28 mediated signaling without substantially agonizing CD28 activity competes for binding to CD28 with DOM21-4, DOM21-18 and/or DOM21-28, and/or competes for binding with one or more of D0M21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, D0M21- 7, DOM21-8, DOM21-9, DOM21-10, D0M21-11, DOM21-12, DOM21-13, DOM21-14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24, DOM21-25, DOM21-26, DOM21-27, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36,
  • the monovalent domain which specifically binds CD28, and/or antagonizes CD28 mediated signaling, and/or antagonizes CD28 mediated signaling without substantially agonizing CD28 activity and/or competes for binding to CD28 with one or more of the D0M21 peptides selected from the following: DOM21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, DOM21-7, DOM21-8, DOM21-9, DOM21-10, D0M21-11, DOM21-12, DOM21-13, D0M21- 14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24 DOM21-25, DOM21-26, DOM21-27, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM
  • the antibody single variable domain and/or monovalent domain which specifically binds CD28, and/or antagonizes CD28 mediated signaling, and/or antagonizes CD28 mediated signaling without substantially agonizing CD28 activity, and/or competes for binding to CD28 with one or more of the D0M21 peptides described above, and/or comprises a sequence which is at least 70% identical to or at least 75% identical to one or more of the D0M21 peptides described above, inhibits binding to CD28 by CD80 and/or CD86, and in one aspect more strongly inhibits the binding to CD28 by CD86 relative to the binding to CD28 by CD80.
  • the antibody single variable domain inhibits the binding to CD28 by CD80 and/or CD86 with an IC 5O in the range of 50 pM up to and including 3.0 ⁇ M, ranging from about 5 nM, about 4 nM, about 3 nM, about 2.5 nM, about 2.0 nM, about 1.9 nM, about 1.8 nM, about 1.7 nM, about 1.6 nM, about 1.5 nM, about 1.4 nM, about 1.3 nM, about 1.2, nM, about 1.1 nM, about 1.0 nM, about 0.9 nM, about 0.8 nM, about 0.7 nM, about 0.6 nM, about 0.5 nM, about 0.4 nM, about 0.3 nM, about 0.2 nM, to about 0.1 nM.
  • the antagonist, monovalent domain and or single variable domain which specifically binds CD28 does not cross react with CTLA4.
  • the CD28 antagonist and/or antibody single variable domain has a CDRl sequence that is at least 50% identical to the CDRl sequence of the group consisting of DOM21-4, DOM21-18 and/or DOM21-28. In one embodiment the CD28 antagonist and/or antibody single variable domain has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of the group consisting of DOM21-4, DOM21-18 and/or DOM21-28. In one embodiment the CD28 antagonist and/or antibody single variable domain has a CDR3 sequence that is at least 50% identical to the CDR3 sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain has a CDRl sequence that is at least 50% identical to the CDRl sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28, and a CDR2 sequence that is at least 50% identical to the CDR2 sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain has a CDR2 sequence that is at least 50% identical to the CDR2 sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28, and a CDR3 sequence that is at least 50% identical to the CDR3 sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain has a CDRl sequence that is at least 50% identical to the CDRl sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28, and a CDR3 sequence that is at least 50% identical to the CDR3 sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain has a CDRl sequence that is at least 50% identical to the CDRl sequence selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28, and a CDR2 sequence that is at least 50% identical to the CDR2 sequence selected from the group consisting of DOM21-4, DOM21- 18 and/or DOM21-28, and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of selected from the group consisting of DOM21-4, DOM21-18 and/or DOM21-28.
  • the antagonist comprises an antibody single variable domain selected from the group consisting of: DOM21-4, DOM21-18 and DOM21-28, or an antibody single variable which is at least 50% identical to the amino acid sequence of an antibody single variable domain selected from the group consisting of: DOM21-4, DOM21-18 and DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain binds to the same epitope of CD28 bound by a antibody single variable domain selected from the group consisting of: DOM21-4, DOM21-18 and DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain binds to the same epitope of CD28 bound by an antibody single variable domain encoded by a nucleic acid molecule comprising a sequence selected from the group consisting of SEQ ID NOs: 1-57.
  • the CD28 antagonist and/or antibody single variable domain comprises one or more of CDRl, CDR2, and CDR3 from the group consisting of: DOM21-4, DOM21-18 and DOM21-28.
  • the CD28 antagonist and/or antibody single variable domain comprises one or more of CDRl, CDR2, and CDR3 of an antibody single variable domain polypeptide encoded by a nucleic acid sequence comprising a sequence selected from the group consisting of SEQ ID NOs: 1-57.
  • the CD28 antagonist and/or antibody single variable domain comprises two or more of CDRl, CDR2, or CDR3 of DOM21-4, DOM21-18 and/or DOM21-28. In one embodiment the CD28 antagonist and/or antibody single variable domain comprises two or more of CDRl, CDR2, and CDR3 of an antibody single variable domain polypeptide encoded by a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs: 1-57.
  • the CD28 antagonist and/or antibody single variable domain further comprises an additional antibody single variable domain or ligand binding site which specifically binds an antigen other than CD28.
  • the antigen other than CD28 is a T cell surface antigen, e.g., a T cell receptor.
  • the T cell receptor binds an antigen including a transplantation antigen and an autoantigen.
  • the autoantigen bound by the T cell receptor in T cells mediating an autoimmune disease includes but is not limited to the diseases of systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, diabetes, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.
  • the T cell receptor can recognize the antigen in the context of class II MHC.
  • the transplantation antigen is bound by the T cell receptor in T cells mediating a transplantation based disease selected from the group consisting of: allograft rejection, xenograft transplant rejection, and graft vs. host disease.
  • the antigen other than CD28 is serum albumin, e.g., human serum albumin.
  • the antagonist of CD28 further comprises PEG. PEG can be linked to said antibody single variable domain, e.g. through a cysteine or a lysine residue.
  • compositions comprising the CD28 antagonist and/or the antibody single variable domain, and a carrier.
  • the composition is a pharmaceutical composition
  • the carrier is a pharmaceutical carrier.
  • composition comprises a therapeutically-effective amount of said antagonist and/or antibody single variable domain.
  • a method of treating or preventing an autoimmune disease in an individual comprising administering the antagonist or composition thereof, of any one of the previous claims to said individual.
  • the autoimmune disease includes, but are preferably not limited to, systemic lupus erythematosis, multiple sclerosis, rheumatoid arthritis, diabetes, diabetes, psoriasis, scleroderma, atherosclerosis, inflammatory bowel disease, Crohn's disease, and ulcerative colitis.
  • a method of treating or preventing a transplantation disease in an individual the method comprising administering the CD28 antagonist or composition thereof, described herein.
  • the transplantation disease includes allograft rejection, xenograft transplant rejection, and graft vs. host disease.
  • the human antibody single variable domain dissociates from human CD28 with a K ⁇ i in the range of 50 nM to 1 pM, inclusive, as measured by surface plasmon resonance.
  • the K d for human CD28 can be 25 nM to 20 pM, 10 nM to 20 pM, 5 nm to 20 pM, 1 nM to 20 pM, 0.5 nM to 20 pM, 0.1 nM to 20 pM, 0.1 nM to 50 nM, 75 pM to 20 pM, 50 pM to 20 pM, or even 20 pM to 1 pM.
  • the antibody single variable domain inhibits the binding of CD28 to CD80. In another embodiment, the antibody single variable domain inhibits the binding of CD28 to CD86. In another embodiment, the antibody single variable domain preferably inhibits the binding of CD28 to CD86 relative to its inhibition of the binding of CD28 to CD80.
  • the binding of the antibody single variable domain to CD28 does not substantially agonize CD28 activity.
  • the human antibody single variable domain inhibits the binding of CD80 to CD28, and does not substantially agonize signaling by CD28. In another embodiment, the human antibody single variable domain inhibits the binding of CD86 to CD28, and does not substantially agonize signaling by CD28.
  • the human antibody single variable domain comprises an antibody single variable domain that binds CD28.
  • the human antibody single variable domain is PEG-linked.
  • the PEG is covalently linked to the human antibody single variable domain.
  • the PEG-linked human antibody single variable domain has a hydrodynamic size of at least 24 kD.
  • the PEG is linked to the antibody single variable domain at a cysteine or lysine residue.
  • the total PEG size is from 20 to 60 kD, inclusive.
  • the PEG-linked human antibody single variable domain has a hydrodynamic size of at least 200 kD.
  • the antibody single variable domain has an increased in vivo t- ⁇ or t- ⁇ half-life relative to the same antibody single variable domain composition lacking polyethylene glycol.
  • the t ⁇ -half -life of the antibody single variable domain composition is increased by 10% or more when compared to an unmodified protein assayed under otherwise identical conditions. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 50% or more. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 2X or more. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 5X or more, e.g., 1OX, 15X, 2OX, 25X, 3OX, 4OX, or more. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 50X or more.
  • the PEG-linked antibody single variable domain has a t ⁇ half- life of 0.25 to 6 hours, inclusive. In another embodiment, the t ⁇ half-life is in the range of 30 minutes to 12 hours, inclusive. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is in the range of 1 to 6 hours.
  • the t ⁇ -half -life of the antibody single variable domain composition is increased by 10% or more when compared to an unmodified protein assayed under otherwise identical conditions. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 50% or more. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 2X or more. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 5X or more, e.g., 10X, 15X, 2OX, 25X, 30X, 40X, or more. In another embodiment, the t ⁇ -half -life of the antibody single variable domain composition is increased by 5OX or more.
  • the antibody single variable domain composition has a t ⁇ half- life in the range of 1 hour to 1 month. In one embodiment, the antibody single variable domain composition has a t ⁇ half-life in the range of 12 hours to 4 weeks. In a preferred embodiment, the antibody single variable domain composition has a t ⁇ half-life of two weeks. In another embodiment, the t ⁇ -half -life is in the range of 12 to 48 hours, inclusive. In another embodiment, the t ⁇ - half -life is in the range of 12 to 26 hours, inclusive. In another embodiment the t ⁇ - half life of is at least 2 weeks.
  • the antibody single variable domain composition has a t ⁇ half-life in a range wherein the low end of the range is at least 12, 13, 14, 15, 20, 24, 36, 48, or 72 hours and the upper end of the range is up to 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days,
  • an antibody single variable domain composition has a t ⁇ half-life in the range of at least 12 hours up to 24 hours, 14 days, 28 days, 4 weeks, and up to one month.
  • a dAb containing composition comprising an antibody single variable domain having an AUC value (area under the curve) in the range of 1 mg.min/ml or more.
  • the lower end of the range is 5, 10, 15, 20, 30, 100, 200, or 300 mg.min/ml.
  • a ligand or composition has an AUC in the range of up to 600 mg.min/ml.
  • the upper end of the range is 500, 400, 300, 200, 150, 100, 75, or 50 mg.min/ml.
  • a ligand will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml,
  • the antibody single variable domains described herein can be linked to human serum albumin (HSA), which also has the effect of increasing the in vivo half - life of the molecule.
  • HSA human serum albumin
  • the human serum albumin coding sequences can be obtained by PCR using primers derived from the cDNA sequence available at GenBank Accession No. NM000477. Such coding sequences can be fused to the coding sequence for a monovalent anti-CD28 antibody single variable domain as described herein, and the fusion can be expressed by one of skill in the art.
  • the t ⁇ -half -life of the HSA-linked human antibody single variable domain composition is increased by 10% or more. In another embodiment, the t ⁇ -half - life of the HSA-linked human antibody single variable domain composition is in the range of 0.25 hours to 6 hours. In another embodiment, the t ⁇ -half -life of the HSA-linked human antibody single variable domain composition is increased by 10% or more. In another embodiment, the t ⁇ -half -life of the HSA-linked human antibody single variable domain composition is in the range of 12 to 48 hours. In another embodiment, the human antibody single variable domain which specifically binds CD28 comprises an amino acid sequence encoded by a polynucleotide having a sequence selected from the group consisting of SEQ ID NO: 1-57.
  • the human antibody single variable domain inhibits binding of CD28 to CD80 with an IC 50 in the range of 1 pM to 1.5 ⁇ M, inclusive; ICs 0 for inhibition of CD28 binding to CD80.
  • the IC 50 can be in the range of 1 pM to 1 ⁇ M, 1 pM to 900 nM, 1 pM to 800 nM, 1 pM to 700 nM, 1 pM to 600 nM, 1 pM to 500 nM, 1 pM to 400 nM, 1 pM to 300 nM, 1 pM to 200 nM, 1 pM to 100 nM, or 1 pM to 50 nM.
  • Further acceptable or preferred ranges include, for example, 50 pM to 1 ⁇ M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM, and 200 pM to 50 nM.
  • the human antibody single variable domain inhibits binding of CD28 to CD86 with an IC 50 in the range of 1 pM to 1.5 ⁇ M, inclusive; IC 50 for inhibition of CD28 binding to CD86.
  • the IC 50 can be in the range of 1 pM to 1 ⁇ M, 1 pM to 900 nM, 1 pM to 800 nM, 1 pM to 700 nM, 1 pM to 600 nM, 1 pM to 500 nM, 1 pM to 400 nM, 1 pM to 300 nM, 1 pM to 200 nM, 1 pM to 100 nM, or 1 pM to 50 nM.
  • Further acceptable or preferred ranges include, for example, 50 pM to 1 ⁇ M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM, and 200 pM to 50 nM.
  • the antibody single variable domain is fused to a second antibody single variable domain which binds a ligand other than CD28.
  • the human antibody single variable domain is free of an Fc domain.
  • the limits of an Fc domain are set out in Kabat et al. (1991, Sequences of Immunological Interest, 5 th ed. U.S. Dept. Health & Human Services, Washington, D.C.; incorporated herein by reference).
  • an Fc domain consists of the CH2-CH3 regions, optionally including a hinge region linked to the CH2.
  • a human antibody single variable domain which has an amino acid sequence at least 85% identical to an amino acid sequence encoded by a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOS: 1-57, which antibody single variable domain specifically and monovalently binds CD28.
  • an antigen-binding polypeptide is provided for, the polypeptide comprising an antibody single variable domain which specifically and monovalently binds CD28.
  • Another embodiment provides for a polypeptide comprising a moiety which specifically binds CD28, which moiety consists of an immunoglobulin single variable domain, preferably an antibody single variable domain.
  • the polypeptide consists of a human antibody single variable domain, preferably an antibody single variable domain.
  • polypeptide inhibits the binding of CD28 to CD80. In another embodiment, the polypeptide inhibits the binding of CD28 to CD86.
  • the polypeptide inhibits the binding of CD28 to CD80 and has an IC 50 in the range of 1 pM to 1.5 ⁇ M, inclusive.
  • the IC 50 can be in the range of 1 pM to 1 ⁇ M, 1 pM to 900 nM, 1 pM to 800 nM, 1 pM to 700 nM, 1 pM to 600 nM, 1 pM to 500 nM, 1 pM to 400 nM, 1 pM to 300 nM, 1 pM to 200 nM, 1 pM to 100 nM, or 1 pM to 50 nM.
  • Further acceptable or preferred ranges include, for example, 50 pM to 1 ⁇ M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM, and 200 pM to 50 nM.
  • the polypeptide inhibits the binding of CD28 to CD86 and has an IC 50 in the range of 1 pM to 1.5 ⁇ M, inclusive.
  • the IC 50 can be in the range of 1 pM to 1 ⁇ M, 1 pM to 900 nM, 1 pM to 800 nM, 1 pM to 700 nM, 1 pM to 600 nM, 1 pM to 500 nM, 1 pM to 400 nM, 1 pM to 300 nM, 1 pM to 200 nM, 1 pM to 100 nM, or 1 pM to 50 nM.
  • Further acceptable or preferred ranges include, for example, 50 pM to 1 ⁇ M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM, and 200 pM to 50 nM.
  • the binding of the polypeptide to CD28 does not substantially agonize CD28 activity.
  • the antibody single variable domain is a human antibody single variable domain, preferably a human antibody single variable domain.
  • the antibody single variable domain is a V H or a V L domain.
  • the polypeptide is PEG-linked. In one embodiment, the PEG is covalently linked. In one preferred embodiment, the PEG-linked antigen-binding polypeptide has a hydrodynamic size of at least 24 kD. In another preferred embodiment, the PEG is linked to the antigen-binding polypeptide at a cysteine or lysine residue. In another preferred embodiment, the total PEG size is from 20 to 60 kD, inclusive. In another preferred embodiment, the PEG-linked antigen-binding polypeptide has a hydrodynamic size of at least 20O kD.
  • the PEG-linked polypeptide has an increased in vivo half-life relative to the same polypeptide composition lacking linked polyethylene glycol.
  • the t ⁇ -half -life of the polypeptide composition is increased by 10% or more.
  • the t ⁇ -half -life of the polypeptide composition is increased by 50% or more.
  • the t ⁇ -half -life of the polypeptide composition is increased by 2X or more.
  • the t ⁇ -half -life of the polypeptide composition is increased by 5X or more, e.g., 10X, 15X, 2OX, 25X, 30X, 40X, or more.
  • the t ⁇ -half -life of the polypeptide composition is increased by 50X or more.
  • the PEG-linked antibody single variable domain has a t ⁇ half- life of 0.25 to 6 hours, inclusive. In another embodiment, the t ⁇ half-life is in the range of 30 minutes to 12 hours, inclusive. In another embodiment, the t ⁇ -half -life of the polypeptide composition is in the range of 1 to 6 hours.
  • the t ⁇ -half -life of the polypeptide composition is increased by 10% or more. In another embodiment, the t ⁇ -half -life of the polypeptide composition is increased by 50% or more. In another embodiment, the t ⁇ -half -life of the polypeptide composition is increased by 2X or more. In another embodiment, the t ⁇ -half -life of the polypeptide composition is increased by 5X or more, e.g., 10X, 15X, 2OX, 25X, 30X, 40X, ⁇ or more. In another embodiment, the t ⁇ -half -life of the polypeptide composition is increased by 5OX or more.
  • the antibody single variable domain composition has a t ⁇ half- life of 1 to 170 hours, inclusive. In another embodiment, the t ⁇ -half -life is in the range of 12 to 48 hours, inclusive. In another embodiment, the t ⁇ -half -life is in the range of 12 to 26 hours, inclusive.
  • the antibody single variable domain composition has a t ⁇ half-life in a range wherein the low end of the range is at least 12, 13, 14, 15, 20, 24, 36, 48, or 72 hours and the upper end of the range is up to 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, and up to 31 days.
  • an antibody single variable domain composition has a t ⁇ half-life in the range of at least 12 hours up to 24 hours, 14 days, 28 days, 4 weeks, and up to one month.
  • the composition has an AUC value (area under the curve) in the range of 1 mg.min/ml or more.
  • the lower end of the range is 5, 10, 15, 20, 30, 100, 200, or 300 mg.min/ml.
  • a ligand or composition has an AUC in the range of up to 600 mg.min/ml.
  • the upper end of the range is 500, 400, 300, 200, 150, 100, 75, or 50 mg.min/ml.
  • a ligand will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50 mg.min/ml.
  • the antibody single variable domain is linked to human serum albumin (HSA).
  • HSA human serum albumin
  • the antibody single variable domain has an increased in vivo half-life relative to the same polypeptide composition lacking linked HSA.
  • the antibody single variable domain has a t ⁇ -half -life that is increased by 10% or more relative to a molecule lacking linked HSA.
  • the t ⁇ -half -life of the polypeptide composition is in the range of 0.25 minutes to 6 hours.
  • the t ⁇ -half -life of the polypeptide composition is increased by 10% or more.
  • the t ⁇ -half -life is in the range of 12 to 48 hours.
  • the antibody single variable domain linked to HSA has a t ⁇ -half -life of at least 50% of the t ⁇ -half -life of HSA alone in a mammal; preferably a primate; preferably a human.
  • the antibody single variable domain linked to HSA has a t ⁇ -half -life of at least 60%, 70%, 80%, 90% and up to 100% or more of the t ⁇ -half -life of HSA alone in a mammal, such as a primate or human.
  • the antigen-binding polypeptide comprises an amino acid sequence encoded by a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs: 1-57.
  • an antibody single variable domain has an amino acid sequence at least 50% identical to an amino acid sequence encoded by a polynucleotide having a sequence selected from the group consisting of SEQ ID NOs: 1-57, which polypeptide specifically and monovalently binds CD28.
  • an antibody single variable domain has an amino acid sequence at least 85% identical to an amino acid sequence encoded by a polynucleotide having a sequence selected from the group consisting of SEQ ID NOs: 1-57, which polypeptide specifically and monovalently binds CD28.
  • an antibody single variable domain antagonizes the binding of CD80 to CD28. In one embodiment, the an antibody single variable domain antagonizes the binding of CD86 to CD28.
  • the an antibody single variable domain inhibits the binding of CD80 to CD28 and has an IC 50 in the range of 1 pM to 1.5 ⁇ M, inclusive.
  • the IC50 can be in the range of 1 pM to 1 ⁇ M, 1 pM to 900 nM, 1 pM to 800 nM, 1 pM to 700 nM, 1 pM to 600 nM, 1 pM to 500 nM, 1 pM to 400 nM, 1 pM to 300 nM, 1 pM to 200 nM, 1 pM to 100 nM, or 1 pM to 50 nM.
  • Further acceptable or preferred ranges include, for example, 50 pM to 1 ⁇ M, 100 pM to 500 nM, 125 pM to 250 nM, 150 pM to 200 nM, 150 pM to 100 nM, and 200 pM to 50 nM.
  • the an antibody single variable domain inhibits the binding of CD86 to CD28 and has an IC 50 in the range of 1 pM to 1.5 ⁇ M, inclusive.
  • the IC50 can be in the range of 1 pM to 1 ⁇ M, 1 pM to 900 nM, 1 pM to 800 nM, 1 pM to 700 nM, 1 pM to 600 nM, 1 pM to 500 nM, 1 pM to 400 nM, 1 pM to 300 nM, 1 pM to 200 nM, 1 pM to 100 nM, or 1 pM to 50 nM.
  • an antibody single variable domain inhibits the interaction of CD80 with CD28, but does not substantially agonize intracellular signaling by CD28.
  • the antigen-binding polypeptide further comprises a second antibody single variable domain which binds a ligand other than CD28.
  • a CD28 antagonist comprising an antibody single variable domain which specifically and monovalently binds CD28 and which comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.
  • the amino acid sequences of FWl, FW2, FW3, and FW4 of the anti- CD28 antibody single variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FWl, FW2, FW3, and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.
  • the amino acid sequences of FWl, FW2, and FW3 of the anti-CD28 variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.
  • the human germline antibody gene segment can be selected from the group consisting of DP47, DP45, DP48, and DPK9.
  • a method of antagonizing the binding of CD80 to CD28 in an individual comprising administering a monovalent anti-CD28 antibody single variable domain as described herein to the individual, wherein the polypeptide antagonizes the binding of CD80 to CD28 in the individual.
  • a method of antagonizing the binding of CD86 to CD28 in an individual comprises administering a monovalent anti-CD28 antibody single variable domain as described herein to the individual, wherein the polypeptide antagonizes the binding of CD86 to CD28 in the individual.
  • a method of antagonizing an activity of CD28 in an individual comprises administering a monovalent anti-CD28 antibody single variable domain as described herein to the individual, wherein the polypeptide antagonizes an activity of CD28.
  • a composition comprising an extended release formulation comprises an immunoglobulin single variable domain, including, but not limited to, a polypeptide comprising a an antibody single variable domain that binds CD28.
  • the immunoglobulin single variable domain is a non-human mammalian antibody single variable domain.
  • the immunoglobulin single variable domain is a human antibody single variable domain.
  • a method of treating or preventing a disease or disorder mediated by CD28 in an individual in need of such treatment comprises administering to the individual a therapeutically effective amount of a composition comprising a monovalent anti-CD28 single human immunoglobulin variable domain, including a composition comprising an antibody single variable domain that binds CD28, whereby reducing the degree of immune system activation would reduce or prevent symptoms.
  • a composition comprising a monovalent anti-CD28 single human immunoglobulin variable domain, including a composition comprising an antibody single variable domain that binds CD28, whereby reducing the degree of immune system activation would reduce or prevent symptoms.
  • An area of particular interest is the prevention of organ transplant rejection (e.g., allograft/xenograft rejection).
  • the disease or disorder is an autoimmune disease or disorder.
  • a method of treating or preventing a symptom of systemic lupus erythematosus (SLE) in an individual comprises administering a monovalent anti-CD28 antibody single variable domain to said individual in an amount effective to treat or prevent a symptom of systemic lupus erythematosis (SLE).
  • Another method for reducing or alleviating a symptom of a disease such as multiple sclerosis, rheumatoid arthritis, allograft rejection, xenograft rejection, and Type I diabetes, and inflammatory bowel disease (IBD) , comprising administering a monovalent anti-CD28 antibody single variable domain to an individual having or suspected of having such a disease, in an amount effective to treat or prevent the disease or a symptom of the disease.
  • An antibody single variable domain that is monovalent for binding to CD28 comprises a universal antibody framework.
  • the universal antibody framework comprises a VH framework selected from the group consisting of DP47, DP45, and DP38, and/or the VL framework is DPK9.
  • the antibody single variable domain comprises a generic ligand binding site.
  • the generic ligand binding site binds a generic ligand selected from the group consisting of protein A, protein L, and protein G.
  • the antibody single variable domain comprises a variable domain having one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequences of one or more of the framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of the corresponding framework region encoded by a human germline antibody gene segment.
  • the antibody single variable domain comprises a variable domain, wherein the amino acid sequences of FWl, FW2, FW3, and FW4 are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the antibody sequences of FWl, FW2, FW3, and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by the human germline antibody gene segment.
  • the antibody single variable domain comprises an antibody variable domain comprising FWl, FW2, and FW3 regions, and the amino acid sequence of said FWl, FW2, and FW3 are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.
  • the human germline antibody gene segment is selected from the group consisting of DP47, DP45, DP48, and DPK9.
  • An antibody single variable domain polypeptide that binds to CD28 has an amino acid sequence that is identical to the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-57, or differs from the selected amino acid sequence at no more than 25 amino acid positions and has a sequence that is at least 50% identical to the selected sequence. In one embodiment, the antibody single variable domain polypeptide differs from the selected amino acid sequence at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
  • the antibody single variable domain polypeptide is at least 50% identical to the selected sequence, for example, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, and up to and including 96%, 97%, 98%, or 99% identical.
  • one or more of the CDR regions of an antibody single variable domain polypeptide is at least 50% identical to the selected sequence, for example, at least 50% identical, at least 55% identical, at least 60% identical, at least 65% identical, at least 70% identical, at least 80% identical, at least 85% identical, at least 90% identical, at least 95% identical, and up to and including 96%, 97%, 98%, or 99% identical.
  • the invention includes an antibody single variable domain polypeptide that binds to CD28, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM21-4, or differs from the amino acid sequence of DOM21-4 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4, or has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4, or has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-4, or differs from the amino acid sequence of DOM21-4 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4 and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4 .
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-4, or differs from the amino acid sequence of DOM21-4 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4 .
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-4, or differs from the amino acid sequence of DOM21-4 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4 .
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-4, or differs from the amino acid sequence of DOM21-4 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4 and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4.
  • the antibody single variable domain polypeptide that binds to CD28 differs form the amino acid sequence of DOM21-4 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4.
  • the invention also includes a CD28 antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4.
  • the invention also includes a CD28 antagonist having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4 and a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4.
  • the invention also includes a CD28 antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-4 and a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-4 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-4.
  • the invention includes an antibody single variable domain polypeptide that binds to CD28, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM21-18, or differs from the amino acid sequence of DOM21-18 at no more than 25 amino acid positions and has a sequence that is at least 80% identical to the sequence of DOM21-18.
  • the antibody single variable domain polypeptide differs form the amino acid sequence of DOM21-18 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
  • the antibody single variable domain polypeptide is at least 80% identical to the sequence of DOM21-18, for example, at least 85% identical, at least 90% identical, at least 95% identical, and up to and including 96%, 97%, 98%, or 99% identical.
  • the invention includes an antibody single variable domain polypeptide that binds to CD28, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM21-4, or differs from the amino acid sequence of DOM21-18 at no more than 25 amino acid, positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18, or has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18, or has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of D0M21-18.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-18, or differs from the amino acid sequence of DOM21-18 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18 and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-18, or differs from the amino acid sequence of DOM21-18 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-18, or differs from the amino acid sequence of DOM21-18 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-18, or differs from the amino acid sequence of DOM21-18 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18 and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the antibody single variable domain polypeptide that binds to CD28 differs form the amino acid sequence of DOM21-18 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18.
  • the invention also includes a CD28 antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18.
  • the invention also includes a CD28 antagonist having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18 and a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18.
  • the invention also includes a CD28 antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-18 and a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-18 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-18.
  • the invention includes an antibody single variable domain polypeptide that binds to CD28, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM21-28, or differs from the amino acid sequence of DOM21-28 at no more than 25 amino acid positions and has a sequence that is at least 80% identical to the sequence of DOM21-28.
  • the antibody single variable domain polypeptide differs form the amino acid sequence of DOM21-28 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
  • the antibody single variable domain polypeptide is at least 80% identical to the sequence of DOM21-28, for example, at least 85% identical, at least 90% identical, at least 95% identical, and up to and including 96%, 97%, 98%, or 99% identical.
  • the invention includes an antibody single variable domain polypeptide that binds to CD28, wherein the polypeptide has an amino acid sequence that is identical to the amino acid sequence of DOM21-28, or differs from the amino acid sequence of DOM21-28 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28, or has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28, or has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-28, or differs from the amino acid sequence of DOM21-28 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28 and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-28, or differs from the amino acid sequence of DOM21-28 at no more than 25 amino acid positions and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-28, or differs from the amino acid sequence of DOM21-28 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the invention also includes an antibody single variable domain polypeptide that binds CD28, wherein the dAb has an amino acid sequence that is identical to the amino acid sequence of DOM21-28, or differs from the amino acid sequence of DOM21-28 at no more than 25 amino acid positions and has a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28 and has a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28 and has a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the antibody single variable domain polypeptide that binds to CD28 differs form the amino acid sequence of DOM21-28 at 25 or fewer amino acid positions, 20 or fewer amino acid positions, 15 or fewer amino acid positions, 10 or fewer amino acid positions, 5 or fewer amino acid positions, 2 or fewer amino acid positions, or as few as one amino acid position.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28.
  • the invention also includes a CD28 antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28.
  • the invention also includes a CD28 antagonist having a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28 and a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28.
  • the invention also includes a CD28 antagonist having a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • the invention also includes a CD28 antagonist having a CDRl sequence that is at least 50% identical to the CDRl sequence of DOM21-28 and a CDR2 sequence that is at least 50% identical to the CDR2 sequence of DOM21-28 and a CDR3 sequence that is at least 50% identical to the CDR3 sequence of DOM21-28.
  • an antagonist of CD28 which either contains or consists of a monovalent polypeptide domain which specifically binds CD28 and which competes for binding to CD28 with an antibody single variable domain selected from the group consisting of D0M21- 4, DOM21-18, DOM21-28, DOM21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, D0M21- 7, DOM21-8, DOM21-9, DOM21-10, D0M21-11, DOM21-12, DOM21-13, DOM21-14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24 DOM21-25, DOM21-26, DOM21-27, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36, DOM21-37,
  • an antagonist of CD28 which either contains or consists of a monovalent polypeptide domain which specifically binds CD28 and which comprises an amino sequence which is at least 70% identical to an amino acid sequence of an antibody single variable domain selected from the group consisting of: DOM21-4, DOM21-18, DOM21-28, D0M21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, DOM21-7, DOM21-8, DOM21-9, DOM21-10, D0M21-11, DOM21-12, DOM21-13, DOM21-14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24 DOM21-25, DOM21-26, DOM21-27, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence that is at least 50% identical to the amino acid sequence of a CDRl of a single variable domain selected from the group consisting of the V L antibody single variable domains of: DOM21-18, DOM21-27, DOM21-28 and DOM21-58.
  • the CDRl amino acid sequence can contain or consist of any of the following amino acid sequences and/or motifs: RASQ, RASQX 1 I, wherein Xj is any amino acid or Xj is an amino acid selected from the group consisting of Y, S and N; RASQXiIG, wherein Xi is any amino acid or Xi is an amino acid selected from the group consisting of Y, S and N; RASQX I IGX 2 X S L, wherein Xi is any amino acid or X 1 is an amino acid selected from the group consisting of Y, S and N, and/or where X 2 is any amino acid or is an amino acid selected from the group consisting of: T, H and D.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence that is at least 50% identical to the CDRl amino acid sequence of a V H antibody single variable domain selected from the group consisting of: DOM21-4, DOM21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, DOM21-7, DOM21-8, DOM21-9, DOM21-10, DOM21-11, DOM21-12, DOM21-13, DOM21-14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24 DOM21-25, DOM21-26, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36, DOM21-37, DOM21-38, DOM21-39,
  • the monovalent polypeptide domain which specifically binds CD28 has a CDR2 amino acid sequence that is at least 50% identical to the amino acid sequence of a CDR2 of a V L single variable domain selected from the group consisting of: DOM21-18, DOM21-27, DOM21-28 and DOM21-58.
  • the CDR2 can contain or consist of any of the following amino acid sequences and/or motifs: X 3 SX b LQS wherein X 3 is any amino acid and/or X b is any amino acid, and/or X 3 is an amino acid selected from the group consisting of: A and I, and/or wherein X b is an amino acid selected from the group consisting of: I, L and R; QASLLQS, RASILQS, WASLLQS and RISRLQS.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDR2 amino acid sequence that is at least 50% identical to the CDR2 amino acid sequence of a V H single variable domain selected from the group consisting of: DOM21-4, DOM21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, DOM21-7, DOM21-8, DOM21-9, DOM21-10, DOM21-11, DOM21-12, DOM21-13, DOM21-14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24 DOM21-25, DOM21-26, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36, DOM21-37, DOM21-38, DOM21-39, DOM
  • the CDR2 can contain or consist of any of the following amino acid sequences and/or motifs: YYADSVKG, TYYAD, TYY, TYYA, TYYADS, TYYADSV, TYYADSVK and TYYADSVKG, wherein T is at Kabat position 57, and wherein YY is at Kabat position 58 and 59, respectively; and/or a T at Kabat position 57, and/or a Y at Kabat position 58, and/or a Y at Kabat position 59.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDR3 amino acid sequence that is at least 50% identical to the amino acid sequence of a CDR3 of a V L single variable domain selected from the group consisting of: DOM21-18, DOM21-27, DOM21-28 and DOM21-58.
  • the CDR3 can contain or consist of any of the following amino acid sequences and/or motifs: QQX c X d X e X f PX g T, wherein each of X 0 , Xd, Xe, Xf and X g is any amino acid, and/or wherein Xc is selected from the group consisting of L, T, G and F, and/or X d is selected from the group consisting of: A, T, M and G, and/or X e is selected from the group consisting of L and T, and/or Xf is selected from the group consisting of: R, Q, T and Y, and X g is selected from the group consisting of M, F and T.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence selected from the group consisting of: RASQYIGTSLN, RASQSIGTGLR, RASQSISHSLV and RASQNIGDRLH, a CDR2 amino acid sequence selected from the group consisting of: QASLLQS, RASILQS, WASLLQS and RISRLQS, and a CDR3 amino acid sequence selected from the group consisting of:QQLALRPMT, QQTTLQPFT, QQGMTTPFT and QQFGLYPTT.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence of RASQYIGTSLN, a CDR2 amino acid sequence of QASLLQS, and a CDR3 amino acid sequence of QQLALRPMT.
  • the monovalent polypeptide domain which specifically binds CD28 has a has a CDRl amino acid sequence of RASQSIGTGLR, a CDR2 amino acid sequence of RASILQS, and a CDR3 amino acid sequence of QQTTLQPFT.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence of RASQSISHSLV, a CDR2 amino acid sequence of WASLLQS, and a CDR3 amino acid sequence of QQGMTTPFT.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence of RASQNIGDRLH, a CDR2 amino acid sequence of RISRLQS, and a CDR3 amino acid sequence of QQFGLYPTT.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDR3 amino acid sequence that is at least 50% identical to the CDR3 amino acid sequence of a V H single variable domain selected from the group consisting of DOM21-4, DOM21-1, DOM21-2, DOM21-3, DOM21-5, DOM21-6, DOM21-7, DOM21-8, DOM21-9, DOM21-10, D0M21-11, DOM21-12, DOM21-13, DOM21-14, DOM21-15, DOM21-16, DOM21-17, DOM21-19, DOM21-20, DOM21-21, DOM21-22, DOM21-23, DOM21-24 DOM21-25, DOM21-26, DOM21-29, DOM21-30, DOM21-31, DOM21-32, DOM21-33, DOM21-34, DOM21-35, DOM21-36, DOM21-37, DOM21-38, DOM21-39, DOM
  • the CDR3 can contain or consist of any of the following amino acid sequences and/or motifs: FDY, wherein D is at Kabat position 101and/or F at Kabat position immediately preceding Kabat position 101, and/or a D at Kabat position 101, and/or a Y at Kabat position 102; and/or first residue of said CDR amino acid sequence is selected from the group consisting of K, E and Q.
  • the monovalent polypeptide domain which specifically binds CD28 has a CDRl amino acid sequence of RYHMA, a CDR2 amino acid sequence of VIDSLGLQTYYADSVKG, and a CDR3 amino acid sequence of EYGGAFDY.
  • the monovalent polypeptide domain which specifically binds CD28 has a VL FRl amino acid sequence that can contain or consist of any of the following amino acid sequences and/or motifs: DIQMTQSPSSLSASVGDRVTITC, and/or has a VL FR2 amino acid sequence comprising WYQQKPGKAPX h LLXiY, wherein each of X h and Xj is any amino acid and/or where X h is selected from the group consisting of: K and M, and/or wherein X; is selected from the group consisting of T and I; and/or a VL FR3 amino acid sequence comprising GVPSRFSGSGSGTDFTLTISSLQPEDF ATYYC, and/or a VL FR4 amino acid sequence comprising FGQGTKVEIKR.
  • the monovalent polypeptide domain which specifically binds CD28 has a VH FRl amino acid sequence that can contain or consist of any of the following amino acid sequences and/or motifs: QLL at Kabat positions 3, 4 and 5, respectively, according to the Kabat numbering system, and/or FTFX j , located at the carboxyl terminus of said FRl, where X j is selected from the group consisting of: E, I, G, T, S, D, R, P, N, A and K, and/or VXLLE, EVXLLE, EVXLLES, wherein optionally X is Q; LLES, LLESG, LLESGG 5 EVQLLESGGGLVQPGGSLRLSCAASGFTF,
  • E is at Kabat position 6 and and/or a L at Kabat position 5, and/or Q at position 3; and/or has a VH FRl with a L at position 5; and/or has a FR2 with a V or an A at position 37 and/or a G at position 44, and/or a W at position 47, and/or GLEW at positions 44-47, and/or VXXXXXGLEW or AXXXXXGLEW, wherein X is any amino acid and A is at Kabat position 37, and/or: VRQ APGKGLEW, AVRQAPGKGLEW and/or AVRQAPGKGLEWVS; and/or a FR3 with a S at position 74, and/or TLY at positions 77-79, and/or a T at position 77, and/or a L at position 78, and/or a Y at position 79, and
  • the monovalent polypeptide domain which specifically binds CD28 is fused to a heterologous protein or molecule.
  • a CD28 antagonist has a CDRl sequence that is at least 50% identical to the CDRl sequence of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-57. In one embodiment, a CD28 antagonist has a CDRl sequence that is at least 50% identical to the CDR2 sequence of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-57. In one embodiment, a CD28 antagonist has a CDRl sequence that is at least 50% identical to the CDR3 sequence of the amino acid sequence selected from the group consisting of SEQ ID NOs: 1-57.
  • the CD28 antagonist inhibits the binding of CD80 to CD28, and/or inhibits the binding of CD80 to CD28, and/or inhibits an activity of CD28.
  • a dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD28 and binding of the second single variable domain to the second antigen acts to increase the half-life of the ligand in vivo.
  • the dual specific ligand is a four chain IgG antibody, wherein at least one chain comprises an antibody single variable domain which specifically binds CD28.
  • At least one chain of the four chain IgG comprises an antibody single variable domain which specifically binds CD28 and at least one chain comprises a single domain such as an antibody single variable domain which independently specifically binds a second molecule, such as a T cell receptor.
  • at least one chain of the four chain IgG comprises an antibody single variable domain which specifically binds CD28 and at least a pair of chains such as a heavy and light chain pair which cooperatively specifically binds a second antigen, such as a T cell receptor.
  • the binding of the T cell receptor can be to the T cell receptor itself or to an epitope formed by the interaction of a T cell receptor and the antigen presented by the T cell receptor.
  • a dual specific ligand comprising an anti-human CD28 antibody single variable domain and an anti-SA antibody single variable domain.
  • the dAbs or antibody single variable domains are camelid V HH domains.
  • first and second antibody single variable domains are heavy chain variable domains; or (ii) the first and the second antibody variable domains are light chain variable domains.
  • the ligand is provided as an IgG immunoglobulin comprising four heavy chain single variable domains or four light chain single variable domains.
  • the heavy chain can comprise camelid V HH domains.
  • the first and second domains bind independently, such that the dual specific ligand may simultaneously bind both the first and second antigens.
  • the first single variable domain has a dissociation constant (Kd) of IxIO '7 M or less for human CD28, and a K o g-rate constant of lxlO "2 s "1 or less, as determined by surface plasmon resonance.
  • the second single variable domain is specific for serum albumin (SA) and has a dissociation constant (K d ) of InM to 500 ⁇ m for SA, as determined by surface plasmon resonance.
  • SA serum albumin
  • K d dissociation constant
  • the second domain binds SA in a standard ligand binding assay with an IC50 of 1 nM to 500 ⁇ M.
  • the second single variable domain may be specific for SA, and comprise the amino acid sequence of MSA-16 (SEQ ID NO:323) or a sequence that is at least 80% identical thereto.
  • the second single variable domain may be specific for SA, and comprise the amino acid sequence of MSA-26 (SEQ ID NO: 325) or a sequence that is at last 80% identical thereto.
  • the anti-CD28 variable domain or dAb comprises a universal framework.
  • the anti-CD28 variable domain or dAb may also comprise a V H framework selected from the group consisting of DP47, DP45 and DP38; or a V L framework which is DPK9.
  • the dual specific ligand or dAb can comprise a binding site for a generic ligand.
  • the generic ligand binding site is selected from the group consisting of protein A, protein L and protein G binding site.
  • the anti-CD28 variable domain or dAb comprises one or more framework regions comprising an amino acid sequence that is the same as the amino acid sequence of a corresponding framework region encoded by a human germline antibody gene segment, or the amino acid sequence of one or more of said framework regions collectively comprises up to 5 amino acid differences relative to the amino acid sequence of said corresponding framework region encoded by a human germline antibody gene segment.
  • the amino acid sequences of FWl, FW2, FW3, and FW4 of the anti- CD28 variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by a human germline antibody gene segment, or the amino acid sequences of FWl, FW2, FW3, and FW4 collectively contain up to 10 amino acid differences relative to the amino acid sequences of corresponding framework regions encoded by said human germline antibody gene segment.
  • the amino acid sequences of said FWl, FW2, and FW3 of the anti- CD28 variable domain or dAb are the same as the amino acid sequences of corresponding framework regions encoded by human germline antibody gene segments.
  • the human germline antibody gene segments may be selected from the group consisting of DP47, DP45, DP48, and DPK9.
  • the germline gene segment is selected from the group consisting of DP47 and DPK9.
  • a method for producing a dual specific ligand as described herein comprising a first immunoglobulin single variable domain having a binding specificity for CD28 and a second single immunoglobulin single variable domain having a binding specificity for a protein which increases the half-life of the ligand in vivo, the method comprising the steps of: selecting a first variable domain by its ability to bind CD28; selecting a second variable domain by its ability to bind to said protein; combining the variable domains; and selecting the ligand by its ability to bind to CD28 and said protein.
  • the first variable domain is selected for binding to CD28 in absence of a complementary variable domain.
  • nucleic acid encoding a dual specific ligand described herein.
  • the nucleic acid may comprise the nucleic acid sequence of MSA- 16 or a sequence that is at least 80% identical thereto, or alternatively may comprise, the nucleic acid sequence of MSA-26 or a sequence that is at least 70% identical thereto.
  • the nucleic acid may be incorporated into a vector, which may be incorporated into a host cell.
  • a pharmaceutical composition comprising a dual specific ligand as described herein and a pharmaceutically acceptable excipient, carrier s or diluent.
  • a dAb monomer specific for CD28 which monomer has a dissociation constant (Kd) of IxIO "8 M or less for human CD28, and a K off rate constant of IxIO "3 s "1 or less, as determined by surface plasmon resonance.
  • the dAb monomer specific for CD28 has a dissociation constant (Ka) of 1x10 "7 M or less, as determined by surface plasmon resonance.
  • the dAb monomer has binding specificity to CD28 with a dissociation constant (IQ) of 1x10 "8 M or less, as determined by surface plasmon resonance.
  • IQ dissociation constant
  • the dAb monomer has binding specificity to CD28 with a dissociation constant (K ⁇ i) of 50 nM to 20 pM, as determined by surface plasmon resonance.
  • the monomer inhibits binding of CD80 to CD28 with an IC50 of 50 nM or less. In one embodiment, the monomer inhibits binding of CD86 to CD28 with an IC50 of 50 nM or less.
  • the dAb monomer has binding specificity to CD28 with a Kofr rate constant of IxIO "3 s '1 or less, IxIO "4 s “1 or less, IxIO "5 s “1 or less, or IxIO "6 s “1 or less, as determined by surface plasmon resonance.
  • the dAb monomer neutralizes CD28 in a standard assay with an ND50 of 50nM or less.
  • a dual specific ligand comprising first and second heavy chain single variable domains, or first and second light chain single variable domains, wherein the first variable domain is an anti-CD28 dAb monomer.
  • the second variable domain has binding specificity for an antigen other than CD28.
  • a dual specific ligand comprising a first immunoglobulin single variable domain having a binding specificity to a first antigen and a second single variable domain having a binding activity to a second antigen, wherein the first antigen is CD28 and the second single variable domain is an Antigen Presenting Cell surface antigen or a T cell surface antigen.
  • the Antigen Presenting Cell surface antigen can be selected from one of the group consisting of dendritic cell surface antigens, activated macrophage surface antigens, activated B cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC antigens.
  • the MHC antigen is a MHC class II antigen
  • the class II antigen can be the alpha and/or beta chain.
  • the Antigen Presenting Cell surface antigen or a T cell surface antigen may be selected from the group consisting of CD40, CD40L, Inducible costimulatory molecule (ICOS), CD27, CD30, OX40, CD45, CD69, CD3, CD70, Inducible costimulatory molecule ligand (ICOSL), OX40L, CD80, CD86, HVEM (Herpes Virus Entry Mediator), and LIGHT, including one of CD40L, Inducible costimulatory molecule (ICOS) 5 CD27, CD30, OX40, CD45, CD69, or CD3.
  • An exemplary surface antigen is a B7 gene surface antigen such as CD86 or CD80.
  • the invention provides a domain antibody that binds to CD28, the antibody having at least three characteristics selected from the group consisting of: prevents CD80 and CD86 binding to CD28; does not cross-react with CTLA4; has a t ⁇ half-life of about 15 seconds to about 12 hours; and has a t ⁇ half-life of about 12 hours to about 96 hours.
  • an antagonist of CD28 as described herein has a serum t ⁇ half-life in the range of aboutl2 hours to about 31 days. In a further embodiment, an antagonist of CD28 has a serum t ⁇ half-life in the range of about 12 hours to about 28 days. In a still further embodiment, an antagonist of CD28 has a serum t ⁇ half-life in the range of about 12 hours to about 14 days.
  • the invention provides a nanobody that modulates, inhibits, prevents or blocks the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell.
  • APC antigen presenting cell
  • the nanobody can be directed against and/or that can specifically bind to a target on a T- cell. In one embodiment, the nanobody inhibits and/or blocks T-cell activation. In one embodiment, the nanobody inhibits and/or blocks cytokine production. In a further embodiment, the nanobody decreases T-cell survival. In a still further embodiment, the nanobody decreases the differentiation of naive T-cells into activated cytokine secreting T-cells.
  • the binding target of the nanobody belongs to the B7:CD28 superfamily.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-1 (CD80) with CD28.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28, while the interaction of B7-1 with CTLA4 is not modulated, inhibited or prevented.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-2 (CD86) with CD28.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-2 with CD28, while the interaction of B7-2 with CTLA4 is not modulated, inhibited or prevented.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28 and the interaction of B7-2 with CD28.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28, while the interaction of B7-2 with CD28 is not modulated, inhibited or prevented.
  • the nanobody modulates, inhibits, prevents and/or blocks the interaction of B7-2 with CD28, while the interaction of B7-1 with CD28 is not modulated, inhibited or prevented.
  • the nanobody can specifically bind to an APC target or a T-cell target with a dissociation constant (K D) of 10 '5 to 10 "12 moles/litre or less, and preferably 10 "7 to 10 '12 moles/litre or less and more preferably 10 ⁇ 8 to 10 "12 moles/litre.
  • K D dissociation constant
  • the nanobody can specifically bind to an APC target or a T-cell target with a rate of association (kon-rate) of between 10 2 M “1 S “1 to about 10 7 M “ ' S “1 , preferably between 10 3 M '1 S “1 and 10 7 M “1 S “1 , more preferably between 10 4 M -1 S “1 and 10 7 M -1 S “1 , such as between 10 5 14 "1 S “1 and 10 7 M -1 S “1 .
  • a rate of association of between 10 2 M “1 S “1 to about 10 7 M " ' S “1 , preferably between 10 3 M '1 S “1 and 10 7 M “1 S “1 , more preferably between 10 4 M -1 S “1 and 10 7 M -1 S “1 , such as between 10 5 14 "1 S “1 and 10 7 M -1 S “1 .
  • the nanobody can specifically bind to an APC target or a T-cell target with a rate of dissociation (koff rate) between I s "1 and 10 "6 S “1 preferably between 10 "2 s ⁇ l and 10 "6 s ⁇ l , more preferably between 10 "3 S “1 and 10 "6 s “! , such as between 10 "4 S “1 and 10 " 6 S “1 .
  • rate of dissociation koff rate
  • the nanobody can specifically bind to an APC target or a T-cell target with an affinity less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM.
  • the nanobody is a naturally occurring Nanobody (from any suitable species) or a synthetic or semi-synthetic Nanobody.
  • the nanobody is a V HH sequence, a partially humanized V HH sequence, a fully humanized V HH sequence, a camelized heavy chain variable domain or an Nanobody that has been obtained by techniques such as affinity maturation.
  • the nanobody i) has at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 115-136, in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences are disregarded; and in which: ii) preferably one or more of the amino acid residues at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to the Kabat numbering are chosen from the Hallmark residues mentioned in Figure 7.
  • the nanobody i) has at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 137-156, 183-187, 188-193, 194-200, 201- 207, 208-213, or 214-317 in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences are disregarded; and in which: ii) preferably one or more of the amino acid residues at positions 11, 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to the Kabat numbering are chosen from the Hallmark residues mentioned in Figure 7.
  • CDRl is chosen from the group consisting of: a) the amino acid sequences of SEQ ID NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ED NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 335-340; and/or - CDR2 is chosen from the group consisting of: d) the amino acid sequences of SEQ ED NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 347-352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 347-352; and/or CDR3 is chosen from the group consisting of: a) the amino acid sequences of S
  • CDRl is chosen from the group consisting of: a) the amino acid sequences of SEQ ID NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ED NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 335-340; and CDR2 is chosen from the group consisting of: d) the amino acid sequences of SEQ ID NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 347-352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ED NO's: 347-352; and CDR3 is chosen from the group consisting of: g) the amino acid sequences of SEQ ID NO's:
  • the CDR sequences have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ ID NO's: 207-212.
  • a nanobody is chosen from the group consisting of SEQ ID NO's: 207-212 or from the group consisting of from amino acid sequences that have more than 80%, preferably more than 90%, more preferably more than 95%, such as 99% or more sequence identity (as defined herein) with at least one of the amino acid sequences of SEQ ED NO's: 207- 212.
  • the nanobody is chosen from the group consisting of SEQ ED NO's: 207-212.
  • the invention also provides an amino acid sequence that modulates, inhibits, prevents or blocks the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell.
  • APC antigen presenting cell
  • the amino acid sequence is directed against and/or that can specifically bind to a target on an APC.
  • the amino acid sequence is directed against and/or that can specifically bind to a target on a T-cell.
  • the amino acid sequence inhibits and/or blocks T-cell activation.
  • the amino acid sequence promotes and/or increases T- cell activation.
  • the amino acid sequence inhibits and/or blocks cytokine production.
  • the amino acid sequence increases cytokine production.
  • the amino acid sequence increases T-cell survival.
  • the amino acid sequence decreases T-cell survival. In one embodiment, the amino acid sequence increases the differentiation of naive T-cells into activated cytokine secreting T-cells.
  • the amino acid sequence decreases the differentiation of naive T- cells into activated cytokine secreting T-cells.
  • the target on a T-cell or APC belongs to the B7:CD28 superfamily.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28 and the interaction of B7-1 with CTLA4.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28, while the interaction of B7-1 with CTLA4 is not modulated, inhibited or prevented.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-2 with CD28.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-2 with CD28 and the interaction of B7-1 with CTLA4.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-2 with CD28, while the interaction of B7-2 with CTLA4 is not modulated, inhibited or prevented.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28 and the interaction of B7-2 with CD28.
  • the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-1 with CD28, while the interaction of B7-2 with CD28 is not modulated, inhibited or prevented. In one embodiment, the amino acid sequence modulates, inhibits, prevents and/or blocks the interaction of B7-2 with CD28, while the interaction of B7-1 with CD28 is not modulated, inhibited or prevented.
  • the invention also provides an amino acid sequence that comprises one or more stretches of amino acid residues chosen from the group consisting of: a) the amino acid sequences of SEQ ED NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ BD NO's: 335-340; d) the amino acid sequences of SEQ ID NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ FD NO's: 347-352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 347-352; g) the amino acid sequences of SEQ ID NO's: 359-364; h) amino
  • At least one of said stretches of amino acid residues of the amino acid sequence forms part of the antigen binding site for binding against CD28.
  • the amino acid sequence comprises two or more stretches of amino acid residues chosen from the group consisting of: a) the amino acid sequences of SEQ ED NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 335-340; d) the amino acid sequences of SEQ ID NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ED NO's: 347-352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 347-352; g) the amino acid sequences of SEQ ID NO's: 359-364; h) amino acid sequences
  • At least two stretches of amino acid residues of the amino acid sequence forms part of the antigen binding site for binding against CD28.
  • the amino acid sequence comprises three or more stretches of amino acid residues, in which the first stretch of amino acid residues is chosen from the group consisting of: a) the amino acid sequences of SEQ ID NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 335-340; the second stretch of amino acid residues is chosen from the group consisting of: d) the amino acid sequences of SEQ ID NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 347-352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 347-352; and
  • At least three stretches of amino acid residues of the amino acid sequence forms part of the antigen binding site for binding against CD28.
  • the CDR sequences of said amino acid sequence have at least 70% amino acid identity, preferably at least 80% amino acid identity, more preferably at least 90% amino acid identity, such as 95% amino acid identity or more or even essentially 100% amino acid identity with the CDR sequences of at least one of the amino acid sequences of SEQ BD NO's: 554-559.
  • the invention further relates to an amino acid sequence that essentially consists of 4 framework regions (FRl to FR4, respectively) and 3 complementarity determining regions (CDRl to CDR3, respectively), in which: CDRl is chosen from the group consisting of: a) the amino acid sequences of SEQ ID NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 335-340; and/or CDR2 is chosen from the group consisting of: d) the amino acid sequences of SEQ ID NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 347- 352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at
  • the amino acid sequence essentially consists of 4 framework regions (FRl to FR4, respectively) and 3 complementarity determining regions (CDRl to CDR3, respectively), in which: -CDRl is chosen from the group consisting of: a) the amino acid sequences of SEQ ID NO's: 335-340; b) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 335-340; c) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences of SEQ ID NO's: 335-340; and CDR2 is chosen from the group consisting of: d) the amino acid sequences of SEQ ID NO's: 347-352; e) amino acid sequences that have at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 347-352; f) amino acid sequences that have 3, 2, or 1 amino acid difference with at least one of the amino acid sequences
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a dissociation constant (K D) of 10 "5 to 10 "12 moles/litre or less
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a dissociation constant (K D) of 10 "7 to 10 "12 moles/litre or less
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a dissociation constant (K D) of 10 "8 to 10 "2 moles/litre.
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of association (k on -rate) of between 10 2 M "! S '1 to about 10 7 M ⁇ S "1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of association (k o ⁇ -rate) of between 10 3 M '1 S “1 and 10 7 M “1 S "1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of association (k ⁇ , n -rate) of between 10 4 M “1 S '1 and 10 7 M “1 S "1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of association (k on -rate) of between 10 5 M ' ' S "1 and 10 7 M “1 S "1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of dissociation (Ic 0Jf rate) between 1 s -1 and 10 '6 s "1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of dissociation (k o g- rate) between 10 "2 s " ' and 10 "6 S “1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of dissociation (k off rate) between 10 "3 S '1 and 10 "6 S “1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with a rate of dissociation (k off rate) between 10 "4 S "1 and 10 '6 S “1 .
  • the amino acid sequence can specifically bind to an APC target or a T-cell target with an affinity less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, such as less than 500 pM.
  • the present disclosure provides single domain variable region polypeptides that are linked to polymers which provide increased stability and half-life.
  • the present disclosure provides improved molecules for the antagonism of CD28 activity including antibody single variable domains of human light chain origin, and including antibody single variable domains of human heavy chain origin.
  • compositions and methods for the attachment of polymer molecules e.g., polyethylene glycol; PEG
  • PEG modification of proteins has been shown to alter the in vivo circulating half-life, antigenicity, solubility, and resistance to proteolysis of the protein (Abuchowski et al., J. Biol. Chem.
  • Figure IA shows a schematic of plasmid pDOM4.
  • Figure IB shows a schematic of plasmid pDOM5.
  • Figure 2 shows ELISAs of soluble monoclonal antibody single variable domain binding to recombinant human CD28/Fc Chimera and Fc control coated plates.
  • Figure 3 shows ELISAs of soluble monoclonal antibody single variable domain binding in the presence or absence of protein A to recombinant human CD28/Fc Chimera and Fc control coated plates.
  • Figure 5 shows the ability of dAb clones to inhibit the activity of CD28 in a cell based in vitro assay.
  • Figure 6 shows the ability of dAb clones DOM21-4 and DOM21-28 to inhibit the activity of CD28 in a cell based in vitro assay.
  • Figure 7 shows a summary of nanobody Hallmark residues.
  • Figure 8 shows the amino acid and nucleic acid sequences of MSA16 and MSA26.
  • Figure 9 shows preferred combinations of CDR sequences, preferred combinations of framework sequences, and preferred combinations of framework and CDR sequences for Nanobodies against CD28.
  • the term "antagonist of CD28" or "anti-CD28 antagonist” or the like includes an agent (e.g., a molecule, a compound) which binds CD28 and can inhibit a (i.e., one or more) functions of CD28.
  • an antagonist of CD28 can inhibit the binding of CD28 to CD80 and/or CD86 and/or inhibit signal transduction mediated through CD28.
  • CD28-mediated processes and cellular responses e.g., CD28-induced T cell activation as indicated by cytokine secretion and/or proliferation in a standard assays
  • CD28-mediated processes and cellular responses e.g., CD28-induced T cell activation as indicated by cytokine secretion and/or proliferation in a standard assays
  • peptide refers to about two to about 50 amino acids that are joined together via peptide bonds.
  • polypeptide refers to at least about 50 amino acids that are joined together by peptide bonds. Polypeptides generally comprise tertiary structure and fold into functional domains.
  • target antigen refers to an antigen which is specifically or selectively bound by a polypeptide or peptide.
  • a polypeptide is an antibody single variable domain, a classical antibody, or antigen-binding fragment thereof
  • the target antigen can be any desired antigen or epitope that specifically binds to the antigen binding site of the antibody single variable domain or antibody. Binding to the target antigen is dependent upon the polypeptide or peptide being functional.
  • an antibody refers to IgG, IgM, IgA, IgD or IgE or a fragment (such as a Fab , F(ab')2, Fv, disulpbide linked Fv, scFv, closed conformation multispecific antibody, disulphide-linked scFv, diabody) whether derived from any species naturally producing an antibody, or created by recombinant DNA technology; whether isolated from serum, B-cells, hybridomas, transfectomas, yeast or bacteria.
  • antibody format refers to any suitable polypeptide structure in which one or more antibody single variable domains can optionally be incorporated into and still retain its ability to bind its target antigen in a monovalent fashion.
  • a variety of suitable antibody formats are known in the art, such as, chimeric antibodies, humanized antibodies, human antibodies, single chain antibodies, bispecific antibodies, antibody heavy chains, antibody light chains, homodimers and heterodimers of antibody heavy chains and/or light chains, antigen- binding fragments of any of the foregoing (e.g., a Fv fragment (e.g., single chain Fv (scFv), a disulfide bonded Fv), a Fab fragment, a Fab' fragment, a F(ab') 2 fragment), an antibody single variable domain (e.g., a dAb, V H , V HH , V L >, and modified versions of any of the foregoing (e.g., modified by the covalent attachment of polyethylene glycol or other suitable polymer or a humanized VHH).
  • a Fv fragment e.g., single chain Fv (scFv), a disulfide bonded Fv
  • Fab fragment e.g., Fab fragment
  • immunoglobulin single variable domain refers to an antibody variable domain (e.g., V H , V HH , V L ) that specifically binds an antigen or epitope independently of other V regions or domains.
  • An antibody single variable domain can be present in a format (e.g., homo- or hetero-multimer) with other variable regions or variable domains where the other regions or domains are not required for antigen binding by the antibody single variable domain (i.e., where the antibody single variable domain binds antigen independently of the additional variable domains).
  • Exemplary formats as herein defined includes any one or more of those selected from the following: an antibody molecule comprising at least (i) the CL (kappa or lambda subclass) domain of an antibody; or (ii) the CHl or CH2 or CH3 domain of an antibody heavy chain; an antibody molecule comprising the CHl and CH2, or the CH2 and CH3, or the CHl and CH3 domains of an antibody heavy chain; an antibody molecule comprising the CHl, CH2 and CH3 domains of an antibody heavy chain; or any of the subset (ii) in conjunction with the CL (kappa or lambda subclass) domain of an antibody.
  • a hinge region domain may also be included.
  • Such combinations of domains may, for example, mimic the format of natural antibodies, such as IgG or IgM, or fragments thereof, such as Fv, scFv, Fab, or F(ab') 2 molecules. Those skilled in the art will be aware that this list is not intended to be exhaustive.
  • a “domain antibody”, a “dAb”, an "immunoglobulin single variable domain” a “single immunoglobulin variable domain”, a “single antibody variable domain” or an “antibody single variable domain” are equivalent.
  • An immunoglobulin single variable domain is in one embodiment a human antibody variable domain, but also includes antibody single variable domains from other species such as rodent (for example, as disclosed in WO 00/29004, the contents of which are incorporated herein by reference in their entirety), nurse shark and Camelid V HH dAbs.
  • Camelid V HH are immunoglobulin single variable domain polypeptides that are derived from species including camel, llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies naturally devoid of light chains.
  • the V HH may be humanized by methods well known in the art.
  • a VH H domain can also be referred to herein as a "nanobody.”
  • a “nanobody” in particular VHH sequences and partially humanized Nanobodies) can be defined as an amino acid sequence with the (general) structure
  • a Nanobody can be an amino acid sequence with the (general) structure
  • FRl to FR4 refer to framework regions 1 to 4, respectively, and in which CDRl to CDR3 refer to the complementarity determining regions 1 to 3, respectively, and in which: i) preferably one or more of the amino acid residues at positions 11 , 37, 44, 45, 47, 83, 84, 103, 104 and 108 according to the Kabat numbering are chosen from the Hallmark residues mentioned in Figure 7; and in which: ii) said amino acid sequence has at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 115-136, in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences (indicated with X in the sequences of SEQ ID NO's: 115-136) are disregarded.
  • a “domain” is a folded protein structure which has tertiary structure independent of the rest of the protein. Generally, domains are responsible for discrete functional properties of proteins, and in many cases may be added, removed or transferred to other proteins without loss of function of the remainder of the protein and/or of the domain.
  • a “monovalent domain” as used herein represents a domain which specifically binds its cognate ligand or a target antigen independently of an additional domain.
  • a monovalent domain as used herein is broader than an antibody single variable domain in that it is not necessarily comprised of antibody related sequences.
  • An “antibody single variable domain” is a folded polypeptide domain comprising sequences characteristic of a classical antibody variable region.
  • an "antibody single variable domain” therefore in one embodiment is a complete antibody variable region which, unlike a classical antibody variable region, monovalently specifically binds antigen.
  • the binding to antigen e.g., CD28
  • the single immunoglobulin V region e.g. an antibody single variable domain, without a requirement for a complementary V region.
  • an antibody single domain is a modified antibody variable region which monovalently binds antigen, where such a modification includes, for example, a variable region in which one or more of the CDRs have been replaced, or in which the antibody framework region(s) have been truncated and/or replaced or fused with a non antibody framework such as fibronectin and lipocallin described infra.
  • the phrase “specifically binds” refers to the binding of an antigen by an antibody variable domain with a dissociation constant (K d ) of 1 ⁇ M or lower as measured by surface plasmon resonance analysis using, for example, a BiacoreTM surface plasmon resonance system and BiacoreTM kinetic evaluation software (e.g., version 2.1).
  • K d dissociation constant
  • the affinity or Kd for a specific binding interaction in an aspect, is about 500 nM or lower, and in another aspect, about 300 nM or lower.
  • the term “binds” is equivalent to the phrase “specifically binds”.
  • a “universal framework” is a single antibody framework sequence corresponding to the regions of an antibody conserved in sequence as defined by Kabat ("Sequences of Proteins of Immunological Interest", US Department of Health and Human Services) or corresponding to the human germline immunoglobulin repertoire or structure as defined by Chothia and Lesk, (1987) J. MoI. Biol. 196:910-917.
  • the use of a single framework, or a set of such frameworks, which has been found to permit the derivation of virtually any binding specificity though variation in the hypervariable regions alone, is included herein.
  • libraries and repertoires can use a single framework, or a set of such frameworks, which has been found to permit the derivation of virtually any binding specificity though variation in the hypervariable regions alone.
  • dose refers to the quantity of ligand administered to a subject all at one time (unit dose), or in two or more administrations over a defined time interval.
  • dose can refer to the quantity of ligand (e.g., ligand comprising an immunoglobulin single variable domain that binds target antigen) administered to a subject over the course of one day (24 hours) (daily dose), two days, one week, two weeks, three weeks or one or more months (e.g., by a single administration, or by two or more administrations).
  • the interval between doses can be any desired amount of time.
  • the term "competes" means that the binding of a first target to its cognate target binding domain is inhibited in the presence of a second binding domain that is specific for said cognate target.
  • binding may be inhibited sterically, for example by physical blocking of a binding domain or by alteration of the structure or environment of a binding domain such that its affinity or avidity for a target is reduced.
  • Competition between a first and a second binding domain can be analyzed by performing competition ELISA and competition Biacore experiments. See WO2006038027. For example, the following two Biacore protocols can be used to determine if two antibody single variable domains compete with each other for binding to CD28.
  • an antigen is immobilized on the sensor surface followed by the pair- wise binding analysis of different antibody single variable domains, hi this example a super-shift in binding following saturation of the chip surface by the first antibody single variable domain indicates that the two antibody single variable domains bind non- overlapping epitopes. If the two antibody single variable domains bound overlapping epitopes, no (or a minimal) super-shift in signal would be observed.
  • the second Biacore protocol involves the capture of one antibody single variable domain on the chip surface.
  • the antigen and then the antibody single variable domain are passed over the chip surface.
  • the level of binding is determined relative to a control consisting of the same antibody single variable domain used for immobilization being passed over the chip surface and competing with itself for binding to antigen.
  • An increase in signal indicates that the two antibody single variable domains do not compete and therefore bind distinct epitopes.
  • No signal increase indicates that the two antibody single variable domains compete and therefore bind overlapping epitopes.
  • Both Biacore protocols are described by Ann-Christin Malmborg and Carl A. K. Borrebaeck, (1995), Biacore as a tool in antibody engineering. Journal of Immunological Methods, 183, 7-13.
  • ELISA based protocols can also be used to determine if two antibody single variable domains compete with each other in binding antigen.
  • VH antibody single variable domains are mixed with VK antibody single variable domains and the level of binding to passively coated antigen (or biotinylated antigen captured by neutavidin coated ELISA plates) determined by detection with protein-L HRP or protein-A HRP as appropriate.
  • VK antibody single variable domain is the detection antibody single variable domain
  • the competing antibody single variable domain (the VH in this example) would be added in molar excess to the detection antibody single variable domain. If the two d antibody single variable domains bound non-overlapping epitopes they would not compete and there would be no decrease in ELISA signal relative to the antibody single variable domain control.
  • a similar approach can be used to determine if two VH antibody single variable domains or two VK antibody single variable domains compete. In this case the competing antibody single variable domain needs to be labelled, for example biotinylated or contain a peptide tag such as the FLAG tag.
  • a second ELISA approach for analyzing the competition between two antibody single variable domains involves the immobilization or passive adsorption onto an ELISA plate of one antibody single variable domain. Antigen is captured by the coated antibody single variable domain and then a second antibody single variable domain is added and the degree of binding is determined as described above.
  • ELISA competition methods direct or bead based
  • examples are: described by Ju-Won Kwak and Chang-Soon Yoon, (1996), Journal of Immunological Methods 191, 49-54, and by Xiao-Chi Jia, et al., (2004), Journal of Immunological Methods 288, 91- 98.
  • Flow cytometry protocols can also be used for analyzing the competition between two antibody single variable domains in a similar manner as described for the ELISA method, except the degree of binding of competing /non-competing antibody single variable domains to cells or beads coated with recombinant antigen is determined by flow cytometry. See Reed DS, et al., (2002), Cytometry, 49(1), 1-7, and see Sai A. Patibandla, et al., (1997), The Journal of Clinical Endocrinology & Metabolism, 82(6), 1885-1893.
  • Crystallography can also be used for analyzing the competition between two antibody single variable domains, for example: forming a CD28 antibody single variable domain plus CD28 co-crystal.
  • sequence identity at the amino acid level can be about 50%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher.
  • sequence identity can be about 50%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher.
  • the nucleic acids may be present in whole cells, in a cell lysate, or in a partially purified or substantially pure form.
  • substantially identical means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 50 percent sequence identity, preferably at least 65, 70, 75, 80, 85 or 90 percent sequence identity, more preferably at least 95 percent sequence identity or more (e.g., 99 percent sequence identity).
  • the software AlignXTM a component of Vector NTI Suite 8.0 (InforMax, Inc.) can be used. The alignment is created using the Clustal W algorithm (Nucleic Acid Research, 22 (22): 4673-4680, 1994).
  • the basic multiple alignment algorithm consists of three main stages: 1) all pairs of sequences are aligned separately in order to calculate a distance matrix giving the divergence of each pair of sequences; 2) a guide tree is calculated from the distance matrix; 3) the sequences are progressively aligned according to the branching order in the guide tree. Accordingly, a crude similarity between all pairs of sequences is calculated, called a "Parities alignment". These scores are then used to calculate a "guide tree" or dendrogram, which tells the multiple alignment stage the order in which to align the sequences for the final multiple alignment. Having calculated the dendrogram, the sequences are aligned in larger and larger groups until the entire sequences are incorporated in the final alignment.
  • Gap extension penalty 0.05
  • the length of a reference sequence aligned for comparison purposes is at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, 80%, 90%, 100% of the length of the reference sequence.
  • the amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
  • the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
  • Amino acid and nucleotide sequence alignments and identity may also be prepared and determined using the algorithm BLAST 2 Sequences, using default parameters (Tatusova, T. A. et al, FEMS Microbiol Lett, /74:187-188 (1999)).
  • a human immunoglobulin single variable domain or an antibody single variable domain has at least 70% amino acid identity (including, for example, 71% 73%, 75%, 77%, 79%, 81%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 99%, or higher identity) to a naturally-occurring human immunoglobulin variable domain sequence.
  • a human antibody single variable domain has at least 85% amino acid similarity or identity (including, for example, 71% 73%, 75%, 77%, 79%, 81%, 83%, 85%, 87%, 90%, 93%, 95%, 97%, 99%, or higher identity) to a naturally-occurring human antibody single variable domain sequence, e.g. a naturally occurring human antibody single variable domain sequence disclosed in Kabat ("Sequences of Proteins of Immunological Interest", U.S. Department of Health and Human Services, 1991).
  • An antibody single variable domain lacks the antibody constant regions. However, one or more, or all of the antibody constant regions can be fused to an antibody single variable domain. Alternatively, fusion proteins comprising an antibody single variable domain and other proteins or polypeptides are encompassed herein.
  • the antibody variable domain of an antibody single variable domain can be a modified.
  • a modified antibody single variable domain retains a dissociation constant of 500 nM or less, (e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM or less, 150 nM or less, 100 nM or less) and retains the target antigen specificity of the full-length domain.
  • An antibody single variable domain is in one embodiment a human antibody variable domain, but also includes an antibody single variable domain from other species such as rodent (for example, as disclosed in WO 00/29004, the contents of which are incorporated by reference in their entirety), nurse shark and camelid V HH dAbs.
  • Camelid V HH are immunoglobulin single variable domain polypeptides that are derived from species including camel, llama, alpacea, dromedary, and guanaco, which produce heavy chain antibodies naturally devoid of light chains.
  • the V HH rnay be humanized.
  • the term "human” when applied to an antibody single variable domain or to an immunoglobulin single variable domain means that the polypeptide has a sequence derived from a human immunoglobulin sequence.
  • a sequence is "derived from" a human immunoglobulin coding sequence when the sequence is either: a) isolated from a human individual or from cells or a cell line derived from a human individual; b) isolated from a library of human antibody gene sequences (or a library of human antibody V domain sequences); or c) when a cloned human antibody sequence (or a cloned human V region sequence (including, e.g., a germline V gene segment)) was used to generate one or more diversified sequences that were then selected for binding to a desired target antigen.
  • Camelid antibodies are described in, for example, U.S. Pat. Nos. 5,759,808; 5,800,988; 5,840,526; 5,874,541; 6,005,079; and 6,015,695, the contents of each of which are incorporated herein in their entirety.
  • Camelid V HH antibody single variable domain polypeptides set forth herein include a class of camelid antibody single variable domain polypeptides having humanlike sequences, where the class is characterized in that the V HH domains carry an amino acid at position 45 selected from glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, methionine, serine, threonine, asparagine, or glutamine, e.g., L45, and further comprise a tryptophan at position 103 according to the Kabat numbering (Kabat et al., 1991, Sequences of Immunological Interest, 5 th ed. U.S. Dept.
  • the V HH has a glycine position 44 and optionally also an arginine, lysine, cysteine or charged amino acid at position 45.
  • Humanized camelid V HH polypeptides are taught, for example in WO04/041862, the teachings of which are incorporated herein in their entirety. It will be understood by one of skill in the art that naturally occurring camelid antibody single variable domain polypeptides may be modified according to the teachings of WO04/041862 (e.g., amino acid substitutions at positions 45 and 103) to generate humanized camelid V HH polypeptides.
  • antibody single variable domain polypeptides which are nurse shark V HH - Nurse shark dAbs are antibody single variable domain polypeptides derived from the nurse shark that comprise heavy chain antibodies naturally devoid of light chain. Nurse Shark single variable domains are described, for example, in Greenberg et al. (Nature 374:168-173, 1995) and U.S. Publication No. 20050043519.
  • epitope refers to a unit of structure of an antigen conventionally bound by an immunoglobulin V H /V L pair. Epitopes define the minimum binding site for an antibody, and thus represent the target of specificity of an antibody. Epitopes can be linear or conformational, and can be a small as three amino acids. In the case of an antibody single variable domain, an epitope represents the unit of structure bound by a single variable domain in isolation. That is, an epitope is the binding site is provided by one immunoglobulin single variable domain.
  • extended release or the equivalent terms “controlled release” or “slow release” refer to drug formulations that release active drug, such as a polypeptide drug, over a period of time following administration to an individual. Extended release of polypeptide drugs, which can occur over a range of desired times, e.g., minutes, hours, days, weeks, or longer, depending upon the drug formulation, is in contrast to standard formulations in which substantially the entire dosage unit is available for immediate absorption or immediate distribution via the bloodstream.
  • Preferred extended release formulations result in a level of circulating drug from a single administration that is sustained, for example, for 8 hours or more, 12 hours or more, 24 hours or more, 36 hours or more, 48 hours or more, 60 hours or more, 72 hours or more 84 hours or more, 96 hours or more, or even, for example, for 1 week or 2 weeks or more, for example, 1 month or more.
  • CD28 activity is an activity involving or resulting from the binding of CD80 and/or CD86 to CD28, and includes, but is not limited to, activation of CD28-mediated T cell signaling.
  • CD28 activity also includes the induction of T cell proliferation and the induction of cytokine secretion, e.g., interleukin 2 (IL-2), by T cells, which can be assayed by methods well known to one of skill in the art.
  • IL-2 interleukin 2
  • the term "does not substantially agonize” means that a given agent, e.g., an anti-CD28 antibody single variable domain, does not activate one or more of the CD28 mediated activities as the term “activate” is defined herein.
  • an agent that "does not substantially agonize” means that the agent does not activate more than 20% of the activity which is activated by CD 80 and/or CD86 binding to CD28, and in an aspect, the agent does not activate more than 10%, 8%, 5%, 3%, or 2%, including zero activation, of the activity which is mediated by CD80 and/or CD86 binding to CD28.
  • an anti- CD28 monovalent polypeptide domain as set forth herein, that does not substantially agonize CD28 activity means that it does not agonize CD28 activity to more than 5% of the CD28 mediated activity obtained upon agonism of CD28 activity by anti-CD28 mAb 9.3 (Gibson, et al. (1996) JBC, 271:7079-7083) under otherwise identical assay conditions.
  • the terms “inhibit,” “inhibits” and “inhibited”, or “prevent” refer to a decrease in or decreased level of a given measurable activity (e.g., binding activity) by at least 10% relative to a reference. Where inhibition is desired, such inhibition is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more, up to and including 100%, i.e., complete inhibition or absence of the given activity. Inhibition of CD28 binding to CD80 or CD86 can be measured as described in the working examples herein.
  • the term “substantially inhibits” refers to a decrease in a given measurable activity (e.g., the binding of CD28 to CD80 or CD86) by at least 50% relative to a reference.
  • substantially inhibits refers to a decrease in a given measurable activity of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and up to and including 100% relative to a reference.
  • inhibits the binding refers to a decrease in binding of CD80 and/or CD86 to CD28 at least 10% in the presence of the CD28 antibody single variable domain, relative to its absence.
  • Inhibits the binding refers to a decrease in binding of at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more, up to and including 100% relative to a reference.
  • Prevents the binding refers to a decreased level of binding of 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more, up to and including 100% relative to a reference.
  • modulating or “to modulate” generally means either reducing or inhibiting the activity of, or alternatively increasing the activity of, the APC target or T-cell target, in particular, a target that belong to the B7:CD28 superfamily (such as B7- 1, B7-2, B7RP-1, PD-Ll, PD-L2, B7H-3 and B7x ["APC targets”] and their receptors CD28, CTLA-4, ICOS, PD-I, BTLA and TEvl-3 ["T-cell targets”]), as measured using a suitable in vitro, cellular or in vivo assay (such as those mentioned herein).
  • B7:CD28 superfamily such as B7- 1, B7-2, B7RP-1, PD-Ll, PD-L2, B7H-3 and B7x ["APC targets”
  • B7-CD28 superfamily such as B7- 1, B7-2, B7RP-1, PD-Ll, PD-L2, B7H-3 and B7x
  • modulating or “to modulate” may mean either reducing or inhibiting the activity of, or alternatively increasing the activity of the APC target or T-cell target, in particular, a target that belong to the B7:CD28 superfamily (such as B7-1, B7-2, B7RP-1, PD-Ll, PD-L2, B7H-3 and B7x ["APC targets”] and their receptors CD28, CTLA-4, ICOS, PD-I, BTLA and TIM-3 ["T-cell targets”]), as measured using a suitable in vitro, cellular or in vivo assay (such as those mentioned herein), by at least 1%, preferably at least 5%, such as at least 10% or at least 25%, for example by at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more, compared to activity of the APC target or T-cell target, in particular, a target that belong to the B7:CD28 superfamily (such as B7-1, B7-2,
  • modulating may also involve effecting a change (which may either be an increase or a descrease) in affinity, avidity, specificity and/or selectivity of the APC target or T-cell target, in particular, a target that belong to the B7:CD28 superfamily (such as B7-1, B7-2, B7RP-1, PD-Ll, PD-L2, B7H-3 and B7x ["APC targets”] and their receptors CD28, CTLA-4, ICOS, PD-I, BTLA and TIM-3 ["T-cell targets”]), for one or more of its targets, ligands, receptors or substrates; and/or effecting a change (which may either be an increase or a decrease) in the sensitivity of the APC target or T-cell target, in particular, a target that belong to the B7:CD28 superfamily (such as B7-1, B7-2, B7RP-1, PD-Ll, PD-L2, B7H-3
  • Modulating may also mean effecting a change (i.e.
  • the APC target or T-cell target in particular, a target that belong to the B7:CD28 superfamily (such as B7-1, B7-2, B7RP-1, PD-Ll , PD-L2, B7H-3 and B7x ["APC targets”] and their receptors CD28, CTLA-4, ICOS, PD-I , BTLA and TIM-3 ["T-cell targets”]), (or in which its substrate(s), ligand(s), receptor(s) or pathway(s) are involved, such as its signalling pathway or metabolic pathway and their associated biological or physiological effects) is involved.
  • B7:CD28 superfamily such as B7-1, B7-2, B7RP-1, PD-Ll , PD-L2, B7H-3 and B7x ["APC targets”] and their receptors CD28, CTLA-4, ICOS, PD-I , BTLA and TIM-3 ["T-cell targets”]
  • an action as an agonist or an antagonist may be determined in any suitable manner and/or using any suitable (in vitro and usually cellular or in assay) assay known per se, such as the assays described herein or in the prior art cited herein.
  • an action as an agonist or antagonist may be such that an intended biological or physiological activity is increased or decreased, respectively, by at least 1%, preferably at least 5%, such as at least 10% or at least 25%, for example by at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more, compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the amino acid sequence, Nanobody or polypeptide of the invention.
  • the terms “activate”, “activates” and “activated” refer to an increase in a given measurable activity by at least 5% relative to a reference, for example, at least 10%, 25%, 50%, 75%, or even 100% or more.
  • CD28 antagonist refers to an agent that inhibits at least one activity mediated by CD28, by inhibiting the binding of CD80 and/or CD86 to CD28.
  • a CD28 activity is "antagonized” if the activity is reduced by at least 10%, and in an exemplary embodiment, at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, or even 100% (i.e., no activity) in the presence of an antagonist, relative to the activity in the absence of an antagonist.
  • a CD28 antagonist as the term is used herein comprises an antibody single variable domain that binds monovalently to CD28.
  • a CD28 antagonist as set forth herein is an agent that inhibits some or all CD28 activity, while at the same time, the agent does not substantially agonize CD28 mediated activity of T cell receptor signaling.
  • CD28 agonist refers to an agent that activates at least one activity mediated by CD28, either alone or when combined with another co-stimulus, relative to a reference.
  • An activity is “agonized” if the activity is increased by at least 10%, e.g., 50%, in the presence, relative to the absence of an agonist.
  • CTL4 activity includes, but is not limited to, inhibition of T cell function. Such functions include, among others, T cell receptor mediated signaling, T cell proliferation, and induction of cytokine secretion.
  • immune disease refers to any disease which is associated with the development of an immune reaction in an individual, including a cellular and/or a humoral immune reaction.
  • immune diseases include, but are not limited to, inflammation, allergy, transplantation, arthritis and autoimmune diseases.
  • autoimmune disease refers to disease conditions and states wherein the immune response of an individual is directed against the individual's own constituents, resulting in an undesirable and often debilitating condition.
  • autoimmune disease is intended to further include autoimmune conditions, syndromes, and the like.
  • Autoimmune diseases include, but are not limited to, Addison's disease, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, Crohn's disease, diabetes (Type I), epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, systemic lupus erythematosus, male infertility, multiple sclerosis, myasthenia gravis, pemphigus, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, spondyloarthropathies, thyroiditis, and vasculitis.
  • Autoimmune-mediated conditions also include, but are not limited to, conditions in which the tissue affected is the primary target, and in some cases, the secondary target.
  • Such conditions include, but are not limited to, ADDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, inherited depression, transplantation of tissues and organs, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus's phenomenon, anaphylaxis, and alcohol and drug addiction.
  • the term "monovalent” means that a given antibody single variable polypeptide domain, CD28 binder, CD28 antagonist, CD28 binding polypeptide or CD28 binding domain or moiety can bind only a single molecule of its target.
  • Naturally-occurring antibodies are generally "divalent", in that they have two functional antigen-binding arms, each arm comprising a VH and a VL domain. Where steric hindrance is not an issue, a divalent antibody can bind two separate molecules of the same antigen. In contrast, a "monovalent” antibody has the capacity to bind only one such antigen molecule.
  • An antibody single variable domain e.g., a V H or a V L domain, has the capacity to bind an antigen such as CD28 ,without the need for a corresponding V L or V H domain, respectively.
  • An antibody single variable domain lacks the capacity to cross link molecules of a single antigen.
  • V H domain and V L domain refer to antibody variable regions, e.g., as generally defined by Kabat et al. (Kabat et al., 1991, Sequences of Immunological Interest, 5 th ed. U.S. Dept. Health & Human Services, Washington, D.C.), which is incorporated herein by reference.
  • linked refers to the attachment of a polymer moiety, such as PEG to an amino acid residue of an antibody single variable domain. Attachment of a PEG polymer to an amino acid residue of an antibody single variable domain, e.g., an anti-CD28 dAb, is referred to as "PEGylation” and may be achieved using several PEG attachment moieties including, but not limited to N-hydroxylsuccinimide (NHS) active ester, succinimidyl propionate (SPA), maleimide (MAL), vinyl sulfone (VS), or thiol.
  • NHS N-hydroxylsuccinimide
  • SPA succinimidyl propionate
  • MAL maleimide
  • VS vinyl sulfone
  • a PEG polymer, or other polymer can be linked to an antibody single variable domain at either a predetermined position, or may be randomly linked to the antibody single variable domain molecule. It is preferred, however, that the PEG polymer be linked to an antibody single variable domain at a predetermined position.
  • a PEG polymer may be linked to any residue in the an antibody single variable domain, however, it is preferable that the polymer is linked to either a lysine or cysteine, which is either naturally occurring in the antibody single variable domain, or which has been engineered into the antibody single variable domain, for example, by mutagenesis of a naturally occurring residue in the antibody single variable domain to either a cysteine or lysine.
  • PEG-linkage can also be mediated through a peptide linker attached to an antibody single variable domain. That is, the PEG moiety can be attached to a peptide linker fused to an antibody single variable domain, where the linker provides the site, e.g., a free cysteine or lysine, for PEG attachment.
  • linker provides the site, e.g., a free cysteine or lysine, for PEG attachment.
  • "linked” can also refer to the association of two or more antibody single variable domains, e.g., dAb monomers, to form a dimer, trimer, tetramer, or other multimer.
  • Antibody single variable domain monomers can be linked to form a multimer by several methods known in the art, including, but not limited to, expression of the antibody single variable domain monomers as a fusion protein, linkage of two or more monomers via a peptide linker between monomers, or by chemically joining monomers after translation, either to each other directly, or through a linker by disulfide bonds, or by linkage to a di-, tri- or multivalent linking moiety (e.g., a multi-arm PEG).
  • dAb multimers are specifically contemplated herein, e.g., in the context of dual- or multi-specific antibody single variable domain constructs, it is emphasized that for any given antibody single variable domain construct, the construct should only be able to bind one molecule of CD28, i.e., the constructs can have only one CD28-binding element, and cannot cross link CD28.
  • polymer refers to a macromolecule made up of repeating monomelic units, and can refer to a synthetic or naturally occurring polymer such as an optionally substituted straight or branched chain polyalkylene, polyalkenylene, or polyoxyalkylene polymer or a branched or unbranched polysaccharide.
  • PEG polyethylene glycol
  • PEG polymer refers to polyethylene glycol, and more specifically can refer to a derivitized form of PEG, including, but not limited to N- hydroxylsuccinimide (NHS) active esters of PEG such as succinimidyl propionate, benzotriazole active esters, PEG derivatized with maleimide, vinyl sulfones, or thiol groups.
  • NHS N- hydroxylsuccinimide
  • PEG formulations can include PEG-O-CH 2 CH 2 CH 2 -CO 2 -NHS; PEG-O-CH 2 -NHS; PEG-O- CH 2 CH 2 -CO 2 -NHS; PEG-S-CH 2 CH 2 -CO-NHS; PEG-O 2 CNH-CH(R)-CO 2 -NHS; PEG-NHCO- CH 2 CH 2 -CO-NHS; and PEG-O-CH 2 -CO 2 -NHS; where R is (CH 2 ) 4 )NHCO 2 (rnPEG).
  • PEG polymers set forth herein may be linear molecules, or may be branched wherein multiple PEG moieties are present in a single polymer. Some particularly preferred PEG conformations include, but are not limited to the following:
  • a "sulfhydryl-selective reagent” is a reagent which is useful for the attachment of a PEG polymer to a thiol-containing amino acid. Thiol groups on the amino acid residue cysteine are particularly useful for interaction with a sulfhydryl-selective reagent. Sulfhydryl-selective reagents which are useful for such attachment include, but are not limited to maleimide, vinyl sulfone, and thiol.
  • sulfhydryl-selective reagents for coupling to cysteine residues is known in the art and may be adapted as needed (See, e.g., Zalipsky, 1995, Bioconjug. Chem. 6:150; Greenwald et al., 2000, CrU. Rev. Ther. Drug Carrier Syst. 17:101; Herman et al, 1994, Macromol. Chem. Phys. 195:203).
  • PEG or another agent e.g., human serum albumin (HSA)
  • HSA human serum albumin
  • "retains activity” refers to a level of activity of a PEG-linked antibody single variable domain which is at least 10% of the level of activity of a non-PEG-linked antibody single variable domain, including at least 20%, 30%, 40%, 50%, 60%, 70%, 80% and up to 90%, including up to 95%, 98%, and up to 100% of the activity of a non-PEG-linked antibody single variable domain comprising the same antigen- binding domain or domains.
  • the activity of a PEG-linked antibody single variable domain compared to a non-PEG linked antibody variable domain should be determined on an antibody single variable domain molar basis; that is equivalent numbers of moles of each of the PEG-linked and non-PEG-linked antibody single variable domains should be used in each trial.
  • determining whether a particular PEG-linked antibody single variable domain "retains activity" it is preferred that the activity of a PEG-linked antibody single variable domain be compared with the activity of the same antibody single variable domain in the absence of PEG.
  • m vivo half-life refers to the time taken for the serum concentration of a CD 28 antagonist and/or an immunoglobulin single variable domain, or an antibody single variable domain, to be reduced by 50%, in vivo, for example due to degradation of and/or clearance or sequestration by natural mechanisms.
  • the anti-CD28 antibody single variable domains or immunoglobulin single variable domain polypeptides described herein can be stabilized in vivo and their half-life increased by binding to molecules, such as PEG, which resist degradation and/or clearance or sequestration.
  • the half-life of an antibody single variable domain is increased if its functional activity persists, in vivo, for a longer period than a similar antibody single variable domain which is not linked to a PEG polymer.
  • the half-life of a PEGylated antibody single variable domain is increased by 10%, 20%, 30%, 40%, 50%, or more relative to a non-PEGylated antibody single variable domain.
  • Increases in the range of 2x, 3x, 4x, 5x, 10x, 2Ox, 3Ox, 40x, 5Ox, or more of the half -life are possible.
  • increases in the range of up to 30x, 4Ox, 50x, 6Ox, 7Ox, 80x, 9Ox, 10Ox, or 150x of the half -life are possible.
  • a PEG-linked antibody single variable domain has a half-life of between 0.25 and two weeks, including between 1 and 100 hours, further including between 30 and 100 hours, and still further including between 50 and 100 hours, and up to 170, 180, 190, and 200 hours or more.
  • resistant to degradation or “resists degradation” with respect to a PEG or other polymer-linked antibody single variable domain monomer or multimer means that the PEG- or other polymer-linked antibody single variable domain monomer or multimer is degraded by no more than 10% when exposed to pepsin at pH 2.0 for 30 minutes and in an aspect, not degraded at all.
  • hydrodynamic size refers to the apparent size of a molecule (e.g., a protein molecule) based on the diffusion of the molecule through an aqueous solution.
  • the diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the "Stokes radius” or “hydrodynamic radius” of the protein particle.
  • the “hydrodynamic size” of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based on the overall conformation of the protein. Hydrodynamic size is measured, for example, by size exclusion chromatography.
  • the hydrodynamic size of a PEG- linked immunoglobulin single variable domain e.g., an antibody single variable domain (including antibody variable domain multimers as described herein), or polypeptide comprising said antibody single variable domain, can be in the range of 24 kDa to 500 kDa; 30 to 500 kDa; 40 to 500 kDa; 50 to 500 kDa; 100 to 500 kDa; 150 to 500 kDa; 200 to 500 kDa; 250 to 500 kDa; 300 to 500 kDa; 350 to 500 kDa; 400 to 500 kDa, and 450 to 500 kDa.
  • the hydrodynamic size of a PEGylated antibody single variable domain is 30 to 40 kDa; 70 to 80 kDa, or 200 to 300 kDa.
  • the polypeptide should have a hydrodynamic size of between 50 and 100 kDa.
  • the polypeptide preparation should have a hydrodynamic size of greater than 200 kDa.
  • IC 5 0 refers to the concentration of an inhibitor necessary to inhibit a given activity by 50%.
  • IC 50 is determined by assaying a given activity, e.g., binding of CD28 to CD80 or CD86, in the presence of varying amounts of the inhibitor (e.g., monovalent anti-CD28 antibody single variable domain), and plotting the inhibitor concentration versus the activity being targeted. Binding to CD28 by CD80 or CD86 is measured herein by the method described the working examples. Alternatively, surface plasmon resonance (SPR) can be used.
  • SPR surface plasmon resonance
  • fused to an antibody single variable domain means that a polypeptide is fused to a given antibody generally through use of recombinant DNA techniques, though fusion may occur chemically at the protein level.
  • an antibody “fused to” another polypeptide e.g., to another antibody of different binding specificity, does not exist in nature and is generated through recombinant means.
  • the term “fused to an antibody single variable domain” also encompasses the linkage of a polypeptide to a given antibody single variable domain through, for example, disulfide or other chemical linkages, where the fused polypeptide is not naturally found fused to the antibody single variable domain. Recombinant and chemical methods of fusing a polypeptide to another polypeptide, e.g., to an antibody, are well known in the art.
  • Fc domain refers to the antibody constant regions and sequences thereof, comprising one or more of the Fc regions, preferably CH2 and CH3 constant regions as delimited according to Kabat et al., supra.
  • the Fc portion of the heavy chain polypeptide has the ability to self-associate, a function which facilitates the formation of divalent antibodies.
  • the term "lacks an Fc domain” means that a given antibody single variable domain lacks at least the portion of an immunoglobulin Fc domain sufficient to mediate the dimerization of Fc-containing monovalent antibody single variable domains. Dimerization of Fc-containing antibody single variable domains is measured, for example, by chromatographic methods or by surface plasmon resonance. An antibody single variable domain lacking an Fc domain avoids Fc-platelet interactions and therefore avoids induction of platelet aggregation.
  • symptom of disease refers to a decrease of the a symptom by at least 10% based on a clinically measurable parameter, or by at least one point on a clinically-accepted scale of disease or symptom severity.
  • symptom(s) of systemic lupus erythematosus refers to any of the clinically relevant symptoms of SLE known to those of skill in the art.
  • Non-limiting examples include the accumulation of IgG autoantibodies (e.g., against nuclear antigens such as chromatin, snRNPs (especially Ul, Sm, Ro/SSA and La/SSB), phospholipids and cell surface molecules), hemolytic anemia, thrombocytopenia, leukopenia, glomerulonephritis, vasculitis, arthritis, and serositis).
  • a reduction in such a symptom is a reduction by at least 10% in a clinically measurable parameter, or by at least one point on a clinically-accepted scale of disease severity.
  • a "generic ligand” is a ligand that binds a substantial proportion of functional members in a given repertoire, e.g., in a phage display library.
  • the same generic ligand can bind many members of the repertoire regardless of their target ligand specificities.
  • the presence of a functional generic ligand binding site indicates that the repertoire member is expressed and folded correctly.
  • binding of the generic ligand to its binding site provides a method for preselecting functional polypeptides from a repertoire of polypeptides.
  • Generic ligands include, for example, Protein A, Protein G and Protein L.
  • Monovalent polypeptide domains which specifically bind CD28, including antibody single variable domains, are provided that are monovalent for binding to CD28. While not being bound by any particular theory, monovalency for CD28 binding removes the possibility for cross-linking cell surface receptors that occurs with prior art antibodies. With respect to inhibiting CD28-mediated T cell activation, a monovalent binder of CD28 has unique advantages with respect to antagonizing a T cell response mediated through CD28 over an anti- CD28 dimeric antibody which clusters the cell surface CD28 molecules promoting T cell stimulation. Thus, the monovalency of CD28 specific antibody single variable domains can inhibit CD28 activity, dampening an immune response, while avoiding potential undesirable stimulatory effects that can occur with antibodies capable of divalent or multivalent binding of CD28. Thus, in a preferred aspect, the anti-CD28 antibodies disclosed herein not only inhibit or antagonize the binding of CD80 or CD86 to CD28, they do not substantially agonize CD28 activity.
  • the antibodies monovalent for CD28 binding are human antibody single variable domains.
  • Human antibody single variable domains can be administered to human patients while largely avoiding the anti-antibody immune response often provoked by the administration of antibodies from other species, e.g., mouse.
  • variable (V) regions that directly participate in antigen interactions
  • constant (C) regions that provide structural support and function in non-antigen-specific interactions with immune effectors.
  • the antigen binding domain of a conventional antibody is formed by the interaction of two separate domains: a heavy chain variable domain (V H ) and a light chain variable domain (V L : which can be either V ⁇ or V ⁇ ).
  • V H heavy chain variable domain
  • V L light chain variable domain
  • the antigen binding site of a conventional antibody is formed by six polypeptide loops: three from the V H domain (Hl, H2 and H3) and three from the V L domain (Ll, L2 and L3).
  • C regions include the light chain C regions (referred to as C L regions) and the heavy chain C regions (referred to as C H I, C H 2 and C H 3 regions).
  • a naturally-occurring, conventional antibody generally comprises two antigen binding domains and is therefore divalent.
  • each antigen binding domain of a naturally occurring, traditional antibody comprises a heavy and light polypeptide chain which together cooperatively form an antigen binding domain.
  • the antigen binding domain of an antibody single variable domain requires only one domain, e.g., one peptide or polypeptide chain.
  • Fab fragment V L -C L /C H 1-V H
  • Fab' fragment a Fab with the heavy chain hinge region
  • F(ab') 2 fragment a dimer of Fab' fragments joined by the heavy chain hinge region
  • single chain Fv variable fragment
  • scFv single chain Fv
  • V L -linker-Vn peptide linker
  • Fab' fragments and scFv fragments are monovalent for antigen binding, as they each comprise only one antigen binding site which comprises 2 variable regions, i.e., a V H /V L dimer.
  • dAb is synonymous with an antibody single variable domain (V H or V L ) polypeptide that specifically binds antigen through a single domain.
  • V H or V L antibody single variable domain
  • Antibody single variable domains for example, V HH
  • V HH are the smallest antigen-binding antibody unit known.
  • human antibodies are preferred, primarily because they are not as likely to provoke an immune response when administered to a patient.
  • isolated non-camelid V H domains tend to be relatively insoluble and are often poorly expressed.
  • Comparisons of camelid V HH with the V H domains of human antibodies reveals several key differences in the framework regions of the camelid V HH domain corresponding to the V H /V L interface of the human V H domains.
  • WO 03/035694 (Muyldermans) reports that the Trp 103- ⁇ Arg mutation improves the solubility of non-camelid V H domains.
  • Davies & Riechmann (1995, Biotechnology N.Y. 13: 475-479) also report production of a phage-displayed repertoire of camelized human V H domains and selection of clones that bind hapten with affinities in the range of 100-400 nM, but clones selected for binding to protein antigen had weaker affinities.
  • General Strategy and Methods for Design of monovalent CD28 antagonists comprising a conventional antigen binding site formed by the VH and VL of a conventional antibody.
  • a hybridoma e.g., a mouse hybridoma
  • the boundaries of V H and V L domains are set out by Kabat et al. (Kabat et al., 1991, Sequences of Immunological Interest, 5 th ed. U.S. Dept. Health & Human Services, Washington, D.C.).
  • V H and V L domains of heavy and light chain genes The information regarding the boundaries of the V H and V L domains of heavy and light chain genes is used to design PCR primers that amplify the V domain from a heavy or light chain coding sequence encoding a conventional antibody known to bind CD28.
  • the amplified V domains are inserted into a suitable expression vector, e.g., pHEN-1 (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137) and expressed, e.g., as a fusion of the V H and V L in an scFv or other suitable monovalent format.
  • pHEN-1 Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137
  • the resulting polypeptide is then screened for high affinity monovalent binding to CD28 by virtue of an antigen binding site formed by the pairs of VH and V L .polypeptides.
  • screening for binding is performed as known in the art or as described herein below.
  • library screening methods can be used to identify monovalent CD28- specific binding proteins.
  • Phage display technology provides an approach for the selection of antibody variable regions which bind a desired target from among large, diverse repertoires of antibody variable regions.
  • These phage-antibody libraries can be grouped into two categories: natural libraries which use rearranged V genes harvested from human B cells (Marks et al., 1991, J. MoI.
  • Methods involving genetic display packages are well- suited for the selection of monovalent CD28-specific antibody constructs because they generally express only monovalent fragments, rather than whole, divalent antibodies, on the display packages.
  • Methods for the preparation of phage display libraries displaying various antibody fragments are described in the preceding references. Such methods are also described, for example, in U.S. Patent No. 6,696,245, which is incorporated herein by reference.
  • the methods described in the '245 patent generally involve the randomization of selected regions of immunoglobulin gene coding regions, in particular V H and V L coding regions, while leaving other regions non-randomized (see below).
  • the '245 patent also describes the generation of scFv constructs comprising individually randomized V H and V L domains.
  • H3 region is much more diverse in terms of sequence, length and structure (due to the use of D segments), it also forms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al. (1996) J. MoI. Biol. 263: 800; Shirai et al. (1996) FEBS Letters 399: 1.
  • Immunoglobulin polypeptide libraries can advantageously be designed to be based on predetermined variable domain main chain conformation. Such libraries may be constructed as described in International Patent Application WO 99/20749, the contents of which are incorporated herein by reference.
  • Such variable region polypeptides can be used for the production of scFvs or Fabs, e.g., an scFv or Fab comprising (i) an antibody heavy chain variable domain (V H ), or antigen binding fragment thereof, which comprises the amino acid sequence of germline V H segment DP-47 and (ii) an antibody light chain variable domain (V L ), or antigen binding fragment thereof, which comprises the amino acid sequence of germline V ⁇ segment DPK9.
  • an antibody single variable domain comprises the amino acid sequence of a given human germline V region gene segment, e.g., V H germline gene segment DP-47, or V ⁇ germline gene segment DPK9. These variable region polypeptides can also be expressed as antibody single variable domains and screened for high affinity binding to CD28.
  • the repertoire can be cloned into or generated in a vector suitable for phage display, e.g., a lambda or filamentous bacteriophage display vector and is then screened for binding to a given target antigen, e.g., CD28.
  • a vector suitable for phage display e.g., a lambda or filamentous bacteriophage display vector and is then screened for binding to a given target antigen, e.g., CD28.
  • An antibody single variable domain is a folded polypeptide domain which comprises sequences characteristic of antibody variable domains and which specifically binds an antigen (e.g., dissociation constant of 500 nM or less), and which binds antigen as a single variable domain; that is, there is one binding site provided by an antibody single variable domain without any complementary variable domain.
  • an antigen e.g., dissociation constant of 500 nM or less
  • An antibody single variable domain therefore includes complete antibody variable domains as well as modified variable domains, for example in which one or more loops have been replaced by sequences which are not characteristic of antibody variable domains or antibody variable domains which have been truncated or comprise N- or C- terminal extensions, as well as folded fragments of variable domains which retain a dissociation constant of 500 nM less (e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM or less, 150 nM or less, 100 nM or less) and the target antigen specificity of the full-length domain.
  • 500 nM less e.g., 450 nM or less, 400 nM or less, 350 nM or less, 300 nM or less, 250 nM or less, 200 nM or less, 150 nM or less, 100 nM or less
  • an antibody single variable domain useful in the compositions and methods set forth herein is selected from the group of V H and V L , including and V HH -
  • the antibody single variable domains of use herein are "human" as that term is defined herein.
  • two or more antibody single variable domains may be linked while still maintaining the ability of each antibody single variable domain to bind its respective antigen independently of each other.
  • the two or more linked antibody single variable domains may be further attached to a skeleton which may, as an alternative, or on addition to a linker described herein, facilitate the formation and/or maintenance of the ability of each antibody single variable domain to bind its respective antigen independently of each other.
  • the monomelic anti-CD28 antibody single variable domain polypeptides disclosed herein may be constructed using scaffold or frameworks as discussed herein.
  • Antibody single variable domain skeletons may be based on antibody chain molecules or may be non-antibody in origin as set forth elsewhere herein.
  • Each epitope binding domain comprises a protein scaffold and one or more CDRs which are involved in the specific interaction of the domain with one or more epitopes.
  • an epitope binding domain disclosed herein comprises three CDRs.
  • Suitable protein scaffolds in addition to those based on antibody domains, may also be based on protein scaffolds or skeletons other than immunoglobulin domains which are non-antibody in origin.
  • natural bacterial receptors such as Staphylococcus protein A have been used as scaffolds for the grafting of CDRs to generate ligands which bind specifically to one or more epitopes. Details of this procedure are described in US 5,831,012.
  • Suitable scaffolds include those based on fibronectin and aff ⁇ bodies (Affibody, Bromma, Sweeden). Details of suitable procedures are described in WO 98/58965.
  • Other suitable scaffolds include lipocallin and CTLA4, as described in van den Beuken et al, J. MoI. Biol. (2001) 310, 591-601, and scaffolds such as those described in WO00/69907 (Medical Research Council), which are based for example on the ring structure of bacterial GroEL or other chaperone polypeptides.
  • non-immunoglobulin based scaffolds which may be used include those based on the LDL receptor class A, EGF domain monomers and multimers, and scaffolds available from Biorexis (King of Prussia, PA) or Avidia (Mountain View, CA).
  • Other non-immunoglobulin scaffolds which may be used are described, for example, in WO05/040229, WO04/044011, and US2005/0089932
  • the members of the immunoglobulin superfamily all share a similar fold for their polypeptide chain.
  • antibodies are highly diverse in terms of their primary sequence
  • comparison of sequences and crystallographic structures has revealed that, contrary to expectation, five of the six antigen binding loops of antibodies (Hl, H2, Ll, L2, L3) adopt a limited number of main-chain conformations, or canonical structures (Chothia and Lesk (1987) J. MoI. Biol, 196: 901; Chothia et al (1989) Nature, 342: 877).
  • Analysis of loop lengths and key residues has therefore enabled prediction of the main-chain conformations of Hl, H2, Ll, L2, and L3 found in the majority of human antibodies (Chothia et al.
  • H3 region is much more diverse in terms of sequence, length, and structure (due to the use of D segments), it also forms a limited number of main-chain conformations for short loop lengths which depend on the length and the presence of particular residues, or types of residue, at key positions in the loop and the antibody framework (Martin et al. (1996) J. MoI Biol, 263: 800; Shirai et al. (1996) FEBS Letters, 399: 1).
  • the antibody single variable domains disclosed herein can be selected and/or assembled from libraries containing variable domains, such as libraries of V H domains and/or libraries of V L domains.
  • the ligands disclosed herein may themselves be provided in the form of libraries.
  • libraries of ligands and/or domains are designed in which certain loop lengths and key residues have been chosen to ensure that the main-chain conformation of the members is known.
  • these are real conformations of immunoglobulin superfamily molecules found in nature, to minimize the chances that they are non-functional, as discussed above.
  • Ge ⁇ nline V gene segments serve as one exemplary basic framework for constructing antibody or T cell receptor libraries; other sequences are also of use. Variations may occur at a low frequency, such that a small number of functional members may possess an altered main-chain conformation, which does not affect its function.
  • Canonical structure theory is also of use to assess the number of different main-chain conformations encoded by ligands, to predict the main-chain conformation based on ligand sequences and to chose residues for diversification which do not affect the canonical structure. It is known that, in the human V ⁇ region, the Ll loop can adopt one of four canonical structures, the L2 loop has a single canonical structure and that 90% of human V ⁇ domains adopt one of four or five canonical structures for the L3 loop (Tomlinson et al. (1995) supra); thus, in the V ⁇ region alone, different canonical structures can combine to create a range of different main-chain conformations.
  • V ⁇ region encodes a different range of canonical structures for the Ll, L2, and L3 loops
  • V ⁇ and V ⁇ regions can pair with any V H region which can encode several canonical structures for the Hl and H2 loops
  • the number of canonical structure combinations observed for these five loops is very large. This implies that the generation of diversity in the main-chain conformation may be essential for the production of a wide range of binding specificities.
  • by constructing an antibody library based on a single known main-chain conformation it has been found, contrary to expectation, that diversity in the main- chain conformation is not required to generate sufficient diversity to target substantially all antigens.
  • the single main-chain conformation need not be a consensus structure a single naturally occurring conformation can be used as the basis for an entire library.
  • the antibody single variable domains disclosed herein possess a single known main-chain conformation.
  • the single main-chain conformation that is chosen is, in an aspect, commonplace among molecules of the immunoglobulin superfamily type in question. A conformation is commonplace when a significant number of naturally occurring molecules are observed to adopt it. Accordingly, in a preferred aspect disclosed herein, the natural occurrence of the different main-chain conformations for each binding loop of an immunoglobulin domain are considered separately and then a naturally occurring variable domain is chosen which possesses the desired combination of main-chain conformations for the different loops.
  • the nearest equivalent may be chosen. It is preferable that the desired combination of main-chain conformations for the different loops is created by selecting germline gene segments which encode the desired main-chain conformations. It is more preferable, that the selected germline gene segments are frequently expressed in nature, and most preferable that they are the most frequently expressed of all natural germline gene segments.
  • the incidence of the different main-chain conformations for each of the antigen binding loops may be considered separately.
  • Hl, H2, Ll, L2, and L3 a given conformation that is adopted by between 20% and 100% of the antigen binding loops of naturally occurring molecules is chosen.
  • its observed incidence is above 35% (i.e. between 35% and 100%) and, ideally, above 50% or even above 65%. Since the vast majority of H3 loops do not have canonical structures, it is preferable to select a main-chain conformation which is commonplace among those loops which do display canonical structures. For each of the loops, the conformation which is observed most often in the natural repertoire is therefore selected.
  • Hl - CS 1 (79% of the expressed repertoire), H2 - CS 3 (46%), Ll - CS 2 of V ⁇ (39%), L2 - CS 1 (100%), L3 - CS 1 of V ⁇ (36%) (calculation assumes a ⁇ : ⁇ ratio of 70:30, Hood et al. (1967) Cold Spring Harbor Symp. Quant. Biol, 48: 133).
  • H3 loops that have canonical structures a CDR3 length (Kabat et al. (1991) Sequences of proteins of immunological interest, U.S.
  • the natural occurrence of combinations of main-chain conformations is used as the basis for choosing the single main-chain conformation.
  • the natural occurrence of canonical structure combinations for any two, three, four, five, or for all six of the antigen binding loops can be determined.
  • the chosen conformation is commonplace in naturally occurring antibodies and most preferable that it observed most frequently in the natural repertoire.
  • Antibody single variable domains are prepared in a number of ways. For each of these approaches, well-known methods of preparing (e.g., amplifying, mutating, etc.) and manipulating nucleic acid sequences are applicable.
  • V H or V L region of a heavy chain or light chain gene for a cloned antibody or V HH known to bind the desired antigen That is, the V H or V L region of a known anti-CD28 antibody coding region can be amplified and expressed as a single domain (or as a fusion of a single domain) and evaluated for binding to CD28.
  • the boundaries of V H and V L regions are set out by Kabat et al. (Kabat et al., 1991, Sequences of Immunological Interest, 5 th ed. U.S. Dept. Health & Human Services, Washington, D.C.).
  • V H and V L regions of heavy and light chain genes The information regarding the boundaries of the V H and V L regions of heavy and light chain genes is used to design PCR primers that amplify the V domain from a cloned heavy or light chain coding sequence encoding an antibody known to bind CD28.
  • the amplified V domain is inserted into a suitable ⁇ expression vector, e.g., pHEN-1 (Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137) and expressed, either alone or as a fusion with another polypeptide sequence.
  • pHEN-1 Hoogenboom et al., 1991, Nucleic Acids Res. 19: 4133-4137
  • the VH gene is produced by the recombination of three gene segments, V H , D and J H .
  • V H three gene segments
  • D and J H the V H segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the V H region (Hl and H2), while the V H , D and JH segments combine to form the third antigen binding loop of the V H region (H3).
  • the v L gene is produced by the recombination of only two gene segments, V L and JL- In humans, there are approximately 40 functional V ⁇ segments (Schable and Zachau (1993) Biol. Chem. Hoppe-Seyler 374: 1001), 31 functional V ⁇ segments (Williams et al. (1996) J. MoI. Biol. 264: 220; Kawasaki et al. (1997) Genome Res. 7: 250), 5 functional J ⁇ segments (Hieter et al. (1982) J. Biol. Chem. 257: 1516) and 4 functional ] ⁇ segments (Vasicek and Leder (1990) J. Exp. Med. 172: 609), depending on the haplotype.
  • the V L segment encodes the region of the polypeptide chain which forms the first and second antigen binding loops of the V L region (Ll and L2), while the V L and JL segments combine to form the third antigen binding loop of the V L region (L3).
  • Antibodies selected from this primary repertoire are believed to be sufficiently diverse to bind almost all antigens with at least moderate affinity.
  • High affinity antibodies are produced in vivo by "affinity maturation" of the rearranged genes, in which point mutations are generated and selected by the immune system on the basis of improved binding.
  • a repertoire of V H or V L domains is screened by, for example, phage display, panning against the desired antigen.
  • Methods for the construction of bacteriophage display libraries and lambda phage expression libraries are well known in the art, and taught, for example, by McCafferty et al., 1990, Nature 348: 552; Kang et al., 1991, Proc. Natl. Acad. Sci. U.S.A., 88: 4363; Clackson et al., 1991, Nature 352: 624; Lowman et al., 1991, Biochemistry 30: 10832; Burton et al., 1991, Proc.
  • Fab phage display libraries are taught, for example, by U.S. 5,922,545.
  • scFv phage libraries are taught, for example, by Huston et al., 1988, Proc. Natl. Acad. Sci U.S.A. 85: 5879-5883; Chaudhary et al., 1990, Proc. Natl. Acad. Sci U.S.A.
  • the repertoire of V H or V L domains can be a naturally-occurring repertoire of immunoglobulin sequences or a synthetic repertoire.
  • a naturally-occurring repertoire is one prepared, for example, from hnmunoglobulin-expressing cells harvested from one or more individuals. Such repertoires can be "naive,” i.e., prepared, for example, from human fetal or newborn immunoglobulin-expressing cells, or rearranged, i.e., prepared from, for example, adult human B cells.
  • Natural repertoires are described, for example, by Marks et al., 1991, J. MoI. Biol. 222: 581 and Vaughan et al., 1996, Nature Biotech. 14: 309. If desired, clones identified from a natural repertoire, or any repertoire, for that matter, that bind the target antigen are then subjected to mutagenesis and further screening in order to produce and select variants with improved binding characteristics.
  • Synthetic repertoires of immunoglobulin single variable domains are prepared by artificially introducing diversity into a cloned V domain. Synthetic repertoires are described, for example, by Hoogenboom & Winter, 1992, J. MoI. Biol. 227: 381; Barbas et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89: 4457; Nissim et al., 1994, EMBO J. 13: 692; Griffiths et al., 1994, EMBO J. 13: 3245; DeKriuf et al., 1995, J. MoI. Biol. 248: 97; and WO 99/20749.
  • V H or VK backgrounds based on artificially diversified germline V H or VK sequences.
  • the V H domain repertoire can be based on cloned germline V H gene segments V3-23/DP47 (Tomlinson et al., 1992, J. MoL Biol. 227: 7768) and JH4b.
  • the V ⁇ domain repertoire can be based, for example, on germline V ⁇ gene segments O2/O12/DPK9 (Cox et al., 1994, Eur. J. Immunol. 24: 827) and J ⁇ l . Diversity is introduced into these or other gene segments by, for example, PCR mutagenesis.
  • DVT codon (A/G/T) (A/G/C)T )
  • DVC codon (A/G/T)(A/G/C)C)
  • DVY codon (A/G/T)(A/G/C)(C/T).
  • the DVT codon encodes 22% serine and 11% tyrosine, asparagine, glycine, alanine, aspartate, threonine and cysteine, which most closely mimics the distribution of amino acid residues for the antigen binding sites of natural human antibodies.
  • Repertoires are made using PCR primers having the selected degenerate codon or codons at each site to be diversified. PCR mutagenesis is well known in the art.
  • diversity is introduced into the sequence of human germline V H gene segments V3-23/DP47 (Tomlinson et al., 1992, J. MoI. Biol. 227: 7768) and JH4b using the NNK codon at sites H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97, and H98, corresponding to diversity in CDRs 1, 2 and 3, with the numbering as used in U.S. Patent No. 6,696,245.
  • diversity is also introduced into the sequence of human germline V H gene segments V3-23/DP47 and JH4b, for example, using the NNK codon at sites H30, H31, H33, H35, H50, H52, H52a, H53, H55, H56, H58, H95, H97, H98, H99, HlOO, HlOOa, and HlOOb, corresponding to diversity in CDRs 1, 2 and 3, with the numbering as used in U.S. Patent No. 6,696,245.
  • diversity is introduced into the sequence of human ge ⁇ nline V ⁇ gene segments O2/O12/DPK9 and J ⁇ l, for example, using the NNK codon at sites L30, L31, L32, L34, L50, L53, L91, L92, L93, L94, and L96, corresponding to diversity in CDRs 1, 2 and 3,with the numbering as used in U.S. Patent No. 6,696,245.
  • nucleic acid molecules and vector constructs required for the compositions and methods set forth herein are available in the art and are constructed and manipulated as set forth in standard laboratory manuals, such as Sambrook et al. (1989) ⁇ , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, USA and subsequent editions.
  • vector refers to a discrete element that is used to introduce heterologous DNA into cells for the expression and/or replication thereof. Methods by which to select or construct and, subsequently, use such vectors are well known to one of skill in the art. Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial chromosomes and episomal vectors. Such vectors may be used for simple cloning and mutagenesis; alternatively, as is typical of vectors in which repertoire (or pre-repertoire) members herein are carried, a gene expression vector is employed.
  • a vector of use set forth herein is selected to accommodate a polypeptide coding sequence of a desired size, typically from 0.25 kilobase (kb) to 40 kb in length.
  • a suitable host cell is transformed with the vector after in vitro cloning manipulations.
  • Each vector contains various functional components, which generally include a cloning (or "polylinker") site, an origin of replication and at least one selectable marker gene. If a given vector is an expression vector, it additionally possesses one or more of the following: enhancer element, promoter, transcription termination and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a polypeptide repertoire member as set forth herein.
  • Both cloning and expression vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
  • this sequence is one that enables the vector to replicate independently of the host chromosomal DNA and includes origins of replication or autonomously replicating sequences.
  • origins of replication or autonomously replicating sequences are well known for a variety of bacteria, yeast and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 micron plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, adenovirus) are useful for cloning vectors in mammalian cells.
  • the origin of replication is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
  • a cloning or expression vector also contains a selection gene also referred to as selectable marker.
  • This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium.
  • Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
  • an E. c ⁇ /z-selectable marker for example, the ⁇ -lactamase gene that confers resistance to the antibiotic ampicillin.
  • E. coli plasmids such as pBR322 or a pUC plasmid such as pUC18 or pUC19.
  • other plasmid microorganism combinations can also be reasonably substituted.
  • Expression vectors usually contain a promoter that is recognized by the host organism and is operably linked to the coding sequence of interest. Such a promoter may be inducible or constitutive.
  • operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • Promoters suitable for use with prokaryotic hosts include, for example, the ⁇ -lactamase and lactose promoter systems, alkaline phosphatase, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. Promoters for use in bacterial systems will also generally contain a Shine-Dalgarno sequence operably linked to the coding sequence.
  • the preferred vectors are expression vectors that enable the expression of a nucleotide sequence corresponding to a polypeptide library member. Thus, selection is performed by separate propagation and expression of a single clone expressing the polypeptide library member or by use of any selection display system.
  • phage or phagemid vectors can be used.
  • Preferred vectors are phagemid vectors, which have an E. coli origin of replication (for double stranded replication) and also a phage origin of replication (for production of single-stranded DNA). The manipulation and expression of such vectors is well known in the art (Hoogenboom and Winter (1992) supra; Nissim et al. (1994) supra).
  • the vector contains a ⁇ -lactamase or other selectable marker gene to confer selectivity on the phagemid, and a lac promoter upstream of a expression cassette that consists (N to C terminal) of a pelB leader sequence (which directs the expressed polypeptide to the periplasmic space), a multiple cloning site (for cloning the nucleotide version of the library member), optionally, one or more peptide tags (for detection), optionally, one or more TAG stop codons and the phage protein pill.
  • the vector encodes, rather than the pelB leader sequence, a eukaryotic GASl leader sequence which serves to direct the secretion of the fusion polypeptide to the periplasmic space in E. coli or to the medium in eukaryotic cell systems.
  • a eukaryotic GASl leader sequence which serves to direct the secretion of the fusion polypeptide to the periplasmic space in E. coli or to the medium in eukaryotic cell systems.
  • IPTG iso-propyl thio- ⁇ -D-galactoside
  • VCS M 13 helper phage
  • a preferred vector is the pHENl phagemid vector (Hoogenboom et al., 1991, Nucl. Acids Res. 19: 4133-4137; sequence is available, e.g., as SEQ ID NO: 7 in WO 03/031611), in which the production of pill fusion protein is under the control of the LacZ promoter, which is inhibited in the presence of glucose and induced with IPTG. When grown in suppressor strains of E.
  • the gene III fusion protein is produced and packaged into phage, while growth in non-suppressor strains, e.g., HB2151, permits the secretion of soluble fusion protein into the bacterial periplasm and into the culture medium. Because the expression of gene III prevents later infection with helper phage, the bacteria harboring the phagemid vectors are propagated in the presence of glucose before infection with VCSMl 3 helper phage for phage rescue.
  • vectors as set forth herein employs conventional ligation techniques. Isolated vectors or DNA fragments are cleaved, tailored, and re-ligated in the form desired to generate the required vector. If desired, sequence analysis to confirm that the correct sequences are present in the constructed vector is performed using standard methods. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing expression and function are known to those skilled in the art. The presence of a gene sequence in a sample is detected, or its amplification and/or expression quantified by conventional methods, such as Southern or Northern analysis, Western blotting, dot blotting of DNA, RNA or protein, in situ hybridization, immunocytochemistry or sequence analysis of nucleic acid or protein molecules. Those skilled in the art will readily envisage how these methods may be modified, if desired.
  • phage Following expression of a repertoire of antibody single variable domains on the surface of phage, selection is performed by contacting the phage repertoire with immobilized target antigen, washing to remove unbound phage, and propagation of the bound phage, the whole process frequently referred to as "panning". This process is applicable to the screening of antibody single variable domains as well as other antibody fragments that can be expressed on a display library, e.g., scFv, Fab, etc.
  • phage are pre-selected for the expression of properly folded member variants by panning against an immobilized generic ligand (e.g., protein A or protein L) that is only bound by folded members.
  • an immobilized generic ligand e.g., protein A or protein L
  • Screening is commonly performed using purified antigen immobilized on a solid support, for example, plastic tubes or wells, or on a chromatography matrix, for example SepharoseTM (Pharmacia). Screening or selection can also be performed on complex antigens, such as the surface of cells (Marks et al., 1993, BioTechnology 11: 1145; de Kruif et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92: 3938). Another alternative involves selection by binding biotinylated antigen in solution, followed by capture on streptavidin-coated beads.
  • panning is performed by immobilizing antigen (generic or specific) on tubes or wells in a plate, e.g., Nunc MAXISORPTM immunotube 8 well strips.
  • Wells are coated with 150 ⁇ l of antigen (100 ⁇ g/ml in PBS) and incubated overnight.
  • the wells are then washed 3 times with PBS and blocked with 400 ⁇ l PBS-2% skim milk (2% MPBS) at 37 0 C for 2 hr.
  • the wells are rinsed 3 times with PBS and phage are added in 2%MPBS.
  • the mixture is incubated at room temperature for 90 minutes and the liquid, containing unbound phage, is removed.
  • Bound phage are eluted by adding 200 ⁇ l of freshly prepared 100 mM triethylamine, mixing well and incubating for 10 min at room temperature. Eluted phage are transferred to a tube containing 100 ⁇ l of 1 M Tris-HCl, pH 7.4 and vortexed to neutralize the triethylamine. Exponentially-growing E. coli host cells (e.g., TGl) are infected with, for example, 150 ml of the eluted phage by incubating for 30 min at 37°C.
  • E. coli host cells e.g., TGl
  • Infected cells are spun down, resuspended in fresh medium and plated in top agarose. Phage plaques are eluted or picked into fresh cultures of host cells to propagate for analysis or for further rounds of selection. One or more rounds of plaque purification are performed if necessary to ensure pure populations of selected phage. Other screening approaches are described by Harrison et al., 1996, supra.
  • variable domain fusion proteins are easily produced in soluble form by infecting non-suppressor strains of bacteria, e.g., HB2151 that permit the secretion of soluble gene III fusion protein.
  • non-suppressor strains of bacteria e.g., HB2151 that permit the secretion of soluble gene III fusion protein.
  • the fusion polypeptide can be secreted by eukaryotic (e.g., yeast or mammalian) or prokaryotic (e.g., E. coli) cells.
  • the V domain sequence can be sub-cloned into an appropriate expression vector to produce soluble protein according to methods known in the art.
  • Antibody single variable domain polypeptides or other monovalent antibody single variable domains secreted into the periplasmic space or into the medium of bacteria are harvested and purified according to known methods (Harrison et al., 1996, supra). Skerra & Pluckthun (1988, Science 240: 1038) and Breitling et al. (1991, Gene 104: 147) describe the harvest of antibody single variable domains from the periplasm, and Better et al. (1988, Science 240: 1041) describes harvest from the culture supernatant.
  • purification can also be achieved by binding to generic ligands, such as protein A or Protein L.
  • the variable domains can be expressed with a peptide tag, e.g., the Myc, HA or 6X-His tags, which facilitates purification by affinity chromatography.
  • monovalent anti-CD28 antibody single variable domains are concentrated by any of several methods well known in the art, including, for example, ultrafiltration, diafiltration and tangential flow filtration.
  • the process of ultrafiltration uses semi-permeable membranes and pressure to separate molecular species on the basis of size and shape. The pressure is provided by gas pressure or by centrifugation.
  • Commercial ultrafiltration products are widely available, e.g., from Millipore (Bedford, MA; examples include the CentriconTM and MicroconTM concentrators) and Vivascience (Hannover, Germany; examples include the VivaspinTM concentrators).
  • a molecular weight cutoff smaller than the target polypeptide usually 1/3 to 1/6 the molecular weight of the target polypeptide, although differences of as little as 10 kD can be used successfully
  • the polypeptide is retained when solvent and smaller solutes pass through the membrane.
  • a molecular weight cutoff of about 5 kD is useful for concentration of anti-CD28 antibody single variable domain polypeptides described herein.
  • Diafiltration which uses ultrafiltration membranes with a "washing" process, is used where it is desired to remove or exchange the salt or buffer in a polypeptide preparation.
  • the polypeptide is concentrated by the passage of solvent and small solutes through the membrane, and remaining salts or buffer are removed by dilution of the retained polypeptide with a new buffer or salt solution or water, as desired, accompanied by continued ultrafiltration.
  • new buffer is added at the same rate that filtrate passes through the membrane.
  • a diafiltration volume is the volume of polypeptide solution prior to the start of diafiltration - using continuous diafiltration, greater than 99.5% of a fully permeable solute can be removed by washing through six diafiltration volumes with the new buffer.
  • the process can be performed in a discontinuous manner, wherein the sample is repeatedly diluted and then filtered back to its original volume to remove or exchange salt or buffer and ultimately concentrate the polypeptide.
  • Equipment for diafiltration and detailed methodologies for its use are available, for example, from Pall Life Sciences (Ann Arbor, MI) and Sartorius AG/Vivascience (Hannover, Germany).
  • Tangential flow filtration also known as “cross-flow filtration,” also uses ultrafiltration membrane. Fluid containing the target polypeptide is pumped tangentially along the surface of the membrane. The pressure causes a portion of the fluid to pass through the membrane while the target polypeptide is retained above the filter. In contrast to standard ultrafiltration, however, the retained molecules do not accumulate on the surface of the membrane, but are carried along by the tangential flow. The solution that does not pass through the filter (containing the target polypeptide) can be repeatedly circulated across the membrane to achieve the desired degree of concentration.
  • Protein concentration is measured in a number of ways that are well known in the art. These include, for example, amino acid analysis, absorbance at 280 run, the "Bradford” and “Lowry” methods, and SDS-PAGE. The most accurate method is total hydrolysis followed by amino acid analysis by HPLC 5 concentration is then determined then comparison with the known sequence of the antibody single variable domain polypeptide. While this method is the most accurate, it is expensive and time-consuming. Protein determination by measurement of UV absorbance at 280 run faster and much less expensive, yet relatively accurate and is preferred as a compromise over amino acid analysis. Absorbance at 280 nm was used to determine protein concentrations reported in the Examples described herein.
  • the SDS-PAGE method uses gel electrophoresis and Coomassie Blue staining in comparison to known concentration standards, e.g., known amounts of an antibody single variable domain polypeptide. Quantitation can be done by eye or by densitometry.
  • Human antibody single variable domain polypeptides described herein retain solubility at high concentration (e.g., at least 4.8 mg ( ⁇ 400 ⁇ M) in aqueous solution (e.g., PBS), and in an aspect, at least 5 mg/ml (-417 ⁇ M), 10 mg/ml (-833 ⁇ M), 20 mg/ml (-1.7 mM), 25 mg/ml (-2.1 mM), 30 mg/ml (-2.5 mM), 35 mg/ml (-2.9 mM), 40 mg/ml (-3.3 mM), 45 mg/ml (-3.75 mM), 50 mg/ml (-4.2 mM), 55 mg/ml (-4.6 mM), 60 mg/ml (-5.0 mM), 65 mg/ml (-5.4 mM), 70 mg/ml (-5.8 mM), 75 mg/ml (-6.3 mM), 100 mg/ml (-8.33 mM), 150 mg/ml (-12.5 mM),
  • antibody single variable domain polypeptides One structural feature that promotes high solubility is the relatively small size of the antibody single variable domain polypeptides.
  • a full length conventional four chain antibody e.g., IgG is about 150 kD in size.
  • antibody single variable domains which all have a general structure comprising 4 framework (FW) regions and 3 CDRs, have a size of approximately 12 kD, or less than 1/10 the size of a conventional antibody.
  • antibody single variable domains are approximately half the size of a scFv molecule (-26 kD), and approximately one-fifth the size of a Fab molecule (-60 kD).
  • an antibody single variable domain-containing structure disclosed herein is 100 kD or less, including structures of, for example, about 90 kD or less, 80 kD or less, 70 kD or less, 60 kD or less, 50 kD or less, 40 kD or less, 30 kD or less, 20 kD or less, down to and including about 12 kD, or an antibody single variable domain in isolation.
  • the solubility of a polypeptide is primarily determined by the interactions of the amino acid side chains with the surrounding solvent. Hydrophobic side chains tend to be localized internally as a polypeptide folds, away from the solvent-interacting surfaces of the polypeptide. Conversely, hydrophilic residues tend to be localized at the solvent-interacting surfaces of a polypeptide. Generally, polypeptides having a primary sequence that permits the molecule to fold to expose more hydrophilic residues to the aqueous environment are more soluble than one that folds to expose fewer hydrophilic residues to the surface. Thus, the arrangement and number of hydrophobic and hydrophilic residues is an important determinant of solubility. Other parameters that determine polypeptide solubility include solvent pH, temperature, and ionic strength. In a common practice, the solubility of polypeptides can be maintained or enhanced by the addition of glycerol (e.g., ⁇ 10% v/v) to the solution.
  • glycerol e.g.,
  • V H domains that vary in the V H domains of camelid species, which are generally more soluble than human V H domains. These include, for example, GIy 44 (GIu in camelids), Leu 45 (Arg in camelids) and Trp 47 (GIy in camelids). Amino acid residue 103 of V H is also implicated in solubility, with mutation from Trp to Arg tending to confer increased V H solubility.
  • antibody single variable domain polypeptides are based on the DP47 germline V H gene segment or the DPK9 germline V ⁇ gene segment.
  • these germline gene segments are capable, particularly when diversified at selected structural locations described herein, of producing specific binding antibody single variable domain polypeptides that are highly soluble.
  • the four framework regions which are, in an aspect, not diversified, can contribute to the high solubility of the resulting proteins.
  • Molecular modeling software can also be used to predict the solubility of a polypeptide sequence relative to that of a polypeptide of known solubility. For example, the substitution or addition of a hydrophobic residue at the solvent-exposed surface, relative to a molecule of known solubility that has a less hydrophobic or even hydrophilic residue exposed in that position is expected to decrease the relative solubility of the polypeptide. Similarly, the substitution or addition of a more hydrophilic residue at such a location is expected to increase the relative solubility.
  • an antibody single variable domain e.g., an antibody single variable domain polypeptide or other monovalent antibody single variable domain
  • SPR Surface Plasmon Resonance
  • Biacore Biacore system
  • antigen is coupled to the Biacore chip at known concentrations, and variable domain polypeptides are introduced.
  • Specific binding between the single variable domain polypeptide and the immobilized antigen results in increased protein concentration on the chip matrix and a change in the SPR signal. Changes in SPR signal are recorded as resonance units (RU) and displayed with respect to time along the Y axis of a sensorgram.
  • RU resonance units
  • Baseline signal is taken with solvent alone (e.g., PBS) passing over the chip.
  • solvent alone e.g., PBS
  • the net difference between baseline signal and signal after completion of antibody single variable domain injection represents the binding value of a given sample.
  • Biacore kinetic evaluation software e.g., version 2.1
  • SPR can be used to monitor antagonism of CD28 binding to CD80 or CD86 by a monovalent anti-CD28 antibody preparation by measuring the displacement or inhibition of binding of CD28 to CD80 or CD86 caused the monovalent antibody preparation.
  • SPR can also be used to monitor the dimerization, or in an aspect, the lack of dimerization, occurring via Fc region in antibody preparations as described herein.
  • High affinity is dependent upon the complementarity between a surface of the antigen and the CDRs of the antibody or antibody fragment.
  • Complementarity is determined by the type and strength of the molecular interactions possible between portions of the target and the CDR, for example, the potential ionic interactions, van der Waals attractions, hydrogen bonding or other interactions that can occur.
  • CDR3 tends to contribute more to antigen binding interactions than CDRs 1 and 2, probably due to its generally larger size, which provides more opportunity for favorable surface interactions. (See, e.g., Padlan et al., 1994, MoI. Immunol. 31: 169-217; Chothia & Lesk, 1987, J. MoI. Biol.
  • High affinity indicates antibody single variable domain/antigen pairings that have a high degree of complementarity, which is directly related to the structures of the variable domain and the target.
  • a monovalent anti-CD28 antibody single variable domain e.g., an antibody single variable domain polypeptide
  • another antibody single variable domain is linked to another antibody single variable domain to form a heterodimer in which each individual antibody single variable domain is capable of binding a different cognate antigen.
  • Fusing antibody single variable domains, such as antibody single variable domains, as heterodimers, wherein each monomer binds a different target antigen can produce a dual-specific ligand capable, for example, of bridging the respective target antigens.
  • dual specific ligands may be used to target cytokines and other molecules which cooperate synergistically in therapeutic situations in the body of an organism.
  • Anti-CD28 antibody single variable domains set forth herein include CD28-binding antibody single variable domain clones, and clones with substantial sequence identity that also bind target antigen with high affinity.
  • a first sequence encoding an antibody single variable domain polypeptide is substantially similar to a second coding sequence if the first sequence hybridizes to the second sequence (or its complement) under highly stringent hybridization conditions (such as those described by Sambrook et al., Molecular Cloning, Laboratory Manuel, Cold Spring, Harbor Laboratory press, New York).
  • Highly stringent hybridization conditions refer to hybridization in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C.
  • Very highly stringent hybridization conditions refer to hybridization in 0.5M sodium phosphate, 7% SDS at 65°C, followed by one or more washes at 0.2X SSC, 1% SDS at 65 0 C.
  • a monovalent anti-CD28 antibody single variable domain as described herein binds to CD28 yet does not substantially agonize CD28 signaling. Activation of the CD28 pathway manifests a number of different outcomes that can be measured in order to assess the effect of a given monovalent anti-CD28 antibody single variable domain on the activity of the pathway.
  • at least one of the following CD28 assays can be used.
  • activation of T cells is measured.
  • human CD4 positive T- cells are stimulated with anti-CD3 plus transfected CHO cells expressing either CD80 or CD86. This results in proliferation of the T cells and is CD28 dependent as anti-CD28 mAbs block the proliferation response.
  • induction of T cell proliferation and induction of cytokine secretion is measured.
  • the assay comprises stimulation of human CD4 positive T cells with anti-CD28 mAb 9.3 (Gibson, et al. (1996) JBC, 271:7079-7083). This results in upregulation of T cell receptor-mediated signaling and secretion of cytokines and is CD28-dependent, as mAb 9.3 blocks the proliferation response.
  • Secreted cytokines that may be measured include, but are not limited to, DL-2, IL-6, EL-IO, IL- 13, TNF- ⁇ and IFN- ⁇ .
  • cytokines may be detected and/or measured according to the disclosure set forth herein.
  • anti-CD28 antibody single variable domains set forth herein can possess multiple functions and activities, and therefore, may be assayed by multiple distinct assays.
  • anti-CD28 antibody single variable domains have multiple defining characteristics (e.g., CD28 binding affinity, CDR domain identity, and amino acid sequence, among others), and therefore, each distinct polypeptide can be characterized in multiple ways and through multiple parameters. The characterization of each such polypeptide, alone or in conjunction with the activity and/or CD28 binding properties of the polypeptide, can therefore provide unique identifying characteristics for the polypeptide.
  • PEGylated monovalent anti-CD28 antibody single variable domains which have increased half-life and in an aspect, also resistance to degradation without a loss in activity (e.g., binding affinity) relative to non-PEGylated antibody single variable domains.
  • monovalent anti-CD28 antibody single variable domains can be coupled, using methods known in the art to polymer molecules (in an aspect, PEG) useful for achieving the increased half-life and degradation resistance properties encompassed herein.
  • Polymer moieties which can be utilized can be synthetic or naturally occurring and include, but are not limited to straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymers, or a branched or unbranched polysaccharide such as a homo- or heteropolysaccharide.
  • Preferred examples of synthetic polymers which may be used include straight or branched chain poly(ethylene glycol) (PEG), poly(propylene glycol), or poly(vinyl alcohol) and derivatives or substituted forms thereof.
  • substituted polymers useful include substituted PEG, including methoxy(polyethylene glycol).
  • Naturally occurring polymer moieties which may be used herein in addition to or in place of PEG include lactose, amylose, dextran, or glycogen, as well as derivatives thereof which would be recognized by one of skill in the art.
  • Derivatized forms of polymer molecules as set forth herein include, for example, derivatives which have additional moieties or reactive groups present therein to permit interaction with amino acid residues of the dAb polypeptides described herein.
  • Such derivatives include N-hydroxylsuccinimide (NHS) active esters, succinimidyl propionate polymers, and sulfhydryl-selective reactive agents such as maleimide, vinyl sulfone, and thiol.
  • NHS N-hydroxylsuccinimide
  • succinimidyl propionate polymers succinimidyl propionate polymers
  • sulfhydryl-selective reactive agents such as maleimide, vinyl sulfone, and thiol.
  • Particularly preferred derivatized polymers include, but are not limited to PEG polymers having the formulae: PEG-O-CH 2 CH 2 CH 2 -CO 2 -NHS; PEG-O-CH 2 -NHS; PEG-O-CH 2 CH 2 -CO 2 -NHS; PEG-S-CH 2 CH 2 -CO-NHS; PEG-O 2 CNH-CH(R)-CO 2 -NHS; PEG-NHCO-CH 2 CH 2 -CO-NHS; and PEG-O-CH 2 -CO 2 -NHS; where R is (CH 2 ) 4 )NHCO 2 (mPEG).
  • PEG polymers useful as set forth herein may be linear molecules, or may be branched wherein multiple PEG moieties are present in a single polymer.
  • Some particularly preferred PEG derivatives which are useful as set forth herein include, but are not limited to mPEG-MAL, mPEG2-MAL, mPEG-(MAL) 2 , multi- arm PEG, mPEG-SPA, mPEG2-NHS, and mPEG2-(MAL) 2 , illustrated below:
  • the reactive group (e.g., MAL, NHS, SPA, VS, or Thiol) may be attached directly to the PEG polymer or may be attached to PEG via a linker molecule.
  • the size of polymers useful as set forth herein can be in the range of between 500 Da to 60 kDa, for example, between 1000 Da and 60 kDa, 10 kDa and 60 kDa, 20 kDa and 60 kDa, 30 kDa and 60 kDa, 40 kDa and 60 kDa, and up to between 50 kDa and 60 kDa.
  • the polymers used herein, particularly PEG can be straight chain polymers or can possess a branched conformation.
  • the polymer molecules useful as set forth herein when attached to a monovalent anti-CD28 antibody single variable domain, will yield a molecule having an average hydrodynamic size of between 24 and 500 kDa.
  • the hydrodynamic size of a polymer molecule used herein refers to the apparent size of a molecule (e.g., a protein molecule) based on the diffusion of the molecule through an aqueous solution. The diffusion, or motion of a protein through solution can be processed to derive an apparent size of the protein, where the size is given by the Stokes radius or hydrodynamic radius of the protein particle.
  • the hydrodynamic size of a protein depends on both mass and shape (conformation), such that two proteins having the same molecular mass may have differing hydrodynamic sizes based on the overall conformation of the protein.
  • the hydrodynamic size of a PEG-linked monovalent anti-CD28 antibody single variable domain e.g., an anti-CD28 antibody single variable domain as described herein, can be in the range of 24 kDa to 500 kDa; 30 to 500 kDa; 40 to 500 kDa; 50 to 500 kDa; 100 to 500 kDa; 150 to 500 kDa; 200 to 500 kDa; 250 to 500 kDa; 300 to 500 kDa; 350 to 500 kDa; 400 to 500 IcDa 1 and 450 to 500 kDa.
  • the hydrodynamic size of a PEGylated antibody single variable domain as described herein is 30 to 40 kDa; 70 to 80 kDa or 200 to 300 kDa.
  • the size of a polymer molecule attached to a monovalent anti-CD28 antibody single variable domain may thus be varied depending upon the desired application. For example, where the PEGylated antibody single variable domain is intended to leave the circulation and enter into peripheral tissues, it is desirable to keep the size of the attached polymer low to facilitate extravazation from the blood stream. Alternatively, where it is desired to have the PEGylated antibody single variable domain remain in the circulation for a longer period of time, a higher molecular weight polymer can be used (e.g., a 30 to 60 kDa polymer).
  • the polymer (PEG) molecules useful as set forth herein can be attached to antibody single variable domains using methods that are well known in the art.
  • the first step in the attachment of PEG or other polymer moieties to an antibody single variable domain is the substitution of the hydroxyl end-groups of the PEG polymer by electrophile-containing functional groups.
  • PEG polymers are attached to either cysteine or lysine residues present in the antibody single variable domain.
  • the cysteine and lysine residues can be naturally occurring, or can be engineered into the antibody single variable domain molecule.
  • cysteine residues can be recombinantly engineered at the C-terminus of antibody single variable domains, or residues at specific solvent accessible locations in the antibody single variable domain can be substituted with cysteine or lysine.
  • a PEG moiety is attached to a cysteine residue which is present in the hinge region at the C-terminus of an antibody single variable domain.
  • a PEG moiety or other polymer is attached to a cysteine or lysine residue which is either naturally occurring at or engineered into the N-terminus of antibody single variable domain polypeptide as set forth herein.
  • a PEG moiety or other polymer is attached to an antibody single variable domain as set forth herein at a cysteine or lysine residue (either naturally occurring or engineered) which is at least 2 residues away from (e.g., internal to) the C- and/or N-terminus of the antibody single variable domain polypeptide.
  • the PEG polymer(s) is attached to one or more cysteine or lysine residues present in a framework region (FR or FWs) and one or more heterologous CDRs of an antibody single variable domain.
  • CDRs and framework regions are those regions of an antibody variable domain as defined in the Kabat database of Sequences of Proteins of Immunological Interest (Kabat et al., 1991, Sequences of Immunological Interest, 5 th ed. U.S. Dept. Health & Human Services, Washington, D.C.).
  • a PEG polymer is linked to a cysteine or lysine residue in the V H framework segment DP47, or the Vk framework segment DPK9.
  • Cysteine and/or lysine residues of DP47 which may be linked to PEG disclosed herein include the cysteine at positions 22, or 96 and the lysine at positions 43, 65, 76, or 98 of SEQ ID NO: 1.
  • Cysteine and/or lysine residues of DPK9 which may be linked to PEG disclosed herein include the cysteine residues at positions 23, or 88 and the lysine residues at positions 39, 42, 45, 103, or 107 of SEQ ID NO: 3.
  • specific cysteine or lysine residues may be linked to PEG in the V H canonical framework region DP38, or DP45.
  • Solvent accessible residues in any given antibody e.g., a dAb, can be determined using methods known in the art such as analysis of the crystal structure of the antibody single variable domain.
  • the residues Gln-13, Pro-14, GIy- 15, Pro-41, Gly-42, Lys-43, Asp-62, Lys-65, Arg-87, Ala-88, Glu-89, GIn-112, Leu-115, Thr- 117, Ser-119, and Ser-120 have been identified as being solvent accessible, and disclosed herein would be attractive candidates for mutation to cysteine or lysine residues for the attachment of a PEG polymer.
  • a PEG polymer is linked to multiple solvent accessible cysteine or lysine residues, or to solvent accessible residues which have been mutated to a cysteine or lysine residue.
  • only one solvent accessible residue is linked to PEG, either where the particular antibody single variable domain only possesses one solvent accessible cysteine or lysine (or residue modified to a cysteine or lysine) or where a particular solvent accessible residue is selected from among several such residues for PEGylation.
  • V k dummy Primary amino acid sequence of V k dummy (SEQ ID NO: 328).
  • PEG attachment schemes disclosed herein are provided by the company Nektar (SanCarlos, CA).
  • Nektar SanCarlos, CA
  • active esters of PEG polymers which have been derivatized with N- hydroxylsuccinimide, such as succinimidyl propionate may be used.
  • PEG polymers which have been derivatized with sulfhydryl- selective reagents such as maleimide, vinyl sulfone, or thiols may be used.
  • PEG derivatives which may be used as disclosed herein to generate PEGylated antibodies can be found in the Nektar Catalog (available on the world wide web at nektar.com).
  • Nektar Catalog available on the world wide web at nektar.com.
  • derivitized forms of PEG may be used as disclosed herein to facilitate attachment of the PEG polymer to an antibody single variable domain.
  • PEG derivatives disclosed herein include, but are not limited to PEG-succinimidyl succinate, urethane linked PEG, PEG phenylcarbonate, PEG succinimidyl carbonate, PEG-carboxymethyl azide, dimethylmaleic anhydride PEG, PEG dithiocarbonate derivatives, PEG-tresylates (2,2,2- trifluoroethanesolfonates), mPEG imidoesters, and other as described in Zalipsky and Lee, (1992) ("Use of functionalized poly(ethylene glycol)s for modification of peptides" in PolvfEthylene Glycol) Chemistry: Biotechnical and Biomedical Applications. J. Milton Harris, Ed., Plenum Press, NY).
  • an anti-CD28 antibody single variable domain composition comprising an antibody single variable domain and PEG polymer wherein the ratio of PEG polymer to antibody single variable domain is a molar ratio of at least 0.25: 1. In a further embodiment, the molar ratio of PEG polymer to antibody single variable domain is 0.33:1 or greater. In a still further embodiment the molar ratio of PEG polymer to antibody single variable domain is 0.5: 1 or greater.
  • ligands disclosed herein or libraries for use herein can be constructed by varying the binding site of the molecule in order to generate a repertoire with structural and/or functional diversity. This means that variants are generated such that they possess sufficient diversity in their structure and/or in their function so that they are capable of providing a range of activities.
  • the desired diversity is typically generated by varying the selected molecule at one or more positions.
  • the positions to be changed can be chosen at random or are in an aspect, selected.
  • the variation can then be achieved either by randomization, during which the resident amino acid is replaced by any amino acid or analogue thereof, natural or synthetic, producing a very large number of variants or by replacing the resident amino acid with one or more of a defined subset of amino acids, producing a more limited number of variants.
  • H3 region of a human tetanus toxoid-binding Fab has been randomized to create a range of new binding specificities (Barbas et al. (1992) Proc. Natl. Acad. ScL USA, 89: 4457). Random or semi-random H3 and L3 regions have been appended to germline V gene segments to produce large libraries with unmutated framework regions (Hoogenboom & Winter (1992) J. MoI. Biol, 227: 381; Barbas et al. (1992) Proc. Natl. Acad. ScL USA, 89: 4457; Nissim er a/.
  • loop randomization has the potential to create approximately more than 10 15 structures for H3 alone and a similarly large number of variants for the other five loops, it is not feasible using current transformation technology or even by using cell free systems to produce a library representing all possible combinations.
  • 6 x 10 10 different antibodies which is only a fraction of the potential diversity for a library of this design, were generated (Griffiths et al. (1994) supra).
  • the binding site for the target is most often the antigen binding site.
  • These residues are extremely diverse in the human antibody repertoire and are known to make contacts in high-resolution antibody/antigen complexes.
  • positions 50 and 53 are diverse in naturally occurring antibodies and are observed to make contact with the antigen.
  • the conventional approach would have been to diversify all the residues in the corresponding Complementarity Determining Region (CDRl) as defined by Kabat et al (Kabat et al., 1991, Sequences of Immunological Interest, 5 ed.
  • CDRl Complementarity Determining Region
  • antibody diversity is the result of two processes: somatic recombination of germline V, D, and J gene segments to create a naive primary repertoire (so called germline and junctional diversity) and somatic hypermutation of the resulting rearranged V genes.
  • somatic hypermutation spreads diversity to regions at the periphery of the antigen binding site that are highly conserved in the primary repertoire (see Tomlinson et al. (1996) J. MoI. Biol, 256: 813).
  • This complementarity has probably evolved as an efficient strategy for searching sequence space and, although apparently unique to antibodies, it can easily be applied to other polypeptide repertoires.
  • the residues which are varied are a subset of those that form the binding site for the target. Different (including overlapping) subsets of residues in the target binding site are diversified at different stages during selection, if desired.
  • an initial 'naive' repertoire is created where some, but not all, of the residues in the antigen binding site are diversified.
  • the term "naive” refers to antibody molecules that have no pre-determined target. These molecules resemble those which are encoded by the immunoglobulin genes of an individual who has not undergone immune diversification, as is the case with fetal and newborn individuals, whose immune systems have not yet been challenged by a wide variety of antigenic stimuli.
  • This repertoire is then selected against a range of antigens or epitopes. If required, further diversity can then be introduced outside the region diversified in the initial repertoire. This matured repertoire can be selected for modified function, specificity or affinity.
  • naive repertoires of binding domains for the construction of ligands or a naive library of ligands, in which some or all of the residues in the antigen binding site are varied.
  • the "primary" library mimics the natural primary repertoire, with diversity restricted to residues at the centre of the antigen binding site that are diverse in the germline V gene segments (germline diversity) or diversified during the recombination process (junctional diversity).
  • residues which are diversified include, but are not limited to, H50, H52, H52a, H53, H55, H56, H58, H95, H96, H97, H98, L50, L53, L91, L92, L93, L94, and L96.
  • residues that are diversified during the recombination process include, but are not limited to: H31, H33, H35, H95, H96, H97, H98, L30, L31, L32, L34, and L96. All the residues listed above as suitable for diversification in these libraries are known to make contacts in one or more antibody-antigen complexes. Since in both libraries, not all of the residues in the antigen binding site are varied, additional diversity is incorporated during selection by varying the remaining residues, if it is desired to do so. It shall be apparent to one skilled in the art that any subset of any of these residues (or additional residues which comprise the antigen binding site) can be used for the initial and/or subsequent diversification of the antigen binding site.
  • a feature of side-chain diversity in the antigen binding site of human antibodies is a pronounced bias which favors certain amino acid residues. If the amino acid composition of the ten most diverse positions in each of the V H , V K , and " V ⁇ regions are summed, more than 76% of the side-chain diversity comes from only seven different residues, these being, serine (24%), tyrosine (14%), asparagine (11%), glycine (9%), alanine (7%), aspartate (6%), and threonine (6%).
  • This bias towards hydrophilic residues and small residues which can provide main-chain flexibility probably reflects the evolution of surfaces which are predisposed to binding a wide range of antigens or epitopes and may help to explain the required promiscuity of antibodies in the primary repertoire.
  • the distribution of amino acids at the positions to be varied mimics that seen in the antigen binding site of antibodies.
  • Such bias in the substitution of amino acids that permits selection of certain polypeptides (not just antibody single variable domains) against a range of target antigens is easily applied to any polypeptide repertoire.
  • There are various methods for biasing the amino acid distribution at the position to be varied including the use of tri-nucleotide mutagenesis, see WO 97/08320), of which the preferred method, due to ease of synthesis, is the use of conventional degenerate codons.
  • codons (AGT)(AGC)T, (AGT)(AGC)C, and (AGT)(AGC)(CT) are those closest to the desired amino acid profile: they encode 22% serine and 11% tyrosine, asparagine, glycine, alanine, aspartate, threonine, and cysteine, and in an aspect, these codons are used in the construction of a library.
  • dual-specific polypeptides comprising antibody single variable domains which each have respective specificities; that is, the first and the second epitopes bound by the dual-specific ligand are in an aspect, different or are two copies of the same epitopes being bound by a respective variable domain.
  • a "dual-specific polypeptide" refers to a polypeptide comprising a first antibody single variable domain and a second antibody single variable domain as herein defined, wherein each of the variable domains is capable of binding one of two different antigens or one of two epitopes on the same antigen.
  • the two epitopes may be on the same antigen.
  • the dual specific polypeptides disclosed herein are composed of antibody single variable domains which have different specificities, and do not contain mutually complementary variable domain pairs which have the same specificity.
  • Dual- specific polypeptides may be, or be part of, polypeptides, proteins, or nucleic acids, which may be naturally occurring or synthetic.
  • the antibody single variable domains disclosed herein may bind an epitope or antigen and act as an antagonist or agonist (e.g., CD28 antagonist).
  • the epitope binding domains of the dual specific polypeptides in one embodiment have the same epitope specificity, and may for example simultaneously bind their epitope when multiple copies of the epitope are present on the same antigen.
  • these epitopes are provided on different antigens such that the ligand can bind the epitopes and bridge the antigens.
  • epitopes and antigens may be for instance human or animal proteins, cell surface proteins, cytokines, cytokine receptors, enzymes co-factors for enzymes or DNA binding proteins.
  • variable domains are derived from an antibody directed against the first and/or second antigen or epitope.
  • variable domains are derived from a repertoire of single variable antibody domains.
  • the repertoire is a repertoire that is not created in an animal or a synthetic repertoire.
  • the single variable domains are not isolated (at least in part) by animal immunization.
  • the antibody single variable domains can be isolated from a naive library.
  • a multi-specific polypeptide comprising a first epitope binding antibody single variable domain having a first epitope binding specificity and a non-complementary second epitope binding antibody single variable domain having a second epitope binding specificity.
  • the first and second binding specificities may be the same or different.
  • a closed conformation multi-specific polypeptide comprising a first epitope antibody single variable domain having a first epitope binding specificity and a non-complementary second epitope antibody single variable domain having a second epitope binding specificity wherein the first and second binding specificities are capable of competing for epitope binding such that the closed conformation multi-specific polypeptide cannot bind both epitopes simultaneously.
  • re open conformation polypeptides comprising non-complementary antibody single variable domains, wherein the domains are specific for a different epitope on the same target. Such polypeptides bind to targets with increased avidity.
  • multivalent polypeptides comprising non-complementary antibody single variable domains specific for the same epitope and directed to targets which comprise multiple copies of said epitope.
  • polypeptides comprising non-complementary antibody single variable domains disclosed herein can be configured to bind individual epitopes with low affinity, such that binding to individual epitopes is not therapeutically significant; but the increased avidity resulting from binding to two epitopes provides a therapeutic benefit.
  • epitopes may be targeted which are present individually on normal cell types, but present together only on abnormal or diseased cells, such as tumor cells. In such a situation, only the abnormal or diseased cells are effectively targeted by the bispecific polypeptides comprising non-complementary antibody single variable domains disclosed herein.
  • Polypeptides comprising non-complementary antibody single variable domains specific for multiple copies of the same epitope, or adjacent epitopes, on the same target may also be trimeric or polymeric (tetrameric or more), that is comprising three, four or more non-complementary antibody single variable domains.
  • ligands may be constructed comprising three or four V H domains or V L domains.
  • polypeptides comprising non-complementary antibody single variable domains which bind to multisubunit targets, wherein each binding domain is specific for a subunit of said target.
  • the ligand may be dimeric, trimeric, or polymeric.
  • dual specific polypeptides comprising a first antibody single variable domain having a binding specificity to a first antigen and a second antibody single variable domain having a binding specificity to a second antigen, wherein the first antigen is CD28 and the second single variable domain is an antigen presenting cell surface antigen or a T cell surface antigen, e.g., T cell receptor.
  • the antigen presenting cell (APC) surface antigen can be selected from one of the group consisting of dendritic cell surface antigens, activated macrophage surface antigens, activated B cell surface antigens, co-stimulatory signal pathway surface antigens, and MHC, such as MHC II alpha or beta.
  • the multi-specific polypeptides according to the above aspects disclosed herein are obtainable by the method comprising the steps of:
  • first epitope binding single variable domain and the second epitope binding single variable domains are non-complementary antibody variable domains, where each single variable domain binds its antigen or cognate ligand independently of the second single variable domain as herein defined.
  • a multi-specific polypeptide may have the following nonlimiting formats: V H ⁇ V H or V L " V L single variable domains.
  • Chelating polypeptides comprising or consisting of antibody single variable domains in particular may be prepared according to a preferred aspect disclosed herein, namely the use of anchor antibody single variable domains, in which a library of dimeric, trimeric, or multimeric antibody single variable domains is constructed using a vector which comprises a constant antibody single variable domain upstream or downstream of a linker sequence, with a repertoire of second, third, and further antibody single variable domains being inserted on the other side of the linker.
  • linkers may be avoided, for example by the use of non-covalent bonding or natural affinity between binding domains such as V H and V ⁇ .
  • a method for preparing a multimeric polypeptide comprising antibody single variable domains comprising the steps of: (a) providing a vector comprising a nucleic acid sequence encoding an antibody single variable domain specific for a first epitope on a target;
  • the first and second epitopes are adjacent such that such a multimeric polypeptide is capable of binding to both epitopes simultaneously, providing the advantages of increased avidity of binding.
  • the increased avidity is obtained by the presence of multiple copies of the epitope on the target, allowing at least two copies to be simultaneously bound in order to obtain the increased avidity effect.
  • At least one epitope binding domain comprises a non-immunoglobulin 'protein scaffold' or 'protein skeleton' as herein defined.
  • Suitable non-immunoglobulin protein scaffolds include but are not limited to any of those selected from the group consisting of: SpA, fibronectin, GroEL and other chaperones, lipocallin, CTLA4, and affibodies, as set forth above.
  • the epitope binding domains are attached to a 'protein skeleton'.
  • a protein skeleton disclosed herein is an immunoglobulin skeleton.
  • the term 'immunoglobulin skeleton' refers to a protein which comprises at least one immunoglobulin fold and which acts as a nucleus for one or more epitope binding domains, as defined herein.
  • immunoglobulin skeletons as herein defined includes any one or more of those selected from the following: an immunoglobulin molecule comprising at least (i) the CL (kappa or lambda subclass) domain of an antibody; or (ii) the CHl or the CH2 or the CH3 domain of an antibody heavy chain; an immunoglobulin molecule comprising the CHl and CH2 domains of the CH2 and CH3 domains, or the CHl and CH3 domains of an antibody heavy chain; an immunoglobulin molecule comprising the CHl, CH2 and CH3 domains of an antibody heavy chain; or any of the subset (ii) in conjunction with the CL (kappa or lambda subclass) domain of an antibody.
  • a binge region domain may also be included.
  • Such combinations of domains may, for example, mimic natural antibodies, such as IgG or IgM, or fragments thereof, such as Fv, scFv, Fab, or F(ab') 2 molecules. Those skilled in the art will be aware that this list is not intended to be exhaustive.
  • Linking of the skeleton to the epitope binding domains may be achieved at the polypeptide level, that is after expression of the nucleic acid encoding the skeleton and/or the epitope binding domains. Alternatively, the linking step may be performed at the nucleic acid level.
  • Methods of linking a protein skeleton disclosed herein, to the one or more epitope binding domains include the use of protein chemistry and/or molecular biology techniques which will be familiar to those skilled in the art and are described herein.
  • the dual- or multispecific polypeptides comprising multiple antibody single variable domains may comprise a first domain capable of binding a target molecule, e.g., CD28, and a second domain capable of binding a molecule or group which extends the half-life of the ligand.
  • a target molecule e.g., CD28
  • the molecule or group may be a bulky agent, such as human serum albumin (HSA) or a cell matrix protein.
  • the phrase "molecule or group which extends the half-life of an antibody single variable domain or polypeptide comprising an antibody single variable domain” refers to a molecule or chemical group which, when bound by a dual-specific or multi-specific polypeptide comprising multiple single variable domains as described herein, increases the in vivo half-life of such a dual specific polypeptide when administered to an animal, relative to a respective dual or multi specific polypeptide that does not bind that molecule or group. Examples of molecules or groups that extend the half-life of a dual specific polypeptide are described herein below.
  • the closed conformation multispecific or dual specific polypeptide may be capable of binding the target molecule only on displacement of the half-life enhancing molecule or group.
  • a closed conformation multispecific polypeptide comprising multiple antibody single variable domains is maintained in circulation in the bloodstream of a subject by a bulky molecule such as HSA.
  • a target molecule such as HSA.
  • competition between the binding domains of the closed conformation multispecif ⁇ c polypeptide comprising multiple antibody single variable domains results in displacement of the HSA and binding of the target. Molecules which increase half-life are discussed in further detail above.
  • Antibody single variable domains and/or polypeptides comprising antibody single variable domains according to any aspect disclosed herein, as well as antibody single variable domain monomers useful in constructing such polypeptides may advantageously dissociate from their cognate target(s) with a K d of 300 nM to 1 pM or 5 pM (i.e., 3 x 10 "7 to 5 x 10 '12 M) , in an aspect, 50 nM to20 pM, or 5 nM to 200 pM or 1 nM to 100 pM, 1 x 10 "7 M or less, 1 x 10 "8 M or less, 1 x 10 "9 M or less, 1 x 10 "10 M or less, 1 x 10 "11 M or less; and/or a K off rate constant of 5 x 10 '1 to 1 x 10 "7 S “1 , in an aspect, 1 x 10 "2 to 1 x 10 "6 S “1 , or 5 x 10° to 1 x 10 "5
  • the invention in one embodiment provides a polypeptide or antagonist (e.g., dual specific polypeptide comprising an anti-CD28 antibody single variable domain (a first antibody single variable domain)) that binds to CD28 and a second antibody single variable domain that binds serum albumin (SA), the second dAb binding SA with a K D as determined by surface plasmon resonance of InM to 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 100, 200, 300, 400 or 500 ⁇ M (i.e., x 10 '9 to 5 x 10 "4 ), or 100 nM to 10 ⁇ M, or 1 to 5 ⁇ M or 3 to 70 nM or 1OnM to 1, 2, 3, 4 or 5 ⁇ M.
  • a polypeptide or antagonist e.g., dual specific polypeptide comprising an anti-CD28 antibody single variable domain (a first antibody single variable domain)
  • SA serum albumin
  • the first antibody single variable domain (or a dAb monomer) binds SA (e.g., Human Serum Albumin) with a K D as determined by surface plasmon resonance of approximately 1, 50, 70, 100, 150, 200, 300 nM or 1, 2 or 3 ⁇ M.
  • SA e.g., Human Serum Albumin
  • K D as determined by surface plasmon resonance of approximately 1, 50, 70, 100, 150, 200, 300 nM or 1, 2 or 3 ⁇ M.
  • the affinity e.g. K D and/or Koff as measured by surface plasmon resonance, e.g.
  • the second dAb for its target is from 1 to 100000 times (e.g., 100 to 100000, or 1000 to 100000, or 10000 to 100000 times) the affinity of the first antibody single variable domain for SA.
  • the serum albumin is human serum albumin (HSA).
  • the first antibody single variable domain binds SA with an affinity of approximately 10 ⁇ M, while the second antibody single variable domain binds its target with an affinity of 100 pM.
  • the serum albumin is human serum albumin (HSA).
  • the first antibody single variable domain binds SA (e.g., HSA) with a K D of approximately 50, for example 70, 100, 150 or 200 nM. Details of dual specific polypeptides comprising antibody single variable domains are found in WO03002609, WO04003019 and WO04058821, which are incorporated by reference herein in their entirety.
  • dimers, trimers and polymers of the aforementioned antibody single variable domain monomers are also provided.
  • Antibody single variable domain monomers, dimers and trimers, disclosed herein can be linked to an antibody Fc region, comprising one or both of C H 2 and C H 3 domains, and optionally a hinge region.
  • vectors encoding ligands linked as a single nucleotide sequence to an Fc region may be used to prepare such polypeptides.
  • ligands disclosed herein may be free of an Fc domain.
  • one or more nucleic acid molecules encoding at least a dual- or multi-specific polypeptide comprising an antibody single variable domain as herein defined.
  • the dual- or multi-specific polypeptide is a closed conformation ligand. In another embodiment, it is an open conformation ligand.
  • the dual- or multi-specific polypeptide may be encoded by a single nucleic acid molecule; alternatively, each dual- or multi- specific polypeptide may be encoded by a separate nucleic acid molecule. Where the dual- or multi-specific polypeptide is encoded by a single nucleic acid molecule, the domains may be expressed as a fusion polypeptide, or may be separately expressed and subsequently linked together, for example using chemical linking agents. Dual- or multi-specific polypeptides expressed from separate nucleic acids will be linked together by appropriate means.
  • the nucleic acid may further encode a signal sequence for export of the polypeptides from a host cell upon expression and may be fused with a surface component of a filamentous bacteriophage particle (or other component of a selection display system) upon expression.
  • Leader sequences which may be used in bacterial expression and/or phage or phagemid display, include pelB, stll, ompA, phoA, bla, ompT and pelA.
  • a vector comprising nucleic acid.
  • a host cell transfected with a vector.
  • Expression from such a vector may be configured to produce, for example on the surface of a bacteriophage particle, epitope binding domains for selection. This allows selection of displayed domains and thus selection of 'multispecific ligands' using the method disclosed herein.
  • a conventional antibody is herein defined as an antibody or fragment (Fab, Fv, disulfide linked Fv, scFv, diabody) which comprises at least one heavy and a light chain variable domain, at least two heavy chain variable domains or at least two light chain variable domains. It may be at least partly derived from any species naturally producing an antibody, or created by recombinant DNA technology; whether isolated from serum, B-cells, hybridomas, transfectomas, yeast or bacteria).
  • the multi-specific polypeptide comprises at least one heavy chain antibody single variable domain and one light chain antibody single variable domain, or two heavy or light chain antibody single variable domains.
  • the multi-specific polypeptide may comprise a V H /V L pair, a pair of V H domains or a pair OfV 1- domains.
  • the first and the second variable domains of such a the multi-specific polypeptide may be on the same polypeptide chain. Alternatively they may be on separate polypeptide chains. In the case that they are on the same polypeptide chain they may be linked by a linker, which is preferentially a peptide sequence, as described above.
  • the first and second variable domains may be covalently or non-covalently associated. In the case that they are covalently associated, the covalent bonds may be disulphide bonds.
  • variable domains are selected from V-gene repertoires selected for instance using phage display technology as herein described, then these variable domains comprise a universal framework region, such that is they may be recognized by a specific generic ligand as herein defined.
  • the use of universal frameworks, generic ligands, and the like is described in WO 99/20749.
  • V-gene repertoires are used variation in polypeptide sequence is, in an aspect, located within the structural loops of the variable domains.
  • the polypeptide sequences of either antibody single variable domain may be altered by DNA shuffling or by mutation.
  • DNA shuffling is known in the art and taught, for example, by Stemmer, 1994, Nature 370: 389-391 and U.S. Patent No. 6,297,053, both of which are incorporated herein by reference.
  • Other methods of mutagenesis are well known to those of skill in the art.
  • the 'dual-specific polypeptide' comprising antibody single variable domains is in the format of a single chain Fv fragment.
  • the 'dual- specific ligand' is in the format of a Fab format.
  • a further aspect disclosed herein provides nucleic acid encoding at least a 'dual-specific polypeptide' as herein defined.
  • both antigens or epitopes may bind simultaneously to the same antibody molecule. Alternatively, they may compete for binding to the same antibody molecule. For example, where both epitopes are bound simultaneously, both antibody single variable domains of a dual specific polypeptide are able to independently bind their target epitopes. Where the antibody single variable domains compete, the one antibody single variable domain is capable of binding its target, but not at the same time as the other antibody single variable domain binds its cognate target; or the first antibody single variable domain is capable of binding its target, but not at the same time as the second antibody single variable domain binds its cognate target.
  • the antibody single variable domains may be derived from variable regions of antibodies directed against target antigens or epitopes, e.g., CD28. Alternatively they may be derived from a repertoire of single antibody domains such as those expressed on the surface of filamentous bacteriophage. Selection may be performed as described below.
  • the nucleic acid molecules and vector constructs required for the performance as disclosed herein may be constructed and manipulated as set forth in standard laboratory manuals, such as Sambrook et al. (1989J Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, USA.
  • nucleic acids useful as disclosed herein is typically carried out in recombinant vectors.
  • a further aspect disclosed herein provides a vector comprising nucleic acid encoding at least a 'dual-specific polypeptide' comprising multiple antibody single variable domains as herein defined.
  • vector refers to a discrete element that is used to introduce heterologous DNA into cells for the expression and/or replication thereof.
  • Methods by which to select or construct and, subsequently, use such vectors are well known to one of ordinary skill in the art. Numerous vectors are publicly available, including bacterial plasmids, bacteriophage, artificial chromosomes, and episomal vectors. Such vectors may be used for simple cloning and mutagenesis; alternatively gene expression vector is employed.
  • a vector of use as disclosed herein may be selected to accommodate a polypeptide coding sequence of a desired size, typically from 0.25 kilobase (kb) to 40 kb or more in length.
  • a suitable host cell is transformed with the vector after in vitro cloning manipulations.
  • Each vector contains various functional components, which generally include a cloning (or "polylinker") site, an origin of replication, and at least one selectable marker gene. If given vector is an expression vector, it additionally possesses one or more of the following: enhancer element, promoter, transcription termination, and signal sequences, each positioned in the vicinity of the cloning site, such that they are operatively linked to the gene encoding a ligand as disclosed herein.
  • Both cloning and expression vectors generally contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells.
  • this sequence is one that enables the vector to replicate independently of the host chromosomal DNA and includes origins of replication or autonomously replicating sequences.
  • origins of replication or autonomously replicating sequences are well known for a variety of bacteria, yeast, and viruses.
  • the origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 micron plasmid origin is suitable for yeast, and various viral origins (e.g. SV 40, adenovirus) are useful for cloning vectors in mammalian cells.
  • the origin of replication is not needed for mammalian expression vectors unless these are used in mammalian cells able to replicate high levels of DNA, such as COS cells.
  • a cloning or expression vector may contain a selection gene also referred to as selectable marker.
  • This gene encodes a protein necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will therefore not survive in the culture medium.
  • Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available in the growth media.
  • Domains useful as disclosed herein, once selected using methods exemplified above, may be combined by a variety of methods known in the art, including covalent and non-covalent methods.
  • Preferred methods include the use of polypeptide linkers, as described, for example, in connection with scFv molecules (Bird et al, (1988) Science 242:423-426). Discussion of suitable linkers is provided in Bird et al. Science 242, 423-426; Hudson et al , Journal Immunol Methods 231 (1999) 177-189; Hudson et al, Proc Nat Acad Sci USA 85, 5879-5883. Linkers are in an aspect, flexible, allowing the two single domains to interact.
  • the linkers used in diabodies, which are less flexible, may also be employed (Holliger et al, (1993) PNAS (USA) 90: 6444-6448).
  • the linker employed is not an immunoglobulin hinge region.
  • Variable domains may be combined using methods other than linkers. For example, the use of disulphide bridges, provided through naturally-occurring or engineered cysteine residues, may be exploited to stabilize V H -V H> V L -V L or V H - V L dimers (Reiter et al, (1994) Protein Eng. 7: 697-704) or by remodeling the interface between the variable domains to improve the "fit" and thus the stability of interaction (Ridgeway et al, (1996) Protein Eng. 7:617-621; Zhu et al., (1997) Protein Science 6: 781-788).
  • variable domains of immunoglobulins and in particular antibody V H domains, may be employed as appropriate.
  • dual specific polypeptides can be in "closed” conformations in solution.
  • a “closed” configuration is that in which the two domains (for example V H and V L ) are present in associated form, such as that of an associated V H -V L pair which forms an antibody binding site.
  • scFv may be in a closed conformation, depending on the arrangement of the linker used to link the V H and V L domains. If this is sufficiently flexible to allow the domains to associate, or rigidly holds them in the associated position, it is likely that the domains will adopt a closed conformation.
  • V H domain pairs and V L domain pairs may exist in a closed conformation. Generally, this will be a function of close association of the domains, such as by a rigid linker, in the ligand molecule. Polypeptides comprising multiple antibody single variable domains in a closed conformation will be unable to bind both the molecule which increases the half-life of the polypeptide comprising multiple antibody single variable domains and a second target molecule. Thus, the polypeptide comprising multiple antibody single variable domains will typically only bind the second target molecule on dissociation from the molecule which increases the half-life of the ligand.
  • V H /V H , V 1 TV L or V H /V L dimers comprising multiple antibody single variable domains without linkers provides for competition between the domains.
  • Polypeptides comprising multiple antibody single variable domains disclosed herein may moreover be in an open conformation. In such a conformation, the ligands will be able to simultaneously bind both the molecule which increases the half-life of the ligand and the second target molecule.
  • the domains in a polypeptide comprising multiple antibody single variable domains in an open configuration are (in the case of V H -V L pairs) held far enough apart for the domains not to interact and form an antibody binding site and not to compete for binding to their respective epitopes.
  • the domains are not forced together by rigid linkers. Naturally, such domain pairings will not compete for antigen binding nor will such pairing produce a single antibody binding site formed by the two paired domains together.
  • Polypeptides comprising multiple antibody single variable domains disclosed herein, presented in a format of Fab fragments and whole antibodies, will exist primarily in the closed conformation, although it will be appreciated that open and closed dual-specific polypeptides are likely to exist in a variety of equilibria under different circumstances. Binding of one domain to a target is likely to shift the balance of the equilibrium towards the open configuration.
  • certain dual-specific polypeptides disclosed herein can exist in two conformations in solution, one of which (the open form) can bind two antigens or epitopes independently, while the alternative conformation (the closed form) can only bind one antigen or epitope; antigens or epitopes thus compete for binding to the ligand in this closed conformation.
  • the open form of the dual specific polypeptides comprising multiple antibody single variable domains disclosed herein may thus exist in equilibrium with the closed form in solution, it is envisaged that the equilibrium will favor the closed form; moreover, the open form can be sequestered by target binding into a closed conformation.
  • certain dual specific polypeptides comprising multiple antibody single variable domains disclosed herein are present in an equilibrium between two (open and closed) conformations.
  • Dual specific polypeptides comprising multiple antibody single variable domains disclosed herein may be modified in order to favor an open or closed conformation. For example, stabilization of V H -V L interactions with disulphide bonds stabilizes the closed conformation.
  • linkers used to join the domains, including V H domain and V L domain pairs may be constructed such that the open from is favored; for example, the linkers may sterically hinder the association of the domains, such as by incorporation of large amino acid residues in opportune locations, or the designing of a suitable rigid structure which will keep the domains physically spaced apart. 6.2.3 Characterization Of The Dual-Specific Polypeptide Comprising Multiple Antibody Single Variable Domains
  • binding of the dual-specific polypeptide comprising multiple antibody single variable domains disclosed herein to its specific antigens or epitopes can be tested by methods which will be familiar to those skilled in the art and include ELISA. In a preferred embodiment, binding is tested using monoclonal phage ELISA.
  • Phage ELISA may be performed according to any suitable procedure: an exemplary protocol is set forth below.
  • phage produced at each round of selection can be screened for binding by ELISA to the selected antigen or epitope, to identify "polyclonal" phage antibodies. Phage from single infected bacterial colonies from these populations can then be screened by ELISA to identify "monoclonal” phage antibodies. It is also desirable to screen soluble antibody fragments for binding to antigen or epitope, and this can also be undertaken by ELISA using reagents, for example, against a C- or N-terminal tag (see for example Winter et al. (1994) Ann. Rev. Immunology 12, 433-55 and references cited therein.
  • the diversity of the selected phage monoclonal antibodies may also be assessed by gel electrophoresis of PCR products (Marks et al. 1991, supra; Nissim et al. 1994 supra), probing (Tomlinson et al, 1992) J. MoI. Biol. 227, 776) or by sequencing of the vector DNA.
  • the PEGylated monovalent anti-CD28 antibody single variable domains as described herein confer a distinct advantage over non-PEGylated antibody single variable domains, in that the PEGylated antibody single variable domains molecules will have a greatly prolonged in vivo half-life. It will be understood, in the context of the present disclosure, that a particular half-life of any composition may be either increased or decreased by the route of administration of the composition to a patient.
  • the increased half-life of the molecules described herein is conferred by the increased hydrodynamic size of the antibody single variable domain resulting from the attachment of PEG polymer(s). More specifically, it is believed that two parameters play an important role in determining the serum half- life of PEGylated antibody single variable domains.
  • the first criterion is the nature and size of the PEG attachment, i.e., if the polymer used is simply a linear chain or a branched/forked chain, wherein the branched/forked chain gives rise to a longer half-life.
  • the second is the location of the PEG moiety or moieties on the antibody single variable domain in the final format and how many "free" unmodified PEG arms the molecule has.
  • the resulting hydrodynamic size of the PEGylated antibody single variable domain as estimated, for example, by size exclusion chromatography, reflects the serum half-life of the molecule. Accordingly, the larger the hydrodynamic size of the PEGylated molecule, the greater the serum half -life.
  • a monovalent anti-CD28 antibody single variable domain as described herein is stabilized in vivo by fusion with a moiety, such as PEG, that increases the hydrodynamic size of the antibody single variable domain.
  • a moiety such as PEG
  • Methods for pharmacokinetic analysis and determination of half-life will be familiar to those skilled in the art. Details may be found in Kenneth et al: Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists and in Peters et al, Pharmacokinetc analysis: A Practical Approach (1996). Reference is also made to "Pharmacokinetics", M Gibaldi & D Perron, published by Marcel Dekker, 2 nd Rev. ex edition (1982), which describes pharmacokinetic parameters such as t- ⁇ and t- ⁇ half lives and area under the curve (AUC).
  • the half -life of a PEGylated antibody single variable domain as described herein is increased by 10%, 20%, 30%, 40%, 50%, or more relative to a non-PEGylated dAb (wherein the antibody single variable domain of the PEGylated antibody single variable domain and non-PEGylated antibody single variable domain are the same).
  • Increases in the range of 2x, 3x, 4x, 5x, 7x, 10x, 2Ox, 30x, 40x, and up to 50x or more of the half -life are possible.
  • increases in the range of up to 30x, 4Ox, 5Ox, 6Ox, 70x, 80x, 9Ox, 10Ox, or 150x of the half -life are possible.
  • Half lives (tVi- ⁇ and tVi- ⁇ ) and AUC can be determined from a curve of serum concentration of ligand against time.
  • the WinNonlin analysis package (available from Pharsight Corp., Mountain View, CA 94040, USA) can be used, for example, to model the curve.
  • a first phase the alpha phase
  • a second phase (beta phase) is the terminal phase when the antibody single variable domain has been distributed and the serum concentration is decreasing as the antibody single variable domain is cleared from the patient.
  • the "t ⁇ half -life" is the half -life of the first phase and the "t ⁇ half -life” is the half -life of the second phase.
  • an antibody single variable domain -containing composition e.g., a antibody single variable domain -effector group composition is contemplated having a t ⁇ half-life in the range of 0.25 hours to 6 hours or more.
  • the lower end of the range is 30 minutes, 45 minutes, 1 hour, 1.3 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 10 hours, 11 hours, or 12 hours.
  • an antibody single variable domain containing composition will have a t ⁇ half-life in the range of up to and including 12 hours.
  • the upper end of the range is 11, 10, 9, 8, 7, 6, or 5 hours.
  • An example of a suitable range is 1.3 to 6 hours, 2 to 5 hours, or 3 to 4 hours.
  • a composition containing an antibody single variable domain has a t ⁇ half-life in the range of 1-170 hours or more.
  • the lower end of the range is 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 24, 36, 48, or 72 hours and the upper end of the range is up to 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, and up to 31 days.
  • an antibody single variable domain composition has a t ⁇ half-life in the range of at least 12 hours up to 24 hours, 14 days, 28 days, 4 weeks, and up to one month.
  • a dAb containing composition disclosed herein will have a t ⁇ half-life in the range 2-100 hours, 4-80 hours, and 10-40 hours. In a further embodiment, it will be in the range 12-48 hours. In a further embodiment still, it will be in the range 12-26 hours.
  • Disclosed herein is a composition containing an antibody single variable domain having a half-life in the range of 1-170 hours or more. In one embodiment, the lower end of the range is 1.3, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 24, 36, 48, or 72 hours.
  • a composition containing an antibody single variable domain has a half-life in the range of up to and including 21 days.
  • the upper end of the range is up to 12 hours, 24 hours, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, and up to 31 days.
  • a composition containing an antibody single variable domain has an AUC value (area under the curve) in the range of 1 mg.min/ml or more. In one embodiment, the lower end of the range is 5, 10, 15, 20, 30, 100, 200, or 300 mg.min/ml. In addition, or alternatively, a composition containing an antibody single variable domain disclosed herein has an AUC in the range of up to 600 mg.min/ml. In one embodiment, the upper end of the range is 500, 400, 300, 200, 150, 100, 75, or 50 mg.min/ml.
  • compositions containing an antibody single variable domain disclosed herein will have an AUC in the range selected from the group consisting of the following: 15 to 150 mg.min/ml, 15 to 100 mg.min/ml, 15 to 75 mg.min/ml, and 15 to 50 mg.min/ml.
  • polypeptides containing one or more antibody single variable domains disclosed herein, including, mono-, dual- and multi-specific polypeptides, in one configuration thereof, are capable of binding to one or more molecules which can increase the half-life of the ligand in vivo.
  • molecules are polypeptides which occur naturally in vivo and which resist degradation or removal by endogenous mechanisms which remove unwanted material from the organism.
  • the molecule which increases the half-life in the organism may be selected from the following:
  • Proteins from the extracellular matrix for example collagen, laminins, integrins, and fibronectin.
  • Collagens are the major proteins of the extracellular matrix.
  • about 15 types of collagen molecules are currently known, found in different parts of the body, e.g. type
  • Plasma proteins such as fibrin, ⁇ -2 macroglobulin, serum albumin, fibrinogen A, fibrinogen B, serum amyloid protein A, heptaglobin, profilin, ubiquitin, uteroglobulin, and ⁇ -2-microglobulin;
  • Enzymes and inhibitors such as plasminogen, lysozyme, cystatin C, alpha- 1 -antitrypsin, and pancreatic trypsin inhibitor.
  • Plasminogen is the inactive precursor of the trypsin-like serine protease plasmin. It is normally found circulating through the blood stream. When plasminogen becomes activated and is converted to plasmin, it unfolds a potent enzymatic domain that dissolves the fibrinogen fibers that entangle the blood cells in a blood clot. This is called fibrinolysis.
  • Immune system proteins such as IgE, IgG, and IgM.
  • Transport proteins such as retinol binding protein, ⁇ -1 microglobulin.
  • ⁇ Defensins such as beta-defensin 1, neutrophil defensins 1, 2, and 3.
  • Proteins found at the blood brain barrier or in neural tissues such as melanocortin receptor, myelin, ascorbate transporter.
  • Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins ⁇ see U.S. Patent No. 5,977,307); brain capillary endothelial cell receptor, transferrin, transferrin receptor, insulin, insulin-like growth factor 1 (IGF 1) receptor, insulin-like growth factor
  • IGF 2 receptor insulin receptor
  • Proteins localised to the kidney such as polycystin, type IV collagen, organic anion transporter Kl, Heymann's antigen.
  • Proteins localised to the liver for example alcohol dehydrogenase, G250.
  • Proteins localised to the lung such as secretory component (binds IgA).
  • HSP 27 Proteins localised to the heart, for example HSP 27. This is associated with dilated cardiomyopathy.
  • Proteins localised to the skin for example keratin.
  • Bone specific proteins such as bone morphogenic proteins (BMPs), which are a subset of the transforming growth factor ⁇ superfamily that demonstrate osteogenic activity. Examples include BMP-2, -4, -5, -6, -7 (also referred to as osteogenic protein (OP-I) and -8 (OP-2).
  • Tumour specific proteins including human trophoblast antigen, herceptin receptor, oestrogen receptor, cathepsins, e.g., cathepsin B (found in liver and spleen).
  • Disease-specific proteins such as antigens expressed only on activated T- cells: including LAG-3 (lymphocyte activation gene), osteoprotegerin ligand (OPGL) (see Nature 402, 304-309; 1999); OX40 (a member of the TNF receptor family, expressed on activated T cells and the only costimulatory T cell molecule known to be specifically up-regulated in human T cell leukemia virus type-I (HTLV-I)-producing cells.) (see J. Immunol.
  • angiogenic growth factors including acidic fibroblast growth factor (FGF-I), basic fibroblast growth factor (FGF-2), vascular endothelial growth factor / vascular permeability factor (VEGF /VPF), transforming growth factor-a (TGF a), tumor necrosis factor-alpha (TNF- ⁇ ), angiogenin, interleukin-3 (IL-3), interleukin-8 (IL-8), platelet-derived endothelial growth factor (PD-ECGF), placental growth factor (PlGF), midkine platelet-derived growth factor-BB (PDGF), fractalkine.
  • FGF-I acidic fibroblast growth factor
  • FGF-2 basic fibroblast growth factor
  • VEGF /VPF vascular endothelial growth factor / vascular permeability factor
  • TGF a tumor necrosis factor-alpha
  • IL-3 interleukin-3
  • IL-8 interleukin-8
  • PD-ECGF platelet-derived endothelial growth
  • HSPs Stress proteins
  • HSPs are normally found intracellularly. When they are found extracellularly, it is an indicator that a cell has died and spilled out its contents. This unprogrammed cell death (necrosis) only occurs when as a result of trauma, disease, or injury, and therefore in vivo, extracellular HSPs trigger a response from the immune system that will fight infection and disease.
  • a dual specific which binds to extracellular HSP can be localized to a disease site.
  • the Brambell receptor also known as FcRB.
  • FcRB The Brambell receptor
  • the functions include the transport of IgG from mother to child across the placenta and the protection of IgG from degradation thereby prolonging its serum half -life of IgG. It is thought that the receptor recycles IgG from endosome (See Holliger et al, Nat. Biotechnol. 1997 JuI; 15(7): 632-6).
  • FcRn neonatal Fc receptor
  • Antibody single variable domains disclosed herein may designed to be specific for the above targets without requiring any increase in or increasing half -life in vivo.
  • antibody single variable domains disclosed herein can be specific for targets selected from the foregoing which are tissue-specific, thereby enabling tissue-specific targeting of the dual specific polypeptide comprising multiple antibody single variable domains, or of the antibody single variable domain monomer that binds a tissue-specific therapeutically relevant target, irrespective of any increase in half-life, although this may result.
  • the dual specific polypeptide comprising multiple antibody single variable domains or the antibody single variable domain monomer targets kidney or liver, this may redirect the dual specific polypeptide or antibody single variable domain monomer to an alternative clearance pathway in vivo (for example, the antibody single variable domain monomer may be directed away from liver clearance to kidney clearance).
  • the PEGylated antibody single variable domain monomer and antibody single variable domain multimers described herein possess increased stability to the action of proteases. In the presence of pepsin many antibody single variable domains are totally degraded at pH 2 because the protein is unfolded under the acid conditions, thus making the protein more accessible to the protease enzyme.
  • PEGylated antibody single variable domain monomer and multimers wherein it is believed that the PEG polymer provides protection of the polypeptide backbone due the physical coverage of the backbone by the PEG polymer, thereby preventing the protease from gaining access to the antibody single variable domain polypeptide backbone and cleaving it.
  • a PEGylated antibody single variable domain having a higher hydrodynamic size (e.g., 200 to 500 kDa) is generated as disclosed herein, because the larger hydrodynamic size will confirm a greater level of protection from protease degradation than a PEGylated dAb having a lower hydrodynamic size.
  • a PEG- or other polymer-linked antibody single variable domain monomer or multimer is degraded by no more than 10% when exposed to one or more of pepsin, trypsin, elastase, chymotrypsin, or carboxypeptidase, wherein if the protease is pepsin then exposure is carried out at pH 2.0 for 30 minutes, and if the protease is one or more of trypsin, elastase, chymotrypsin, or carboxypeptidase, then exposure is carried out at pH 8.0 for 30 minutes.
  • a PEG- or other polymer-linked antibody single variable domain monomer or multimer is degraded by no more than 10% when exposed to pepsin at pH 2.0 for 30 minutes, in an aspect, no more than 5%, and in another aspect, not degraded at all.
  • a PEG- or other polymer-linked antibody single variable domain multimer e.g., hetero- or homodimer, trimer, tetramer, octamer, etc.
  • a PEG- or other polymer-linked antibody single variable domain multimer e.g., hetero- or homodimer, trimer, tetramer, octamer, etc.
  • a PEG- or other polymer-linked antibody single variable domain monomer or multimer is degraded by no more than 10% when exposed to trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes, in an aspect, no more than 5%, and, in a further aspect, not degraded at all.
  • a PEG- or other polymer-linked antibody single variable domain multimer (e.g., hetero- or homodimer, trimer, tetramer, octamer, etc.) disclosed herein is degraded by less than 5%, and is, in an aspect, not degraded at all in the presence of trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes.
  • the relative ratios of protease:PEG-antibody single variable domain polypeptide may be altered as disclosed herein to achieve the desired level of degradation as described above.
  • the ratio or protease to PEG-antibody single variable domain may be from about 1:30, to about 10:40, to about 20:50, to about 30:50, about 40:50, about 50:50, about 50:40, about 50:30, about 50:20, about 50:10, about 50:1, about 40:1, and about 30:1.
  • an antibody single variable domain comprising linking an antibody single variable domain monomer or multimer to a PEG polymer according to any of the embodiments described herein.
  • the antibody single variable domain is degraded by no more than 10% in the presence of pepsin at pH 2.0 for 30 minutes.
  • a PEG-linked antibody single variable domain multimer is degraded by no more than 5%, and, in an aspect, not degraded at all in the presence of pepsin at pH 2.0 for 30 minutes, hi an alternate embodiment, the antibody single variable domain is degraded by no more than 10% when exposed to trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes, in an aspect, no more than 5%, and, in another aspect, not degraded at all.
  • Degradation of PEG-linked antibody single variable domain monomers and multimers as set forth herein may be measured using methods which are well known to those of skill in the art. For example, following incubation of a PEG-linked antibody single variable domain with pepsin at pH 2.0 for 30 minutes, or with trypsin, elastase, chymotrypsin, or carboxypeptidase at pH 8.0 for 30 minutes, the antibody single variable domain samples may be analyzed by gel filtration, wherein degradation of the antibody single variable domain monomer or multimer is evidenced by a gel band of a smaller molecular weight than an un-degraded (i.e., control antibody single variable domain not treated with pepsin, trypsin, chymotrypsin, elastase, or carboxypeptidase) dAb.
  • an un-degraded i.e., control antibody single variable domain not treated with pepsin, trypsin, chymotrypsin, elastas
  • Molecular weight of the antibody single variable domain bands on the gel may be determined by comparing the migration of the band with the migration of a molecular weight ladder. Other methods of measuring protein degradation are known in the art and may be adapted to evaluate the PEG-linked antibody single variable domain monomers and multimers as disclosed herein.
  • Anti-CD28 antibody single variable domains as described herein are useful for antagonizing the activity of a CD28. Therefore, anti-CD28 antibody single variable domains as described herein can be used to treat a patient having a condition, disease or disorder mediated in whole or in part by CD28 activity.
  • Anti-CD28 antibody single variable domains as described herein are useful for the treatment or prevention of diseases or disorders in which inappropriate activation of a CD28 - mediated pathway is involved. Anti-CD28 antibody single variable domains as described herein are also useful for the treatment, prevention, or alleviation of symptoms of diseases or disorders in which inappropriate activation of a CD28 -mediated pathway is involved.
  • autoimmune diseases frequently involve inappropriate regulation or activity of CD28 pathways.
  • Administration of an anti-CD28 antibody single variable domain as described herein to an individual suffering from such a disease, including an autoimmune disease can reduce one or more symptoms of the disease.
  • diseases for which the antibody single variable domains described herein can be therapeutically useful include, but are not limited to, Addison's disease, allergy, ankylosing spondylitis, asthma, atherosclerosis, autoimmune diseases of the ear, autoimmune diseases of the eye, autoimmune hepatitis, autoimmune parotitis, colitis, coronary heart disease, Crohn's disease, diabetes (Type I), diabetes, including Type 1 and/or Type 2 diabetes, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel disease (IBD), immune response to recombinant drug products, e
  • IBD
  • Autoimmune-mediated conditions also include, but are not limited to, conditions in which the tissue affected is the primary target, and in some cases, the secondary target.
  • Such conditions include, but are not limited to, AIDS, atopic allergy, bronchial asthma, eczema, leprosy, schizophrenia, inherited depression, transplantation of tissues and organs, chronic fatigue syndrome, Alzheimer's disease, Parkinson's disease, myocardial infarction, stroke, autism, epilepsy, Arthus's phenomenon, anaphylaxis, and alcohol and drug addiction.
  • anti-CD28 antibody single variable domains described herein are additionally useful in the way that generally any antibody preparation is useful, e.g., for in vivo imaging or diagnostic uses, in vitro diagnostic uses, etc.
  • anti-CD28 antibody single variable domains e.g., with a fluorescent, colorimetric, en2ymatic or radioactive label.
  • Methods of labeling antibody single variable domains are well known in the art.
  • the antibody single variable domains set forth herein can be incorporated into pharmaceutical compositions suitable for administration to a subject.
  • the pharmaceutical composition comprises a monovalent anti-CD28 antibody single variable domain and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial, and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible.
  • pharmaceutically acceptable carrier excludes tissue culture medium comprising bovine or horse serum.
  • pharmaceutically acceptable carriers include one or more of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol and the like, as well as combinations thereof.
  • compositions as described herein may be in a variety of forms. These include, for example, liquid, semi-solid, and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, powders, liposomes, and suppositories. The preferred form depends on the intended mode of administration and therapeutic application.
  • Typical preferred compositions are in the form of injectable or infusible solutions, such as compositions similar to those used for passive immunization of humans with other antibodies.
  • the preferred mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular).
  • compositions typically must be sterile and stable under the conditions of manufacture and storage.
  • the composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high drug concentration.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the antibody single variable domains described herein can be administered by a variety of methods known in the art, although for many therapeutic applications, the preferred route/mode of administration is intravenous injection or infusion.
  • the polypeptide can also be administered by intramuscular or subcutaneous injection.
  • the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems.
  • Antibody single variable domains and other relatively small monovalent antibody single variable domains are well suited for formulation as extended release preparations due, in part, to their small size, the number of moles per dose can be significantly higher than the dosage of, for example, full sized antibodies.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
  • Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.
  • agents that delays absorption for example, monostearate salts and gelatin.
  • Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., SUSTAINED AND CONTROLLED RELEASE DRUG DELIVERY SYSTEMS, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Additional methods applicable to the controlled or extended release of polypeptide agents such as the monovalent antibody single variable domains disclosed herein are described, for example, in U.S. Patent Nos. 6,306,406 and 6,346,274, as well as, for example, in U.S. Patent Publication Nos. US20020182254 and US20020051808, all of which are incorporated herein by reference.
  • a monovalent anti-CD28 antibody single variable domain is coformulated with and/or coadministered with one or more additional therapeutic agents.
  • a monovalent anti-CD28 antibody single variable domain can be coformulated and/or coadministered with one or more additional antibodies that bind other targets (e.g., antibodies that bind other cytokines or that bind cell surface molecules), or, for example, one or more cytokines.
  • targets e.g., antibodies that bind other cytokines or that bind cell surface molecules
  • cytokines e.g., antibodies that bind other cytokines or that bind cell surface molecules
  • compositions disclosed herein can include a "therapeutically effective amount” or a “prophylactically effective amount” of a monovalent anti-CD28 antibody single variable domain.
  • a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
  • a therapeutically effective amount of the antibody single variable domain can vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the monovalent anti-CD28 antibody single variable domain to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which any toxic or detrimental effects of the antibody or antibody portion are outweighed by the therapeutically beneficial effects.
  • prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, because a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.
  • Dosage regimens may be adjusted to provide the optimum desired response (e.g., a therapeutic or prophylactic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • a non-limiting range for a therapeutically or prophylactically effective amount of a monovalent anti-CD28 antibody single variable domain is 0.1-20 mg/kg, and in an aspect, 1-10 mg/kg. It is to be noted that dosage values can vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the administering clinician.
  • the efficacy of treatment with a monovalent anti-CD28 antibody single variable domain as described herein is judged by the skilled clinician on the basis of improvement in one or more symptoms or indicators of the disease state or disorder being treated.
  • An improvement of at least 10% (increase or decrease, depending upon the indicator being measured) in one or more clinical indicators is considered "effective treatment," although greater improvements are preferred, such as 20%, 30%, 40%, 50%, 75%, 90%, or even 100%, or, depending upon the indicator being measured, more than 100% (e.g., two-fold, three-fold, ten-fold, etc., up to and including attainment of a disease- free state.
  • Indicators can be physical measurements, e.g., enzyme, cytokine, growth factor or metabolite levels, rate of cell growth or cell death, or the presence or amount of abnormal cells.
  • One can also measure, for example, differences in the amount of time between flare-ups of symptoms of the disease or disorder (e.g., for remitting/relapsing diseases, such as multiple sclerosis).
  • non-physical measurements such as a reported reduction in pain or discomfort or other indicator of disease status can be relied upon to gauge the effectiveness of treatment.
  • CDAI Crohn's Disease Activity Index
  • SPI SPI
  • PASI Psoriasis Area Severity Index
  • the PASI is most commonly used method to assess psoriasis disease severity in clinical trials, although it can be exceedingly cumbersome for use in daily clinical practice.
  • the method involves the body being divided into four sections (Legs, which have 40% of a person's skin; the Body (trunk area: stomach, chest, back, etc.) with 30%; the Arms (20%); and the Head (10%)). Each of these areas is scored by itself, and then the four scores are combined into the final PASI. For each section, the percent of area of skin involved, is estimated and then, transformed into a grade from 0 to 6:
  • the severity is estimated by four different parameters: Itching, Erythema (redness), Scaling and Thickness (psoriatic skin is thicker than normal skin). Severity parameters are measured on a scale of 0 to 4, from none to maximum.
  • the total PASI is calculated as a sum of PASIs for all four skin sections.
  • Computer-aided measurement of psoriatic lesion area was found to improve the power of the clinical trial, compared to the standard approach. The physician's estimations of the psoriatic lesion area tend to overestimate.
  • the modified PASI which involves computer aided area measurement as a continuous variable is named: Computer aided psoriasis continuous area and severity score cPcASI]
  • psoriasis is ameliorated by administering to an individual having psoriasis, an antagonist anti-CD28 dAb, or composition thereof, described herein.
  • organ transplant patients have improved as a result of advances in organ preservation and immunosuppressive treatments, (Chien et al. (2004) Current Pharmaceutical Biotechnology, 5: 551-566).
  • organ rejection especially the acute rejection that occurs in the first few weeks following surgery, as well as chronic graft rejection, is still one of the major causes of functional failure in organ transplantation.
  • Current diagnosis or confirmation of graft rejection following solid organ transplantation requires biopsy of the tissue in order to detect the infiltration of immune cells (e.g., T-cells, macrophages, etc.) into the graft and other pathological changes.
  • immune cells e.g., T-cells, macrophages, etc.
  • Tissue biopsy is not only invasive, it is associated with increased health risk to the patent and is prone to sampling errors that can lead to false negative results.
  • Alternative noninvasive methods are being developed, such as magnetic resonance imaging (MRI) which can be used to monitor the accumulation of immune cells at the rejected organ.
  • MRI magnetic resonance imaging
  • Acute rejection occurs within a week to approximately 4 months after transplantation according to a Medscape article published on the web at medscape.com/viewarticle/436533_12.
  • Acute rejection is a cellular immune response involving mononuclear, cytotoxic and Th cells, monokines, and lymphokines.
  • Quiescent, nonactivated Th cells encounter specific class II antigens displayed on the donor organ, become activated, and synthesize receptors for lymphokines that are simultaneously released from monocytes.
  • Activated monocytes release the lymphokine IL-I, which causes clonal expansion of activated Th cells.
  • Monocytes also release the lymphokine IL-2, which activates and causes the clonal expansion of CTLs.
  • one embodiment of the instant invention encompasses blocking the activation and/or proliferation of T cells using a CD28 dAb described herein, that functions as an antagonist to CD28 mediated T cell signaling.
  • Chronic rejection is a prolonged process of declining allograft function. Chronic rejection probably begins at the time of transplantation, but may take months or years to manifest clinically according to a Medscape article published on the web at medscape.com/viewarticle/436533_12. While the clinical and biochemical signs are organ- specific, the result of chronic rejection is the same for all solid organ allografts. Slowly deteriorating graft function (DGF) caused by fibrosis of the graft parenchyma and widespread arteriopathy are the hallmarks of chronic rejection that lead to loss of function and eventual graft loss. T cells and B cells contribute to the damage characteristic of chronic rejection, Demetris AJ, Duquesnor RJ, Fung JJ, et al.
  • DGF slowly deteriorating graft function
  • symptoms originating from the rejection of an organ transplant are ameliorated by administering an antagonist anti-CD28 dAb described herein, or a composition comprising said anti-CD28 dAb.
  • An anti-CD28 dAb can be administered in conjunction with additional medicants as part of a therapeutic regimen, including pravastatin, an HMG CoA reductase inhibitor with relatively low lipophilicity, has been associated with enhanced heart allograft survival and a reduced incidence of acute rejection among recipients of kidney allografts.
  • prophylaxis performed using a composition as described herein is “effective” if the onset or severity of one or more symptoms is delayed or reduced by at least 10%, or abolished, relative to such symptoms in a similar individual (human or animal model) not treated with the composition.
  • the monovalent anti-CD28 antibody single variable domains described herein must bind human CD28, where one is to evaluate its effect in an animal model system, the polypeptide must cross-react with one or more antigens in the animal model system, in an aspect, at high affinity.
  • One of skill in the art can readily determine if this condition is satisfied for a given animal model system and a given monovalent anti-CD28 antibody single variable domain. If this condition is satisfied, the efficacy of the monovalent anti-CD28 antibody single variable domain can be examined by administering it to an animal model under conditions which mimic a disease state and monitoring one or more indicators of that disease state for at least a 10% improvement.
  • Monovalent anti-CD28 antibody single variable domains as described herein are useful for the treatment of autoimmune disorders in which CD28 signaling is inappropriately active. There are several animal models in which the therapeutic efficacy of a given monovalent anti- CD28 antibody single variable domain can be assessed, as discussed below.
  • IBD inflammatory bowel disease
  • Pathogenesis is due in part to the secretion of proinflammatory cytokines.
  • the induction of colitis can be prevented by cotransfer of another CD4(+) subpopulation, the CD4(+)CD45RBlow T cells.
  • This population behaves analogously to the CD4(+)CD45RBhigh population in terms of the acquisition of activation markers and homing to the host intestine.
  • their lymphokine profile when activated is different, and anti-inflammatory cytokines secreted and/or induced by CD4(+)CD45RBlow T cells prevent colitis.
  • chronic inflammation generated by administering CD4(+)CD45RBhigh cells in the above mouse model is ameliorated by administering an antagonist anti-CD28 dAb described herein.
  • chronic inflammation generated by administering CD4(+)CD45RBhigh cells in the above mouse model is prevented by administering an antagonist anti-CD28 dAb described herein before or simultaneously with the administration of CD4(+)CD45RBhigh cells in the above mouse model.
  • RA Rheumatoid arthritis
  • RA Rheumatoid arthritis
  • this mouse model is generated by crossing a T cell receptor (TCR) transgenic line with the NOD strain. All offspring develop a joint disease highly reminiscent of RA in man.
  • TCR T cell receptor
  • the trigger for the murine disorder is chance recognition of a NOD-derived major histocompatibility complex (MHC) class II molecule by the transgenic TCR; progression to arthritis involves CD4+ T, B, and probably myeloid cells.
  • MHC major histocompatibility complex
  • Kouskoff et al. propose that a joint-specific disease need not arise from response to a joint-specific antigen but can be precipitated by a breakdown in general mechanisms of self-tolerance resulting in systemic self- reactivity, and suggests that human RA develops by an analogous mechanism.
  • RA which spontaneously develops in the above mouse model is ameliorated by administering an antagonist anti-CD28 dAb described herein.
  • the spontaneous development of RA in the above mouse model is prevented by administering an antagonist anti-CD28 dAb described herein before or simultaneously with the first appearance of symptoms of RA.
  • Brand et al. describe an animal model for arthritis in which an experimental autoimmune disease, Collagen-induced arthritis (CIA), is elicited in susceptible strains of rodents (rat and mouse) and nonhuman primates by immunization with type II collagen (CII), the major constituent protein of articular cartilage, Brand DD et al. Methods MoI Med. (2004), 102:295- 312. Following immunization, these animals develop an autoimmune polyarthritis that shares several clinical and histological features with rheumatoid arthritis.
  • CIA Collagen-induced arthritis
  • CII type II collagen
  • CIA in rodents is linked to the class II molecules of the major histocompatibility complex (MHC), and the immune response to CII is characterized by both the stimulation of collagen-specific T cells and the production of high titers of antibody specific for both the immunogen (heterologous CII) and the autoantigen (mouse CII).
  • MHC major histocompatibility complex
  • murine CIA is characterized by an intense synovitis that corresponds precisely with the clinical onset of arthritis. Because of the pathological similarities between CIA and rheumatoid arthritis, the CIA model has been the subject of extensive investigation.
  • collagen-induced arthritis elicited in the above mouse model can be ameliorated by administering an antagonist anti-CD28 dAb described herein.
  • collagen-induced arthritis elicited in the above mouse model is prevented by administering an antagonist anti-CD28 dAb described herein before or simultaneously with the first appearance of an intense synovitis that corresponds precisely with the clinical onset of arthritis.
  • collagen-induced arthritis elicited in the above mouse model is prevented by administering an antagonist anti-CD28 dAb described herein before or simultaneously with the administration of CII. 10.4 Acute Mouse Model for antigen induced autoimmunity
  • Pape et al. describe the use of adoptive transfer of T-cell-antigen-receptor-transgenic T cell into mice for the study of T-cell activation in vivo, in Pape et al. Immunol Rev. (1997 Apr), 156:67-78.
  • Pape et al. have used this system to show that naive T cells are initially activated within the T-cell zones of secondary lymphoid tissue to proliferate in a B7-dependent manner. If adjuvants or inflammatory cytokines are present during this period, enhanced numbers of T cells accumulate, migrate into B-cell-rich follicles, and acquire the capacity to produce IFN-gamma and help B cells produce IgG2a.
  • Pape et al. indicate that inflammatory mediators play a key role in regulating the anatomic location, clonal expansion, survival and lymphokine production potential of antigen-stimulated T cells in vivo.
  • one aspect of the instant invention is to ameliorate an autoimmune diseases generated by administration of TCR-transgenic T cells uniformly expressing an identifiable TCR of known peptide/MHC specificity to a specific autoantigen, by administering an antagonist anti-CD28 dAb described herein.
  • the anti-CD28 dab is divalent, binding to both CD28 and to said TCR.
  • one aspect of the instant invention is to prevent the occurrence of an autoimmune diseases generated by administration of TCR-transgenic T cells uniformly expressing an identifiable TCR of known peptide/MHC specificity to a specific autoantigen, by administering an antagonist anti-CD28 dAb described herein before or concomitantly with the administration of the transgenic TCR T cells.
  • the anti-CD28 dab is divalent, binding to both CD28 and to said TCR.
  • Antibody single variable domains with CD28 binding properties were selected from a library of VH and VK polypeptides. Selections were carried out with recombinant human CD28/Fc Chimera (R&D Systems, Abingdon, UK). The dAb library used for selections was based on a single human VH framework (V3-23 [locus] DP47 [V Base Entry] and JH4b) and a single human VL framework (012/02 [locus] DP ⁇ 9 [V Base Entry] and J ⁇ l).
  • the dAb genes were genetically linked to the fd phage gene III protein under the control of the GASl leader sequence in the pDOM4 vector ( Figure IA) which contained all the fd genes necessary to generate infective phage particles.
  • the first round of phage selection was performed by premixing phage library (4 pools for the VH libraries [VHl 1- 13, VH14-15, VH16-17, VH18-19] and a single pool for the VK library) with 2% MPBS (Phosphate Buffered Saline supplemented with 2% Marvel dried skim milk powder) and adding CD28-Fc (R&D Systems, UK) to a final concentration of 10OnM.
  • the mixture was incubated for at least 1 hour at room temperature with mixing end-over-end then the antigen-phage complexes captured using protein G Dynabeads (Dynal, Sweden) and washed 8 times with 1ml PBST (PBS supplemented with 0.1% Tween 20) followed by a singe wash in 1ml PBS.
  • the washed phage were eluted from the antigen/bead complex by incubating with 0.5ml of lmg/ml trypsin Type XIII from Bovine Pancreas (Sigma Aldrich, UK) in PBS (supplemented with 5mM Tris-HCl pH 7.4, O.lmM CaC12). Eluted phage were used to infect E.coli and the output phage titres were determined to be between 1x10 4 to 1x10 5 t.u./ml.
  • a second round of selection was performed using enriched phage recovered from the previous round of selection with a final concentration of 5OnM CD28-Fc followed by capture using protein G beads as described above.
  • Output titres were in the range lxl0 6 to 1x10 9 t.u./ml.
  • a third round of selection using 1OnM CD28-Fc followed by capture using protein G beads was performed.
  • the eluted phage titres were in the range of 2x10 9 to 8x10 9 t.u./ml.
  • Monoclonal phage ELISAs were carried out following selection rounds 2 and 3. All washes were performed using 3 washes of 250 ⁇ l PBST followed by 3 washes of 250 ⁇ l PBS. Plates were coated overnight at 4°C with lmg/ml and 0.6mg/ml CD28-Fc in PBS respectively. Plates were washed, then blocked with 2% MPBS for Ih at room temperature. The plates were washed and phage supernatants added to an equal volume of 2% MPBS and incubated for Ih at room temperature. The plates were washed and bound phage detected with anti-M13-HRP conjugate (GE Healthcare, UK) diluted 1:5000 in 2% MPBS and incubated for 1 hour at room temperature.
  • anti-M13-HRP conjugate GE Healthcare, UK
  • the plates were blocked for Ih at room temperature with 200 ⁇ l of PBS containing 1% Tween 20 and then washed.
  • the clarified antibody single variable domain containing culture supernatant was added to the ELISA plate in the presence of either protein A for VH (Sigma, UK) or protein L for VK (Sigma, UK) to increase the ELISA signal strength by cross-linking the VH or VK antibody single variable domains, respectively.
  • the plates were incubated for Ih at room temperature and then washed.
  • Bound antibody single variable domain was detected using a two step process, first 9E10 (anti- myc IgG, Sigma- Aldrich, UK) diluted 1:2000 in PBST was added for Ih at room temperature and then washed, followed by anti-mouse Fc-HRP diluted 1:2000 in PBST for Ih at room temperature. The plates were washed and the ELISA developed using SureBlue 1 -Component TMB Micro Well Peroxidase solution (KPL Inc, USA) and the color was allowed to develop. The colorimetric reaction was stopped by the addition of an equal volume of IM HCL and the ELISA plate was read at 450nm.
  • CD28 specific clones were identified by comparison to a control plate coated with Fc alone (see Figure 3 for example of soluble ELISA). All specific clones were DNA sequenced and initially 28 unique clones were identified (see below for sequences). An additional two plates of antibody single variable domain supernatants were screened for binding to CD28-Fc by BIAcore analysis (GE Healthcare, UK). From this screening, an additional 30 unique sequences were identified (see below for sequences).
  • dAbs Seven of the dAbs (DOM21-4, DOM21-6, DOM21-18, DOM21-20, DOM21-22, DOM21-27 and DOM21-28) were expressed and purified on a larger scale. Endotoxin depleted dAbs samples at a stock concentration of lOO ⁇ M were used to determine whether the dAbs could inhibit the activity of CD28 in a cell based in vitro assay similar to that described by Boulougouris G, J Immunol. 1998, 161(8): 3919-3924. Proliferation assays were performed in triplicate in 96-well plates in a final volume of 200 ⁇ l per well using RPMI 1640 medium containing 10% FCS and antibiotics.
  • Human CD4 positive T-cells (5 x 10 4 ) were cultured in the presence of l ⁇ g/ml anti-CD3 antibody (OKT3) plus transfected CHO cells expressing either CD80 or CD86 and dAb or control antibody at a range of concentrations. Assays were incubated at 37°C for between 18h to 72h in the presence of 1 ⁇ Ci [ 3 H]thymidine per well. Cells were harvested onto 96-well filter plates using a Packard (Meriden, CT) 96-well harvester, and [ 3 H]thymidine uptake was determined via liquid scintillation counting.
  • l ⁇ g/ml anti-CD3 antibody OKT3
  • Assays were incubated at 37°C for between 18h to 72h in the presence of 1 ⁇ Ci [ 3 H]thymidine per well. Cells were harvested onto 96-well filter plates using a Packard (Meriden, CT) 96-well harvester, and [ 3 H]thy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

La présente invention concerne un domaine de polypeptide monovalent qui se lie spécifiquement à CD28, ainsi qu’un antagoniste de CD28, où le composé antagoniste comprend un domaine de polypeptide monovalent qui se lie spécifiquement à CD28. Cette invention inclut des domaines de polypeptide monovalents comprenant un domaine variable unique d’anticorps qui se lie de manière monovalente à CD28. Un domaine variable unique d’anticorps qui est monovalent pour la liaison à CD28 peut inhiber l’activité CD28. Dans un aspect, un domaine variable unique d’anticorps anti-CD28 est constitué de ou comprend un domaine variable unique d’anticorps qui se lie spécifiquement à et a un effet antagoniste sur l’activité CD28, dans un aspect, sans avoir d’effet agoniste sur l’activité CD28. Dans un autre aspect, le domaine variable unique d’anticorps anti-CD28 monovalent est un domaine variable unique d’anticorps humain. L'invention concerne en outre des procédés d’antagonisme des interactions de CD80 et/ou CD86 avec CD28 chez un individu et des procédés de traitement de maladies ou troubles impliquant les interactions de CD80 et/ou CD86 avec CD28, les procédés impliquant l’administration d’un domaine variable unique d’anticorps anti-CD28 monovalent à l’individu.
PCT/GB2009/001762 2008-07-18 2009-07-17 Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation WO2010007376A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09784717A EP2315778A2 (fr) 2008-07-18 2009-07-17 Compositions monovalentes pour la liaison à cd28 et procédés d utilisation
JP2011517992A JP2012507260A (ja) 2008-07-18 2009-07-17 Ｃｄ２８結合のための一価の組成物及び使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US755308P 2008-07-18 2008-07-18
US17603608A 2008-07-18 2008-07-18
US12/176,036 2008-07-18
US61/007,553 2008-07-18

Publications (2)

Publication Number Publication Date
WO2010007376A2 true WO2010007376A2 (fr) 2010-01-21
WO2010007376A3 WO2010007376A3 (fr) 2010-05-27

Family

ID=41316544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001762 WO2010007376A2 (fr) 2008-07-18 2009-07-17 Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation

Country Status (4)

Country Link
EP (1) EP2315778A2 (fr)
JP (1) JP2012507260A (fr)
AR (1) AR073459A1 (fr)
WO (1) WO2010007376A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015090229A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Récepteur d'antigène chimérique régulable
WO2015142661A1 (fr) 2014-03-15 2015-09-24 Novartis Ag Récepteur d'antigène chimèrique régulable
WO2016014553A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
WO2017087588A1 (fr) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Liants ctla4
WO2017087589A3 (fr) * 2015-11-18 2017-07-13 Merck Sharp & Dohme Corp. Liants pd1 et/ou lag3
AU2016302951B2 (en) * 2015-07-31 2019-10-10 3D Medicines (Beijing) Co., Ltd. Single domain antibody for programmed death-ligand (PD-L1) and derived protein thereof
WO2019241730A2 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3660042A1 (fr) 2014-07-31 2020-06-03 Novartis AG Lymphocytes t contenant des récepteurs d'antigènes chimériques optimisés par sous-ensemble
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2021127217A1 (fr) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
WO2022006179A1 (fr) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
CN117534761A (zh) * 2023-11-20 2024-02-09 上海百英生物科技股份有限公司 一种抗cd28纳米抗体及其制备方法与应用
WO2024133246A1 (fr) * 2022-12-19 2024-06-27 Sanofi Anticorps bispécifiques cd28/ox40
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3009661A1 (fr) * 2016-01-11 2017-07-20 Inhibrx, Inc. Proteines de fusion se liant a gitr multivalentes et multispecifiques
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249700A1 (en) * 1995-07-25 2005-11-10 Allison James P Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO2006030220A1 (fr) * 2004-09-17 2006-03-23 Domantis Limited Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
WO2008071447A2 (fr) * 2006-12-15 2008-06-19 Ablynx N.V. Séquences d'acides aminés qui modulent l'interaction entre des cellules du système immunitaire

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249700A1 (en) * 1995-07-25 2005-11-10 Allison James P Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO2006030220A1 (fr) * 2004-09-17 2006-03-23 Domantis Limited Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
WO2008071447A2 (fr) * 2006-12-15 2008-06-19 Ablynx N.V. Séquences d'acides aminés qui modulent l'interaction entre des cellules du système immunitaire

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015090229A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Récepteur d'antigène chimérique régulable
EP4420663A2 (fr) 2013-12-20 2024-08-28 Novartis AG Récepteur d'antigène chimère régulable
WO2015142661A1 (fr) 2014-03-15 2015-09-24 Novartis Ag Récepteur d'antigène chimèrique régulable
EP3811970A1 (fr) 2014-03-15 2021-04-28 Novartis AG Récepteur d'antigène chimérique régulable
WO2016014553A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
EP4205749A1 (fr) 2014-07-31 2023-07-05 Novartis AG Cellules contenant un récepteur d'antigène chimérique optimisé en sous-ensemble
EP3660042A1 (fr) 2014-07-31 2020-06-03 Novartis AG Lymphocytes t contenant des récepteurs d'antigènes chimériques optimisés par sous-ensemble
AU2016302951B2 (en) * 2015-07-31 2019-10-10 3D Medicines (Beijing) Co., Ltd. Single domain antibody for programmed death-ligand (PD-L1) and derived protein thereof
US10323090B2 (en) * 2015-11-18 2019-06-18 Merck Sharp & Dohme Corp. PD1 and/or LAG3 binders
IL259224B1 (en) * 2015-11-18 2023-03-01 Merck Sharp & Dohme Substances that bind to pd1 and/or lag3
US10501542B2 (en) 2015-11-18 2019-12-10 Merck Sharp & Dohme Corp. CTLA4 binders
WO2017087588A1 (fr) * 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Liants ctla4
AU2016355569B2 (en) * 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
AU2016355570B2 (en) * 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
CN108473565A (zh) * 2015-11-18 2018-08-31 默沙东公司 Ctla4结合剂
WO2017087589A3 (fr) * 2015-11-18 2017-07-13 Merck Sharp & Dohme Corp. Liants pd1 et/ou lag3
CN108473585A (zh) * 2015-11-18 2018-08-31 默沙东公司 Pd1和/或lag3结合剂
IL259224B2 (en) * 2015-11-18 2023-07-01 Merck Sharp & Dohme Substances that bind to pd1 and/or lag3
EA038179B1 (ru) * 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
US11155619B2 (en) 2015-11-18 2021-10-26 Merck Sharp & Dohme Corp. PD1 and/or LAG3 binders
US11168135B2 (en) 2015-11-18 2021-11-09 Merck Sharp & Dohme Corp. PD1 and/or LAG3 binders
US11168136B2 (en) 2015-11-18 2021-11-09 Merck Sharp & Dohme Corp. PD1 and/or LAG3 binders
US11649290B2 (en) 2015-11-18 2023-05-16 Merck Sharp & Dohme Llc CTLA4 binders
TWI754621B (zh) * 2015-11-18 2022-02-11 美商默沙東藥廠 Pd1及／或 lag3結合劑
CN108473585B (zh) * 2015-11-18 2022-04-05 默沙东公司 Pd1和/或lag3结合剂
CN108473565B (zh) * 2015-11-18 2022-05-27 默沙东公司 Ctla4结合剂
AU2020202238B2 (en) * 2015-11-18 2022-07-28 Merck Sharp & Dohme Llc PD1 and/or LAG3 binders
JP2019503655A (ja) * 2015-11-18 2019-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｔｌａ４結合性物質
WO2019241730A2 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2021127217A1 (fr) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
WO2022006179A1 (fr) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Virus modifiés pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
WO2024133246A1 (fr) * 2022-12-19 2024-06-27 Sanofi Anticorps bispécifiques cd28/ox40
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
CN117534761A (zh) * 2023-11-20 2024-02-09 上海百英生物科技股份有限公司 一种抗cd28纳米抗体及其制备方法与应用

Also Published As

Publication number Publication date
AR073459A1 (es) 2010-11-10
WO2010007376A3 (fr) 2010-05-27
JP2012507260A (ja) 2012-03-29
EP2315778A2 (fr) 2011-05-04

Similar Documents

Publication Publication Date Title
US12012452B2 (en) Compositions monovalent for CD28 binding and methods of use
US20130230540A1 (en) Compositions monovalent for cd28 binding and methods of use
WO2010007376A2 (fr) Compositions monovalentes pour la liaison à cd28 et procédés d’utilisation
CA2581017C (fr) Compositions monovalentes pour la liaison au cd40l et procedes d'utilisation
WO2014120916A1 (fr) Anticorps à domaines pegylés monovalents pour la liaison à cd28 et leurs méthodes d'utilisation
AU2015202447B2 (en) Compositions monovalent for cd28 binding and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784717

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase in:

Ref document number: 2011517992

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009784717

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE